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Abstract 
 
Identifying positional candidate genes on chromosome 10 that  
are involved in APP processing 
Preeti Khandelwal 
Aleister J. Saunders 
 
 
A central event in Alzheimer's disease (AD) is the regulated intramembraneous 
proteolysis of the β-amyloid precursor protein (APP), to generate the β-amyloid (Aβ) 
peptide and the APP intracellular domain (AICD). Aβ is the major component of 
amyloid plaques and AICD displays transcriptional activation properties. We have 
taken advantage of AICD transactivation properties to develop a genetic screen to 
identify regulators of APP metabolism. This screen relies on an APP-Gal4 fusion 
protein, which upon normal proteolysis, produces AICD-Gal4. Production of AICD-
Gal4 induces Gal4-UAS driven luciferase expression. Therefore, when regulators of 
APP metabolism are modulated, luciferase expression is altered. To validate this 
experimental approach we modulated α-, β-, and γ-secretase levels and activities. 
Changes in AICD-Gal4 levels as measured by Western blot analysis were strongly and 
significantly correlated to the observed changes in AICD-Gal4 mediated luciferase 
activity. Taken together, we have shown that this screen can identify known APP 
metabolism regulators that control proteolysis, intracellular trafficking, maturation and 
levels of APP and its proteolytic products.  
 
 
  xiii 
Genes that increase AD risk are not fully accounted for and genome scans suggest 
large genomic regions contain AD positional candidate genes. Our goal is to identify 
these genes that function to modulate APP processing and Aβ generation. Here we are 
using RNA interference to silence expression of positional candidate genes and 
monitor changes in APP processing, using an AICD-mediated reporter gene 
expression assay in human neuroblastoma cell lines. The validity and sensitivity of 
this assay system was tested by pharmacologically and genetically targeting the α-, β-, 
and γ- secretases. To identify modulators of APP metabolism, genes on chromosomes 
10 were screened for their ability to modulate APP metabolism. Here we identify 16 
putative regulators of APP metabolism and characterize them to elucidate their 
mechanism of action. We further determine the mechanism by which two putative 
regulators; PPP3CB, the catalytic subunit of calcium dependent serein/threonine 
phosphatase and SUFU, a component of the hedgehog pathway modulate APP 
metabolism. 
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Chapter 1 : Introduction 
 
Background and significance: 
Alzheimer's disease (AD) is a progressive and irreversible brain disorder with 
no known cure. It’s the most common form of neurodegenerative disease and the sixth 
leading cause of death in the elderly (Sparks, 2008). Due to the baby boom and an 
increase in life expectancy world wide, there is an increase in the number of elderly 
people who are 85 years and older. Currently there are approximately 5.2 million 
people in the United States living with AD. The direct and indirect costs of AD to 
Medicare, Medicaid and businesses amount to approximately $100 billion each year 
(alz.org). With an expected increase in the expected AD population in years to come, 
it is very important to understand the underlying cause of the disease for the 
development of more effective diagnosis and treatment. 
AD is a complex disease caused by a combination of age, genetic, and 
environmental factors. These factors cause or increase the risk of developing the 
disease.  The pathological hallmarks of AD are the presence of dense intraneuronal 
neurofibrillary tangles (composed of hyperphosporylated Tau protein) and 
extracellular amyloid plaques. Amyloid beta (composed mainly of amyloid beta 
peptide) is naturally produced in the brain. While in AD brains Aβ peptides 
accumulate to form plaques, in healthy brains these aggregates are not common. 
Plaque formation could be the result of either an increase in Aβ production or a 
decrease in the Aβ clearance. Aβ oligomers are believed to induce synaptic loss 
resulting in neuronal death (Shankar et al., 2008).  
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Loss of cholinergic neurons in the hippocampus and cortex of patients with 
AD results in the shortage of neurotransmitter which leads to cognitive impairment. 
Symptoms of the disease generally start with memory loss, impaired judgment, 
personality changes, disorientation, and loss of language skills.  
Genetics of AD 
AD is a disease of aging and genetics. The Early onset form of the disease 
(EAOD) is manifested before the age of 60 and accounts for approximately 10% of 
total AD cases. EOAD cases are rare and can be attributed to mutations that are fully 
penentrant in nature can result in EOAD from inheritance of one out of over 120 
known mutations occurring in three genes: Amyloid Precursor Protein (APP; 
chromosome 21), Presenilin1s and Presenilin2 (PS2; chromosome 1). However, most 
of the AD cases are prevalent after the age of 65. These late onsets (LOAD) cases are 
non-familial and sporadic, involving genetic variants of high prevalence and low 
penetrance. These gene variants do not cause AD but in turn increase the risk of 
developing AD. To date, the only confirmed LOAD risk factor is the apolipoprotein E 
gene (ApoE). The ε4 allele of this gene has been shown to be moderately penentrant 
accounting for up to 50% of the LOAD cases (Table1-1). However, genes that 
account for the other 50% of the LOAD cases are unknown. Genome-wide linkage 
analysis and linkage disequilibrium studies have provided information on the 
existence of multiple putative AD genes on several chromosomes, with chromosomes 
12, 10, and 9 being the strongest.  
To date, four genes have been implicated in familial AD, mutations in which 
affect the level of Aβ. Specifically, mutations in APP, PS1, and PS2 result in EOAD 
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while the fourth gene that encodes apolipoprotein E (ApoE) is a major risk factor for 
both EOAD and LOAD (Corder et al., 1993). The ApoE gene has 3 alleles called ε2, 
ε3 (the most common form), and ε4. ApoE ε4 has been associated with a high risk for 
AD,  and has been shown to increase the rate of Aβ deposition in animal models 
(Myers and Goate, 2001). This increase may be due to a decreased clearance of Aβ or 
to an increase in Aβ aggregation. Although carrying the ε4 allele of APOE is a major 
risk factor for AD, studies estimate that approximately 50% of LOAD patients do not 
have the ε4 allele. This indicates that there are additional environmental and genetic 
factors  other than APOE that may be located on other chromosomes, that are involved 
with the production of the disease (Myers and Goate, 2001). This fact led many groups 
to begin searching for genes that are involved with the development of AD. There are 
more than 100 genes that have been linked to AD pathogenesis. However, none of the 
results have been confirmed due to a lack of replication.  Daw et al. has proposed the 
existence of 4-7 additional AD gene loci other than APOE that can result in LOAD 
(Daw et al., 2000). Based on the data obtained from genome-wide linkage analysis and 
linkage disequilibrium studies, several groups have reported presence of candidate 
genes on multiple chromosomes, with highest LOD (Likelihood Of Disease) score on 
chromosomes 12, 10, and 9. The most prominent among all the chromosomes has 
been the linkage on chromosome 10 which has been observed in a number of non-
overlapping samples from studies employing distinct approaches.  
Specifically, Bertram et al. focused on markers on 10q in the region in 1426 
members of 435 multiplex AD families. They genotyped seven microsatellite markers 
and obtained a LOD score of 3.5 at 134 cM in whole sample and in families with 
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LOAD (onset at >65 years). A LOD score of 3 or greater indicates that two genetic 
loci are near each other on a chromosome and are likely inherited together. (Figure1-
2) 
Myers et al. performed a genome wide screen in sib pairs with LOAD and used 
multiple stages of analysis to detect the presence of susceptibility loci other than 
APOE. In their initial screen, they observed linkage regions on 16 chromosomes with 
LOD scores>1. They particularly observed high LOAD scores for chromosomes 5, 9, 
10, and 19. In the second stage, they used 429 sib pairs and observed a LOD score of 
3.83 on chromosome 10 at around 30–50 cM  proximal (Myers et al., 2002a). 
(Figure1-2) 
It is known that there is an association between familial AD and elevated Aβ42 
levels. The levels of plasma Aβ42 are seen to be increased in AD patients as well as in 
the first-degree relatives of patients with typical LOAD. Ertekin-Taner et al. 
hypothesized that if a locusi could modify plasma Aβ42, it might also be able to 
modify risk for AD. So they focused on the identification of a quantitative trait locus 
that controls plasma Aβ42 levels using a linkage approach, and genotyped markers on 
chromosomes 1, 5, 9, 10, and 19 in cognitively normal individuals from these families. 
They obtained a maximum lod score of 3.93 on chromosome 10 at around 30–50 cM 
proximal. These genetic results suggest the existence of a novel LOAD locus on 
chromosome 10, variants of which result in an increase of Aβ (Ertekin-Taner et al., 
2000). (Figure1-2) 
 In 2002, Li et al. performed a genome screen in 449 families with AD to 
identify genes that influence age of onset.  They identified a single peak on 10q with a 
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LOD score of 2.62 around 125 cM (Li et al., 2002).In summary, independent genetic 
linkage association analyze have identified regions of Chr.10 to be linked and/or 
associated with increased AD risk. (Figure1-2) 
Genes are considered as biological candidates that are believed to modulate Aβ 
metabolism. To accelerate the understanding of a complex disease like AD, it is 
essential to identify genes that modulate AD risk and determine their mode of action. 
APP biology 
APP is a type-I transmembrane glycoprotein (Kang et al., 1987) located on 
chromosome 21. It is composed of a large extracellular amino-terminal domain and a 
small intracellular carboxy-domain (Annaert and De Strooper, 2002). This protein is 
expressed in most tissue types including endothelia, glia, and neurons in the brain 
(Turner et al., 2003). Differential splicing of APP mRNA results in at least 8 different 
isoforms, with APP695, APP751, and APP770 being predominant. In neurons, 
APP695 is the predominant isoform (De Strooper and Annaert, 2000). Although the 
function of APP remains uncertain, it has been proposed that APP is involved in 
axonal transport, neurotrophic signaling, cell adhesion, and cell
 
signaling (Reinhard et 
al., 2005; Zheng and
 
Koo, 2006 ; Hoareau et al., 2006). Proteolytic processing of APP 
generates the Aβ peptide. Aβ is 39-43 amino acids in length, composed of 11-15 
amino acids of the transmembrane domain and 28 amino acids of the extracellular 
domain (Glenner and Wong, 1984; Masters et al., 1985). The most common isoforms 
are Aβ40 and Aβ42. Aβ42 is prone to form plaques due to its hydrophobic and 
fibrillogenic nature.  Mutations in APP, specifically the ones near the C-terminus 
region of Aβ increase the production of Aβ42. APP is a part of a larger gene family 
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that includes proteins such as APP-like proteins 1 and 2 (APLP1 and APLP2) (De 
Strooper and Annaert, 2000). However, there are no known FAD mutations in these 
two genes. 
Knockout studies in mice shows that a single knockout of APP the gene in 
mice is not lethal. However, these knockout mice display impairment in spatial 
learning and long-term potentiation
 
(LTP). They appear to have reduced locomotor 
activity, reduced weight and eventual reactive gliosis in their brains (Zheng et al., 
1995).  Overexpression of sAPPα, a by-product of APP processing, rescued these 
deficits. This suggests that the ectodomain of APP is sufficient for normal function of 
adult brain (Ring et al., 2007). Conversely, APP-APLP2 and APLP1-APLP2 double 
knockout or APP-APLP1-APLP2
 
triple knockout causes early postnatal lethality 
(Heber et al., 2000). The double knockout mice show neuromuscular defect (Wang et 
al., 2005)while the triple knockout mice display phenotypes that are similar to type II 
lissencephaly(Herms et al., 2004).   
Although the precise physiological role(s) of APP is not well understood, 
experiments indicate that APP and its fragments play an important role in axonal 
transport, cell adhesion, cell survival, cholesterol metabolism, gene transcription and 
cognitive processes(Kamal et al., 2000; Turner et al., 2003). 
APP processing and metabolism 
Upon synthesis, APP is trafficked via a protein secretory pathway to the 
plasma membrane. During this process, it undergoes a series of post-transcriptional 
modifications. APP undergoes N-glycosylation in the endoplasmic reticulum and cis-
Golgi followed by O-glycosylation in medial- and trans-Golgi. The N-glycosylated 
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form of APP is called immature APP (imAPP) while the N- and O- glycosylated form 
is called mature APP (mAPP). APP is then transported to the plasma membrane via 
vesicles. At the membrane, some of the APP undergoes proteolysis while the rest 
undergoes endocytosis into endosome/ lysosome for recycling back to the plasma 
membrane or for degradation. Some of the APP protein internalized in the endosomes 
undergoes proteolysis while the remaining undergoes lysosome-mediated degradation. 
(Kang et al., 1987; King and Scott Turner, 2004; Russo et al., 2001; Suzuki et al., 
1994). 
Once APP reaches the plasma membrane, it can be subjected to Regulated 
Intramemberenous Proteolysis (RIP) which can result in Aβ generation (Brown et al., 
2000; Ebinu and Yankner, 2002; Urban and Freeman, 2002). RIP of APP requires 
successive proteolytic cleavages: the first is the ecto/luminal domain and the second is 
within the transmembrane domain. These two cleavages are performed by three 
distinct proteases called α-, β- and γ-secretases. (Figure1-1) 
The first cleavage occurs at the cell surface by members of “a disintegrin and 
metalloprotease domain” family called α-secretase. ADAM17(Tumor necrosis factor α 
converting enzyme-TACE),  ADAM10, ADAM9, and BACE2 have shown to possess 
α-secretase activity (Lopez-Perez et al., 2001; Buxbaum et al., 1998).  
Proteolysis of APP by α-secretase results in the generation of a large soluble 
extracellular N-terminal fragment (sAPPα), which is 105–125 kDa in size, and an 83 
residue long membrane associated C-terminal fragment (CTF-83), approximately 10-
kDa in size. This secretase cleaves APP in the Aβ domain abolishing Aβ peptide 
generation. Hence this pathway is called the non-amyloidogenic pathway. 
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Alternatively, β-site-APP-cleaving enzyme (BACE), a transmembrane aspartyl 
protease cleaves APP within the luminal/extra cellular domain releasing a soluble APP 
fragment (sAPPβ) leaving behind a membrane associated 99 residue long CTF (CTF-
β). Since BACE has optimal activity at low pH, most of the CTF-β is generated in the 
endosomal compartment while some is generated in the TGN. The CTFs obtained 
from α-secretase- and β-secretase- mediated cleavage is a substrates for the second 
proteolytic cleavage step of RIP, a γ-secretase mediated cleavage.  
γ-secretase mediated cleavage of APP is facilitated by a complex of four 
proteins: presenilin (PS),
 
NCSTN, APH1 and PEN2 (St George-Hyslop, 2000; 
Edbauer et
 
al., 2003; Go et al., 2004). These proteins are mainly located on the plasma 
membrane, in early endosomes (Runz et al., 2002), late endosomes,
 
autophagic 
vacuoles (Yu et al., 2005; Yu et al., 2004), and lysosomes
 
(Pasternak et al., 2003; 
Pasternak et al., 2004; Cupers et al.,
 
2001). 
γ – secretase complex is formed and its enzymatic activity has been detected in 
multiple compartments including the ER, ERGIC, Golgi, TGN, endosomes and the 
plasma membrane. In non-neuronal and neuroblastoma cells, Aβ is primarily 
generated in TGB and endosomes(Small and Gandy, 2006).  γ- secretase mediated 
intramemberaneos cleavage of CTF83 and CTF99 produces P3 and Aβ peptides 
respectively.  
Apart from α- ,β-, and γ- cleavage, APP undergoes PS dependent cleavage at 
the ε- cleavage site. This site is distal to the γ-cleavage site between Leu-49 and Val-
50 (numbered relative to the Aβ sequence). ε- cleavage occurs in the late secretory 
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pathway by γ-secretase and is sensitive to γ-secretase inhibitors (Weidemann et al., 
2002). 
APP contains eight putative phosphorylation sites Y653, S665, T688, Y682, 
T686, and, Y687 respectively in the cytoplasmic and luminal region(based on 
APP695)(Lee et al., 2003b). Phosphorylation at Thr668 is carried out by GSK3β and 
CDK5 in neurons and by  Cdk1/cdc2 in non-neurons (Reviewed in (Suzuki and 
Nakaya, 2008). Thr669 is the major phosphorylation site on APP. Thr668 
phosphorylation is believed to induce a conformation change in the cytoplasmic region 
of APP, resulting in its interaction with Fe65. Fe65 is believed to play an important 
role in signal transduction and gene activation. Intracellular location of Fe65 is 
determined by the phosporylated state of APP at Thr668. Proteolysis of APP by 
caspase-3 and caspase-8 at Asp664 and Ala665 generates a cytotoxic fragment. 
Thr888 phosporylation of APP is believed to prevent this cleavage by caspases 
(Gervais et al., 1999; Taru et al., 2004). 
Thus the phosphorylation state of APP not only modulates its interaction with 
adaptor proteins, it also rescues APP from caspase-mediated cleavage and toxicity. 
α-secretase  
The α-secretases are primarily localized at the plasma membrane and cleaves APP in 
the extracellular domain thereby releasing sAPPα.  Members of the ADAM family (A 
Disintegrin And Metalloprotease) namely, ADAM17, ADAM9, and ADAM10 all 
display α-secretase activity. ADAM10 is constitutively expressed in astrocytes in the 
normal and inflamed human CNS (Kieseier et al., 2003), while ADAM10 and ADAM-
17 have been shown to be highly expressed in microglia (Nuttall et al., 2007). 
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Interestingly, BACE2, is another candidate for α-secretase is found in the 'Down 
critical region' of chromosome 21. Though BACE2 has β-secretase activity, it 
preferentially cleaves within the Aβ region between Phe 19 and Phe 20 thus acting like 
α-secretase (Farzan et al., 2000; Yan et al., 2001). Members of ADAM family of 
proteases mediate proteolytic cleavage of the extracellular ectodomain of membrane-
bound proteins. Once APP reaches the cell surface, it rapidly undergoes processing by 
α-secretase(De Strooper and Annaert, 2000). α-secretase cleaves APP at Lys16-Leu17 
within the Aβ sequence precluding the formation of Aβ and generating sAPPα 
(Figure1-2) (Figure1-3). The soluble fragments released by this mechanism play an 
important role in normal cell functioning like activating cell signaling pathways 
important in development, and the activation of growth factors, and cytokines etc 
(Huovila et al., 2005). 
 Overexpression of ADAM10 in transgenic mice overexpressing APP showed 
an increase in sAPPα levels, a decrease in Aβ levels and a reduction in plaque 
deposition. These mice showed an improvement in long-term potentiation (LTP) as 
well as in cognitive deficits as compared to controls. Conversely, expression of 
catalytically inactive ADAM10 in double-transgenic mice resulted in an enhancement 
of plaque number and size (Postina et al., 2004).  
 α-secretase cleavage can be regulated by the activation of protein kinase C 
(Xu et al., 1995) and is influenced by multiple factors including neurotransmitters, 
growth factors, cytokines, and hormones (Mills and Reiner, 1999). It has been shown 
that ADAM10 activity can be increased by proinflammatory cytokines like TNF-α, 
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IFN-γ and IL-1β, and TGF-β. In human astrocytic cells, α-secretase activity and levels 
of ADAM 10 and ADAM 17 have been shown to be increased by IL-1 α 
(Bandyopadhyay et al., 2006). 
β- Secretase 
BACE1 is the enzyme capable of performing β-secretase cleavage and is also 
just known as BACE (β-site APP Cleaving Enzyme). It is a type-1 transmembrane 
aspartyl protease, ubiquitously expressed in all cell types, though the highest level of 
BACE activity has been observed in tissues and cell lines of neuronal origin. 
Astrocytes show a decreased BACE activity compared to cells of neuronal origin. 
Highest BACE activity was detected within the subcellular compartments of the 
secretory pathway, including the TGN and endosomes. BACE has been shown to 
cleave only membrane-bound substrates or substrates closely associated with a 
membrane-bound protein.  
BACE is a 75kD, 501 amino acid peptide produced in an inactive form (pro-
enzyme). Upon removal of the signal peptide from the pro-enzyme, BACE is cleaved 
by a furine like protease (Bennett et al., 2000). It undergoes complex post-
transcriptional modifications like phosphorylation, N-glycosylation, palmitoylation, 
and pro-peptide cleavage (23 amino acid prodomain is removed by furin or furin-like 
proteases) (Benjannet et al., 2001; Walter et al., 2001). BACE undergoes trafficking 
via a secretory pathway and is then transported to the plasma membrane and clustered 
within lipid rafts (Ehehalt et al., 2003). Mature BACE undergoes internalization with 
APP into the endosomes (Huse et al., 2000; Walter et al., 2001). BACE has the highest 
activity in endosomes as its optimal pH is acidic (~4.5)(Vassar, 2001). Since mature 
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BACE has a long life span, it cycles between the cell surface, endosomal system, and 
through the trans-Golgi network multiple times. BACE mainly localizes in late 
Golgi/TGN and endosomes. BACE1 undergoes degradation by endoproteolysis within 
its catalytic domain, ubiquitin- proteasomal pathway(Qing et al., 2004), and lysosomal 
pathway (Koh et al., 2005). 
BACE cleaves APP at Asp1 or Glu11 (numbering relative to the first amino 
acid in Aβ) releasing soluble fragments sAPPβ and sAPPβ′, respectively (Figure1-2). 
Membrane bound COOH-APP fragment is then cleaved by γ-secretase to release Aβ1-
40 or Aβ11-40(Lee et al., 2003a; Vassar et al., 1999) (Figure1-3). 
 Based on knockout studies in BACE1-/-mice, it was established that BACE1 
was the major β-secretase in the brain. The knockout showed that the absence of 
BACE1 did not adversely affect embryonic development or significantly affect the 
morphology, physiology, biochemistry, or gross behavior of post-natal or adults. 
These mice did not display differences in behavior or in neuromuscular parameters 
when compared to wild type mice. Based on these initial findings it was concluded 
that BACE1 absence did not affect the normal development of embryonic, postnatal, 
or adult mouse. The Swedish APP mutation is a type of FAD mutation which results 
in an enhanced BACE1 activity. Increased activity result in increased Aβ production 
as well as increased number of plaques. Tg2576 which are transgenic mice 
overexpressing Swedish APP (swAPP) produce considerably higher amounts of Aβ 
when compared to wild type mice. Double knock out BACE-/- Tg2576 mice do not 
produce sAPPβ, CTFβ, or any of the forms of Aβ, nor do they produce Aβ plaques 
compared to single knockout BACE+/- Tg2576 or wild type mutant BACE+/+ 
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Tg2576 mice. This suggests that β-secretase activity is required for the production of 
Aβ as well as plaques, and that BACE1 is required for β-secretase activity. 
BACE1 expression has also been associated with stress related events like 
ROS generation and the inflammatory response(Tamagno et al., 2002). 
Proinflammatory cytokines like interferon-γ have been shown to induce BACE1 
expression in cells (Cho et al., 2007). 
γ- Secretase  
γ- Secretase is a high molecular weight multimeric complex composed of the 4 
proteins Presenilin1 (PS1), Pen2, Aph-1 and Nicastrin (NCSTN). The presence of 
these four proteins is required for γ-secretase activity.  
PSs are transmembrane proteins which undergo endoproteolysis within the 
large loop that spans transmembrane helices 6 and 7 to form two fragments: PS1-NTF 
and the PS1-CTF. Although cleaved, the fragments still associate with one another. 
The amounts of PS fragments are highly regulated by unknown mechanisms in cells, 
and excess fragments undergo rapid degradation. Both PS1 and PS2 form independent 
complexes as the endoproteolytic fragments generated from either PS1 or PS2 do not 
interact with fragments of other proteins. Not all mutations in PS1 and its homolog, 
PS2, increase Aβ42 production. Some PS1 mutations have shown to decrease γ-
secretase activity (Kim and Kim, 2008). In the absence of PS1 and PS2, the production 
of Aβ is abolished (Herreman et al., 2000; Zhang et al., 2000). Thus, PS is considered 
to be the catalytic subunit of the complex. Conventional PS1 knockout resulted in 
prenatal death in mice and hence conditional knockout mice are used for PS1 
knockout studies. Forebrain specific PS1 knockout mice are found to be normal except 
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that they exhibit reduced enrichment-induced neurogenesis in the dentate gyrus. The 
PS2 gene was believed to be compensating for the loss of PS1. To obtain complete 
deletion of PS genes, PS2 knockout mice were crossed with conventional PS1 
knockout mice. Severe embryonic lethality at embryonic day 9.5 was observed. This 
indicated that the PS genes are critical for normal embryonic development. In the case 
of adult mice, PS deletion resulted in massive forebrain degeneration (Feng et al., 
2004) 
NCSTN is the second member of the γ-secretase complex. It is a type-1 
transmembrane protein which undergoes glycosylation to form mature NCSTN. The 
mature form of NCSTN interacts with PS1 and is hypothesized to be one of the 
limiting factors of γ-secretase activity. In C. elegans and D. melanogaster, genetic 
ablation of NCSTN results in a phenotype similar to deletion of PS. Overexpression 
PS and NCSTN does not result in increased γ-secretase activity, suggesting that there 
additional limiting factors involved. 
 Two final members of γ-secretase, APH-1 and PEN-2 were identified in C. 
elegans from a genetic screen designed to modify a PS-deficient phenotype (De 
Strooper, 2003; Francis et al., 2002; Goutte et al., 2002). Genetic analysis 
demonstrated that both APH-1 and PEN2 were essential for PS endoproteolysis and γ-
secretase activity(Luo et al., 2003). 
During the assembly of γ-secretase, NCSTN and Aph-1 form a sub complex to 
stabilize PS1. During this process, Aph-1 stabilizes NCSTN. Pen-2 is required for 
endoproteolysis of PS as well as stabilization of the fragments. Reduction in the 
amount of Pen2 results in a buildup of FL PS1. On the other hand, a decrease in PS1 
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levels results in a decrease in Pen2 levels. Aph-1 has been shown to stabilize NCSTN, 
suggesting that Aph-1 functions as a general scaffold for the assembly of γ-
secretase(Edbauer et al., 2002b; Kimberly et al., 2002; Yang et al., 2002). 
Coexpression of all four proteins results in an increase in PS heterodimers, in 
glycosylation of NCT and enhancement of γ-secretase activity. Decrease in the levels 
of any one of the γ-secretase complex proteins has been shown to decrease the levels 
of other proteins of the complex and prevents the maturation of NCSTN, thereby 
decreasing γ-secretase activity. The majority of mature proteins of the γ-secretase 
complex localize in ER-Golgi Intermediate Compartment, Golgi, TGN, and 
endosomes. It has been shown that the γ-secretase complex is localized in an active 
form in the ER, late-Golgi/TGN, endosomes, and plasma membrane. It is estimated 
that only 6% of the γ-secretase activity occurs on the cell surface and most of the Aβ 
is generated in the TGN. This is likely due to APP trafficking through secretory and 
endosomal pathways(Tang and Liou, 2007). 
γ-secretase mediated cleavage of C83 and C99 results in the production of P3, 
Aβ and AICD fragments (Figure1-1).γ-secretase is responsible for cleaving many 
substrates including ErbB4, Notch, D- and E-cadherins, LRP (low-density-lipoprotein 
receptor protein), CD44 and syndecan-3. Many of its targets play a critical role in 
development which makes γ-secretase a difficult drug target. 
Aβ metabolism 
Aβ peptide exists as multiple peptides of different sizes ranging from 38 to 43 
amino acids, Aβ40 and Aβ42 being the two predominant forms. In the CSF, 90-95% 
of secreted Aβ is Aβ40 while only 10% is Aβ42. The exact mechanism by which these 
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peptides are generated is not well understood (Zhao et al., 2007). The main constituent 
of amyloid plaques is Aβ42 which is deposited initially, perhaps because of its ability 
to form insoluble aggregates, more rapidly than Aβ40. 
 In AD brain, Aβ has been shown to accumulate both inside (intracellular Aβ) 
as well as outside (extracellular Aβ) the neurons. Extracellular plaques are thought to 
be cause inflammation, oxidative stress, and apoptosis thereby resulting in synaptic 
and neuronal loss, while intracellular Aβ in the neurons is thought to cause 
neurotoxicity. Intracellular Aβ oligomers are suspected to be the source of 
extracellular diffusible or fibrillar plaques found in AD brain (Walsh et al., 2000). 
Cognitive defects have been reported in animal models in the presence of intracellular 
Aβ even though extracellular plaques are absent. This suggests that intracellular Aβ 
results in toxicity before it is released to form plaques. Soluble Aβ42 monomers form 
soluble oligomers that can eventually diffuse into synaptic clefts. 
In human brain, the number of Aβ plaques does not correlate well the with 
severity of dementia. However, a robust correlation between soluble Aβ levels and the 
extent of synaptic loss and severity of cognitive impairment has been shown (Lue et 
al., 1999; McLean et al., 1999; Walsh et al., 2002). In a normal rodent hippocampus, 
Aβ oligomers have been shown to inhibit long-term potentiation (LTP), enhance long-
term depression (LTD) and reduce dendritic spine density (Shankar et al., 2008). 
 Aβ is believed to be generated in the endosomal-lysosomal compartments and 
precedes its extracellular deposition. An intracellular Aβ pool has been proposed to 
interact with surface receptors, affecting the membrane lipid bilayer
 
directly. 
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However, the exact mechanism by which Aβ causes neurotoxicity and neuronal loss is 
not completely understood (Gouras et al., 2005).  
Not much is known about the normal role of Aβ in the brain. Aβ40 is 
suggested to act as a cellular antioxidant while both Aβ40 and 42 have been suggested 
to modulate potassium channels in neurons (Plant et al., 2003).  In rodents, Aβ 
oligoments have been shown to inhibit long-term potentiation (LTP), enhance Long-
term depression (LTD) and reduce dendritic sipine density in the hippocampus. 
Soluble Aβ peptide has been shown to distupt memory of rearned behaviour in rats 
(Matos et al., 2008). 
Aβ undergoes catabolism by proteases and peptidases. Some of the Aβ 
degrading candidate genes are Neprilysin (NEP), IDE, Endothelin-Converting Enzyme 
(ECE)-1, Angiotensin-Converting Enzyme (ACE) and plasmin tissue Plasminogen 
Activator (tPA), and urokinase-type plasminogen Activator (uPA) system(Wang et al., 
2006).  
APP/AICD mediated Nuclear Signaling 
In addition to Aβ, γ-secretase cleavage of APP results in formation of of APP 
IntraCellular Domain (AICD). AICD is produced in both amyloidogenic and non-
amyloidogenic pathways and therefore corresponds to the total amount of APP being 
γ-secretase processed. There are various AICD isoforms corresponding to different 
cleavage sites on APP. AICD59 and AICD57 correspond to γ-secretase cleavage that 
also produces β40 and Aβ42, respectively (Sastre et al., 2001). AICD48 (Yu et al., 
2001) and AICD51 (Sato et al., 2003)are suggested to be released by ε-cleavage 
mediated by γ-secretase. AICD31 is produced by cleavage of APP by caspase (Lu et 
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al., 2000). All these isoforms have been detected in cell culture and animal models. 
However, all these isoforms contain the YENPTY motif that is required for interaction 
of AICD with different adaptor proteins. Phosphorylation of AICD has been shown to 
modify its binding affinity with these adaptor proteins. T668 is believed to modify the 
interaction of AICD with Fe65.This is, however, controversial as both diminished 
binding(Ando et al., 2001) and elevated interaction (Chang et al., 2006)have been 
reported upon T668 phosphorylation. Y682 phosphorylation is another important 
phosphorylation site in AICD.  Point mutation of Y682 completely abolishes AICD-
mediated transcriptional activation (Scheinfeld et al., 2002). APP is also at 
phosporylated S0655 and T654 (Gandy et al., 1988). The functional impact of this 
phosphorylation is not known. AICD is difficult to study because of its small size and 
its rapid degradation. 
              AICD binds to adaptor proteins like PAT, NUMB, PIN1, FKBP12, 
SHCA/SHCC and with members of  X11, Fe65, MINT, PAT and JIP families of 
proteins (Reviewed in (Muller et al., 2008).  Genes proposed to be regulated by 
AICD-mediated transactivation include the prostate cancer anti-metastasis gene 
(KAI1),involved with motility, invasion, signaling, suppressor of tumor metastasis); 
glycogen synthase kinase 3β (GSK3β), involved with tau phosphorylation; BACE and 
Neprilysin involved with Aβ degradation; p53involved with tumor suppression; HES1 
involved with differentiation; and LRP1, EGFR, ACE1, and ACE2 involved with 
thymidylate synthase (Kim et al., 2003; Sapountzi et al., 2006; Ryan and Pimplikar, 
2005; Hebert et al.., 2006,reviewed in (Muller et al., 2008)).  
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The GYENPTY motif of AICD binds to the phosphotyrosine binding domain 2 
(PTB2) of FE65, an adaptor protein. FE65 is also believed to prevent the rapid 
degradation of AICD by the proteasome or insulin-degrading enzyme (IDE). In the 
nucleus, AICD and Fe65 are thought to form a complex with the histone acetyl-
transferase tat-interactive protein (Tip60) (Cao and Sudhof, 2001, 2004). This 
complex is shown to activate transcription.  However, this model is controversial. 
There are several other models that exist. The main difference between all the models 
is the cellular compartment in which the AICD, Fe65 and Tip60 interact. Most of the 
evidence supporting these models comes from studies that use artificial reporter 
systems in cell lines overexpressing AICD or full length APP. These models have 
been  reviewed very well by Muller et al (Muller et al., 2008). However, all the 
models require AICD, Fe65 and Tip60 for transcriptional activation.  
Deletion of two members of the FE65 family, Fe65 and Fe65L1 results 
substantial neurodevelopmental defects, a phenotype similar to what is observed in 
knockout of APP family members(Heber et al., 2000). 
This suggests that APP is an important component of a signal transduction 
pathway (Guenette et al., 2006; Suzuki et al., 2006). Therefore, differences in AICD 
mediated signaling may be an important component of AD pathophysiology.  
Modulation of APP metabolism 
Research conducted over the past two decades has demonstrated that Aβ 
oligomerization initiates a chain of events that results in oxidative stress and 
inflammation that eventually results in neuronal dysfunction and pathological 
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characteristics of AD. Intracellular as well as extracellular Aβ levels are direct related 
to APP metabolism. Changes in APP metabolism at the transcriptional and 
translational level can result in altered Aβ production. Following are a few examples 
of how alteration of APP and/or secretase metabolism result in altered Aβ production. 
 SORL1 (sortilin-related receptor, L (DLR class) A repeats-containing) is 
known to modulate APP trafficking. This gene is highly expressed in the brain and is 
specifically involved in neuronal transport processes within the trans-Golgi network 
and endosomes. It has been shown that SORL1 interacts and modulates trafficking of 
APP. It acts as a gatekeeper for α- and β- secretase-mediated pathways and determines 
the cellular destination for APP. During APP processing, some of the mature APP 
undergoes re-internalization from the plasma membrane and is delivered to the late 
endosome for processing by β- and γ-secretase to produce sAPPβ and Aβ. Binding of 
SORL1 to APP results in a decrease of sAPPβ and Aβ. SORL1 directs APP into the 
recycling pathway away from the endosomes (Rogaeva et al., 2007). By enhancing the 
trafficking of APP to the cell surface, SORL1 seems to favor the nonamyloidogenic 
pathway. In SORL1 deficient mouse model, more APP enters the amyloidogenic 
pathway, resulting in higher concentrations of sAPPβ and Aβ. Thus, SORL1 protects 
APP from β-secretase activity (Spoelgen et al., 2006). Variants in SORL1 have been 
reported to be associated with LOAD. These variants are believed to regulate tissue-
specific expression of SORL1. SORL1 neuronal expression is reduced in LOAD 
patients. The neuronal expression of SORL1 correlated with overall performance on 
two psychometric measures in these patients (Rogaeva et al., 2007). Taken together, 
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neuropathological and functional experiments implicate SORL1 with AD 
pathogenesis.  
UBIQLN1 is another gene that can regulate APP metabolism. The gene is 
located on chromosome 9q22, a locus implicared in numerous genetic linkage studies 
to AD (Blacker et al., 2003b; Kehoe et al., 1999; Myers et al., 2000; Myers et al., 
2002a; Pericak-Vance et al., 1997; Pericak-Vance et al., 2000; Rogaeva et al., 1998). 
UBQLN1 is an ubiquitin-like (UBL) protein with a UBL
 
and ubiquitin-associated 
(UBA) domains in its N and C termini,respectively. Ubiquilin-1 has been shown to 
modulate endoproteolysis of PS protein. Over expression of Ubiquilin 1 and Ubiquilin 
2 in HEK293 results increased accumulation of FL-PS, and decreased PS-NTF and 
PS-CTF, Pen2 and NCSTN levels. Conversely, knockdown of UBQLN1 and 
UBQLN2 results in increased PS-NTF, PS-CTF, Pen2, and NCSTN levels. This 
suggests that Ubiquilin regulates the γ-secretase complex (Massey et al., 2005).  
UBQLN1 has also been shown to affect APP levels. Knockdown of UBQLN1 in 
human embryonic kidney (HEK293) and H4 cells (human neuroglioma) cells results 
in an increase in the rate of APP maturation
 
and trafficking through the secretory 
pathway, resulting in an increased
 secretion of sAPP and Aβ. However, Hiltunen et al 
did not see any change in secretase levels or activity upon knocking down UBQLN1 
(Hiltunen et al., 2006). In SH-SY5Y cells, knock-down of UBQLN1 decreased total, 
mature, and immature full-length APP, sAPPα, C83 and AICD steady-state levels and 
the ratio of mature to immature APP, while over-expression increased these same 
steady-state levels. In addition, Ubiquilin 1 over-expression increased PS1 
endoproteolysis. However, the opposite effects on APP and presenilin metabolism 
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were observed in HEK-293 cells(Zhang et al., 2007). This could be due to inherent 
differences in these two cell types. 
In D. melanogaster, loss of Ubiquilin (Ubqn) suppresses the phenotype that 
arises from loss of Presenilin
 
(Psn) function. UBQLN1 Overexpression of Ubqn in the 
eyes results in an γ secretase-dependent retinal degeneration of apoptotic nature. The 
retinal degeneration caused by ubqn overexpression was suppressed when Psn was 
overexpressed and enhanced when a dominant negative Psn was expressed(Ganguly et 
al., 2008). UBQLN1 has been shown to regulate proteasomal degradation of proteins 
like cyclin A, γ-aminobutyric acid receptor, and hepatitis C virus RNA-dependent 
RNA polymerase proteins (Hiltunen et al., 2006).  
In the brains of AD patients, there is increased Ubiquilin 1 in neurons 
containing neurofibrillary tangles (NFTs), as compared to non-AD brains(Mah et al., 
2000). A polymorphism in the UBQLN1 gene has been shown to increase AD risk in 
family-based and large case-control samples (Bertram et al., 2005; Kamboh et al., 
2006; Slifer et al., 2005)  
All the genes identified to date that are associated with AD have mutations that 
predisposes individual to altered APP and Aβ metabolism. The amount of neurotoxic 
Aβ is determined by (1) Aβ production via APP metaboism and (2) Aβ degradation 
and clearance. Another protease that is involved with AD is Insulin Degrading 
Enzyme (IDE). IDE is located on chromosome 10 in a region that has been associated 
with AD and potentially harbors novel genes for LOAD. This protein has been shown 
to degrade insulin, amylin and Aβ, and has been hypothesized as a candidate gene for 
both type 2 diabetes and AD (Ling et al., 2003). IDE is a neutral thiol metalloprotease 
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which requires both thiol and bivalent cations like zinc for its activity(Ogawa et al., 
1992). Knockout of IDE in mice results in hyperinsulinemia, glucose intolerance, 
elevated levels of soluble Aβ and a substantial increase APP-CTFs in the brain 
(Venugopal et al., 2007). Both in vitro and in vivo data suggests that IDE participates 
in the degradation of Aβ and in regulating its physiological levels(Qiu et al., 1998). 
Several studies have reported an association between IDE haplotypes and SNPs within 
the IDE gene and AD (Miners et al., 2008; Vepsalainen et al., 2007). Conversely, 
there are studies that found no significant association. In hippocampus and cortex of 
sporadic AD samples, expression and activity of IDE has been reported to be reduced 
(Miners et al., 2008). It has been proposed that the decrease in IDE activity may be 
accounted by lower IDE mRNA levels. 
Apart from genetic factors, environmental exposures to metals and oxidative 
stress have also been suggested to contribute to AD pathology. There are multiple 
studies focusing on the involvement of metals like Al, Hg, Pb, Fe, Cu, and, Zn with 
AD. Aβ and APP metabolism appear to be sensitive to regulation by  and may be 
involved with AD pathogenesis (Huang et al., 2004). It has been suggested that 
dysregulation of cerebral biometal dysregulation can promote AD. 
Brain normally concentrates metals like Cu, Fe and Zn in the neocortex. It has 
been suggested that cerebral homeostasis of these metal ions are closely associated 
with the disease (Lovell et al., 1998). Lee, et al showed that endogenous synaptic Zn 
contributed to cerebral Aβ deposition in a transgenic AD mice model lacking Zinc 
transporter3 (Lee et al., 2002). Trace amounts of Cu when fed to AD rabbit have been 
shown to induce amyloid plaques and learning deficits (Sparks and Schreurs, 2003). 
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Copper depletion has also been shown to down-regulate APP expression. In APP 
knock-out mice, cellular copper levels are increased in primary cortical neurons and 
embryonic fibroblasts. Interestingly, a reduction in Aβ plaque burden was observed in 
vivo upon both dietary Cu exposure and elevation of endogenous Cu (Bayer et al., 
2003; Phinney et al., 2003). In AD brain, the imbalance in Fe and Cu ions may result 
in the generation of reactive oxygen species (ROS), DNA oxidation and lipid 
peroxidation (Mecocci et al., 1994). Data suggests that elevated oxidative stress is due 
to the interaction between Aβ and redox active metals (Huang et al., 2004). All this 
suggests a complex role of Cu in APP metallobiology. However, more work needs to 
be done to identify the mechanism by which these metal ions are involved with the 
disease (Liu et al., 2006).  
Calcium is another biometal that has drawn a lot of attention recently in the 
AD field. The levels of free calcium, protein bound calcium (Palotas et al., 2002) as 
well as calcium dependent transglutaminase activity (Johnson et al., 1997) were found 
to be elevated in AD brain samples. In APP knockdown cells, a decrease in the release 
of calcium from intracellular stores is observed (Rojas et al., 2008). This disturbance 
was rescued by overexpression of APP fragments containing the AICD sequence, 
showing a tight link between calcium and AICD levels. Recently, Cho et al showed 
that intracellular calcium regulates BACE1 expression. The BACE1 expression was 
shown to be regulated by nuclear factor activated T cells 1 (NFAT1) signaling, which 
is controlled by a calcium- dependent protein phosphatase, CaN (Cho et al., 2008). 
These are a few examples of mechanisms by which APP processing and Aβ 
generation, secretion, or degradation can be modulated by diverse classes of proteins. 
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Therefore, it is important to identify regulators which upon being mis-regulated 
increase or decrease APP metabolism and Aβ levels. So far, only three genes have 
been identified, mutations in which results in the rare, autosomal dominant Early-
Onset form of AD (EOAD). Mutations in β-amyloid precursor protein (APP) (Goate et 
al., 1991), presenilin1 (PSEN1) (Sherrington et al., 1995), and presenilin2 (PSEN2) 
(Levy-Lahad et al., 1995) result in increased Aβ42 peptide production.Aβ42 is the 
main component of amyloid plaques. However, the majority of the AD cases occurs 
after 65 years of age and is referred to as Late Onset Alzheimer’s disease (LOAD). 
The genetic basis of LOAD has been extensively investigated and only one gene has 
been universally identified as a risk factor, the ε4 allele of the APOE gene (Corder et 
al., 1993). APOE however does not account for all the LOAD cases. This led to the 
hypothesis that there are additional genes yet to be identified that contribute to LOAD 
(Kamboh, 2004). 
 Since APP metabolism is so closely involved with Aβ production and AD, it is 
important to identify regulators of APP metabolism. For this purpose, we utilized the 
transcriptional activity of AICD to identify APP metabolism regulators.  Cao and 
Sudhof demonstrated that AICD forms a multimeric complex with Fe65 and Tip60 to 
activate transcription (Cao and Sudhof, 2001). They created a APP695 fusion with the  
Gal4 DNA- binding domain (Figure1-4, Figure1-5). This hetrologous domain was 
sandwiched between the Aβ and AICD sequences (APP-Gal4). APP-Gal4 undergoes 
normal proteolysis by α-, β-, and γ-secretase to produce AICD-Gal4, which forms a 
complex with endogenous Fe65 and Tip60 to activate transcription of a firefly 
luciferase gene under the control of Gal4 –UAS (GAL4-UAS-LUC) (Figure1-6). 
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Disruption of the AICD-Gal4/ FE65 interaction via mutagenesis within AICD 
abolishes transcriptional activation. Coexpression of mutant form of APP-Gal4, 
APP*-Gal4 (mutation in AICD-Fe65 binding site) and GAL4-UAS-Luc abolished 
luciferase activity. Similarly, co-expression Gal4 and GAL4-UAS-Luc also failed to 
generate luciferase activity. For identification of modulators of APP processing 
/metabolism, we will utilize the transcriptional activation properties of AICD to create 
a luciferase based reporter of APP metabolism. This assay will provide an easy and 
quick means to identify genes that regulate APP metabolism. 
It has been shown that both amyloidogenic and non-amyloidogenic cleavage 
pathways are conserved in both neuronal and non-neuronal cells. However, the 
intracellular sites of APP processing are cell type dependent. Non-neuronal cells 
prefer the non- amyloidogenic processing pathway while neuronal cell lines do not 
prefer the same. Hence, non-neuronal cell lines are not a significant source of Aβ. 
Since we are focusing on identification of regulatory genes that modulate Aβ 
production, we chose SH-SY5Y cells, which are a human brain neuroblastoma cell 
line that is widely used. We established and validated this reporter assay in SH-SY5Y 
cells. We then knocked down candidate genes located in the chromosome 10q21-26 
and monitor luciferase activity. Genes that significantly increase or decrease luciferase 
activities were considered as putative candidate genes. These genes were subjected to 
a secondary assay to confirm their role as APP metabolism regulators.  
Since cell lines do not accurately depict the actual physiology of neurons in the 
brain, we began to use AD animal models to further confirm the mechanisms by which 
these genes modulate APP metabolism. Specifically, we are using Drosophila as a 
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model system to study AD. Drosophila endogenously produces all the four 
components of γ-secretase complex. Moreover, expression of human APP in D. 
melanogaster results in processing the activity of an endogenous γ-secretase 
(Fossgreen et al., 1998; Guo et al., 2003). Thus D. melanogaster is an excellent tool to 
study neurodegeneration (Marsh and Thompson, 2006; Sang and Jackson, 2005). We 
utilized the previously created D. melanogaster γ-secretase reporter flies (Gross et al., 
2008; Guo et al., 2003).  These flies express a C99-Gal4 fusion protein in the 
developing retina (Gross et al., 2008; Guo et al., 2003).  Proteolytic processing of this 
fusion protein is carried by endogenous secretase activity in the fly retina (Gross et al., 
2008; Guo et al., 2003). Processing releases the AICD-Gal4 fragment that  activates 
the transcription of a cell death activator called Grim (Chen et al., 1996). Expression 
of Grim causes apoptosis in the eye. Apoptosis results in a rough eye phenotype, loss 
of pigmentation, disrupted bristle morphology. This reporter fly, then, allowed us to 
validate and confirn the results we obtained in the cell culture model. 
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Figure 1-1:  APP processing.  
Biochemical pathways leading to the formation of Aβ from APP.  APP undergoes α 
and β cleavage of to produce a large, soluble ectodomain (sAPPα and sAPPβ) and a 
membrane-associated carboxy-terminal fragment (CTF83, CTF88, CTF99). Cleavage 
of APP by α-secretase precludes production of Aβ. CTFs undergo γ-secretase cleavage 
to produce small peptides (Aβ and p3). 
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Figure 1-2: AD Linkage regions on chromosome 10.  
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Table 1-1: Genes implicated in abnormal APP metabolism 
 
 
 
 
 
Figure 1-3: Sites of processing of APP by secretases 
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Figure 1-4: APP-Gal4 fusion protein utilized for luciferase reporter assay.  
 
 
 
Figure 1-5: APP-Gal4 fusion amino acid sequence 
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Figure 1-6: Luciferase based reporter assay:  
Model depicting APP-Gal4 reporter system. Firefly luciferase activity is significantly 
increased in SH-SY5Y cells stably expressing APP-Gal4 and Gal4-UAS Luciferase 
compared to SY5Y cells stably expressing either Gal4 / Gal4-UAS Luciferase or 
APP*-Gal4 / Gal4-UAS Luciferase. 
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Chapter 2 : An AICD-based functional screen to identify APP metabolism 
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Abstract 
Background. A central event in Alzheimer’s disease (AD) is the regulated 
intramembraneous proteolysis of the -amyloid precursor protein (APP), to generate 
the -amyloid (A ) peptide and the APP intracellular domain (AICD). A  is the major 
component of amyloid plaques and AICD displays transcriptional activation 
properties. We have taken advantage of AICD transactivation properties to develop a 
genetic screen to identify regulators of APP metabolism. This screen relies on an APP-
Gal4 fusion protein, which upon normal proteolysis, produces AICD-Gal4. Production 
of AICD-Gal4 induces Gal4-UAS driven luciferase expression. Therefore, when 
regulators of APP metabolism are modulated, luciferase expression is altered.  
Results. To validate this experimental approach we modulated -, -, and -
secretase levels and activities. Changes in AICD-Gal4 levels as measured by Western 
blot analysis were strongly and significantly correlated to the observed changes in 
AICD-Gal4 mediated luciferase activity. To determine if a known regulator of APP 
trafficking/maturation and Presenilin1 endoproteolysis could be detected using the 
AICD-Gal4 mediated luciferase assay, we knocked-down Ubiquilin 1 and observed 
decreased luciferase activity. We confirmed that Ubiquilin 1 modulated AICD-Gal4 
levels by Western blot analysis and also observed that Ubiquilin 1 modulated total 
APP levels, the ratio of mature to immature APP, as well as PS1 endoproteolysis.  
Conclusions. Taken together, we have shown that this screen can identify 
known APP metabolism regulators that control proteolysis, intracellular trafficking, 
maturation and levels of APP and its proteolytic products. We demonstrate for the first 
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time that Ubiquilin 1 regulates APP metabolism in the human neuroblastoma cell line, 
SH-SY5Y.  
 
Background 
Alzheimer’s disease (AD) is characterized by significant accumulation of cerebral 
amyloid plaques and intraneuronal neurofibrillary tangles. Amyloid plaques are 
composed mainly of the -amyloid peptide (A ). A  is a normal product of amyloid 
precursor protein (APP) metabolism. Several genes have been identified encoding 
enzymes that directly metabolize APP to generate A ; however, it is not fully 
understood how APP metabolism is regulated. Here we describe and validate a novel 
experimental approach for identifying genes encoding regulators of APP metabolism.   
A  is generated by the successive proteolytic processing of APP, a process 
referred to as regulated intramembrane proteolysis (RIP) (Brown et al., 2000; Ebinu 
and Yankner, 2002; Urban and Freeman, 2002). RIP occurs when a transmembrane 
protein is cleaved within the transmembrane domain, releasing a cytoplasmic fragment 
that can activate gene expression in the nucleus (Ebinu and Yankner, 2002). RIP 
requires two cleavage events; the first, outside the membrane, often in response to 
ligand binding, can trigger the second, intramembraneous, cleavage. RIP liberates 
small, intracellular protein domains that are involved in nuclear signaling processes 
(Ebinu and Yankner, 2002; Urban and Freeman, 2002). Therefore, regulation of RIP is 
critical for controlling nuclear signaling. Identifying the regulatory mechanisms 
controlling these proteolytic steps is important for a fuller understanding of these 
processes. 
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APP is a type I transmembrane glycoprotein and is suggested to function in 
neuroprotection, synaptic transmission, signal transduction, and axonal transport 
(Annaert and De Strooper, 2002; Sisodia, 2002). Upon being synthesized, APP 
undergoes maturation in the protein secretory pathway. APP is N-glycosylated in the 
ER and cis-Golgi followed by O-glycosylation in medial- and trans-Golgi. RIP of APP 
can occur via two alternative routes: amyloidogenic and non-amyloidogenic. In 
amyloidogenic processing, APP undergoes sequential cleavage by -secretase (BACE) 
and -secretase to generate A  (Hardy and Selkoe, 2002). BACE cleavage occurs in 
the APP extracellular domain to produce a soluble extracellular fragment called 
sAPP  and a membrane associated, 99-residue C-terminal fragment called C99 
(Vassar et al., 1999) The C99 fragment is a substrate for subsequent cleavage by the -
secretase complex (Edbauer et al., 2003; Kimberly et al., 2003). The active -secretase 
complex is composed of the amino- and carboxy-terminal fragments of presenilin1 
(PS1), a highly glycosylated form of nicastrin (NCSTN), Aph1  and Pen-2 (Edbauer 
et al., 2003; Kimberly et al., 2003). The amino- and carboxy –terminal fragments of 
PS1 (~27 and ~17 kDa respectively) are derived by endoproteolytic cleavage of the 
inactive, full length PS1 protein within the large hydrophilic loop that spans between 
transmembrane helices 6 and 7 and are thought to interact with each other (Thinakaran 
et al., 1996). The products of -secretase cleavage are the cytoplasmic APP 
Intracellular Domain (AICD) fragment and A  peptides of varying length, mainly 40 
and 42 residues long (Gu et al., 2001; Sastre et al., 2001; Yu et al., 2001). In non-
amyloidogenic processing, the initial extracellular cleavage of APP is catalyzed by 
one of a group of proteases termed -secretases. These enzymes include ADAM9, 
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ADAM10, and ADAM17 (TACE). -secretase cleavage produces a soluble 
extracellular fragment called sAPP  and a membrane associated, 83-residue C-
terminal fragment called C83. This C83 fragment is then cleaved by the -secretase 
complex to produce AICD and a p3 peptide, which is not involved in amyloidogenesis 
(Hardy and Selkoe, 2002). 
A common feature of RIP processing is the liberation of an intracellular protein 
domain that initiates nuclear signaling (Ebinu and Yankner, 2002; Urban and 
Freeman, 2002). In the case of APP processing, nuclear signaling can be initiated by 
the production of the intracellular AICD fragment. Once generated by -secretase, the 
AICD fragment can be stabilized and transported to the nucleus by the cytoplasmic 
adaptor protein Fe65 (Cupers et al., 2001; Kimberly et al., 2001). Upon entering the 
nucleus the AICD/Fe65 complex can form a tripartite, transcriptionally active complex 
with the histone acetyltransferase Tip60 (Cao and Sudhof, 2001, 2004). Consistent 
with this model, cells concomitantly over-expressing an APP-Gal4-DNA binding 
domain fusion protein and Fe65, and carrying a Gal4 UAS-driven reporter construct 
display a >2000 fold increase in reporter transcription compared to cells over-
expressing just the Gal4 DNA binding domain and Fe65 (Cao and Sudhof, 2001). This 
increase in transactivation activity is dependent on Tip60 and can be abolished when 
the interaction between AICD and Fe65 is disrupted by mutagenesis of the AICD 
NPTY motif, the binding site for Fe65 (Cao and Sudhof, 2001). However, these data 
do not rule out a possible effect of full-length APP in inducing nuclear signaling. 
Indeed, APP nuclear signaling can occur in the absence of -secretase activity and 
therefore does not require the AICD fragment (Hass and Yankner, 2005). The relative 
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contribution of AICD-mediated versus holo-APP mediated nuclear signaling is not 
clear at this time (Cao and Sudhof, 2001, 2004; Hass and Yankner, 2005). 
The genomic targets of AICD- or APP-mediated nuclear signaling are not clearly 
defined. APP, BACE, Tip60, GSK-3 , Mn-SOD, KAI1, NEP and other genes have all 
been reported to be targets of APP mediated transcriptional activation (Baek et al., 
2002; Creaven et al., 1999; Pardossi-Piquard et al., 2005; von Rotz et al., 2004); 
however, there is a paucity of confirmatory reports (Hass and Yankner, 2005). At this 
time, the biological role of AICD-mediated transactivation is not clear (Chen and 
Selkoe, 2007; Herz, 2007; Pardossi-Piquard et al., 2005). Despite this confusion, 
evidence suggests that defective APP signaling is involved in AD pathogenesis (Chen 
et al., 2002a; Moehlmann et al., 2002; Saura et al., 2004; Schroeter et al., 2003; Song 
et al., 1999).   
Given the centrality of APP in AD, it is crucial to identify regulators of APP 
metabolism, including, but not limited to, APP proteolysis. Regulation of APP 
metabolism can occur by numerous mechanisms, including regulation of APP 
transcription, APP translation, APP maturation, intracellular trafficking of full-length 
APP and APP cleavage products, APP proteolysis, and APP degradation. While 
Komano and colleagues have used a genetic screen to specifically identify regulators 
of -secretase activity (Komano et al., 2002), a screen that will identify APP 
metabolism regulators that act through multiple mechanisms is needed.  
Here we describe a novel experimental approach to identify a variety of regulators 
of APP metabolism. We use an AICD-Gal4 mediated luciferase expression assay as a 
general reporter of APP metabolism in the human neuroblastoma cell lines, SH-SY5Y. 
  39 
To validate this assay, we utilized pharmacologic agents, as well as forward and 
reverse genetics, to modulate APP proteolysis, AICD trafficking and AICD 
transactivation. To determine if regulators of APP maturation and PS1 endoproteolysis 
also can be detected with this screening approach, we knocked-down Ubiquilin 1 and 
observed decreased AICD-Gal4 luciferase activity. Using Western blot analysis, we 
show that Ubiquilin 1 controls APP levels, the ratio of mature to immature APP, as 
well as presenilin1 endoproteolysis, confirming the previously reported role of 
Ubiquilin 1 in APP and presenilin1 metabolism in non-neuronal human cell lines 
(Hiltunen et al., 2006; Mah et al., 2000; Massey et al., 2004; Massey et al., 2005). 
Taken together, our results validate the use of the AICD-Gal4 mediated luciferase 
assay in combination with forward and reverse genetics as a screen to identify APP 
metabolism regulators. 
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Results 
Establishment of a functional assay to identify APP metabolism regulators. 
We utilized the APP-Gal4 / Gal4-UAS luciferase reporter system (Figure 1A) 
developed by Cao and Südhof (Cao and Sudhof, 2001). We established this assay 
system in our laboratory by creating a SH-SY5Y, human neuroblastoma, cell line that 
stably expresses the assay components. Three different stable cell lines have been 
generated; all stably carry a luciferase reporter gene under the control of the Gal4-
UAS (Gal4-UAS luciferase). In addition to this reporter gene, one cell line expresses 
the Gal4 DNA binding domain alone (SY5Y-Gal4), the second cell line expresses 
APP695 fused to the Gal4 DNA binding domain (SY5Y-APP-Gal4), and the third cell 
line expresses a mutated version of APP695-Gal4 (SY5Y-APP*-Gal4). This mutation 
in APP alters the NPTY motif (P685A; Y687A) and disrupts Fe65 binding to this site 
(Cao and Sudhof, 2001). Once these cells were established, luciferase assays were 
performed to determine the relative luciferase activity of the cell lines (Figure 1B). 
SY5Y-APP-Gal4 cells have a statistically significant (p < 0.01) ~20 fold increase in 
luciferase activity compared to SY5Y cells expressing either Gal4 or APP*-Gal4.  
Pharmacologic modulation of - and -secretase activity alters AICD-Gal4 
mediated luciferase activity. To determine if monitoring AICD-Gal4 mediated 
luciferase activity is a valid method to detect alterations in APP metabolism, we used 
pharmacologic agents known to modulate APP proteolytic processing and compared 
the effects of these agents on levels of APP proteolytic products and AICD-Gal4 
mediated luciferase activity.  To accomplish this, we treated our SY5Y-APP-Gal4 
cells with pharmacologic modulators of -, -, and -secretase activity and measured 
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the effects using Western blot analyses for APP cleavage products as well as AICD-
Gal4 mediated luciferase activity.  
L-685,458 is a transition state inhibitor of -secretase that prevents A  and 
AICD generation (Tian et al., 2003). We treated SY5Y-APP-Gal4 cells with L-
685,458 (2.5 M for 10 hours) or with vehicle (DMSO) and collected cell lysates. We 
performed Western blot analysis on these cell lysates using an antibody to the C-
terminus of human APP. In vehicle treated cells we observe bands migrating at ~28 
and ~26 kDa (Figure 2A). Cao and Sudhof observed a similar doublet at 
approximately the same relative molecular weight. They identified these bands as 
C83-Gal4 and AICD-Gal4, respectively. In L-685,458 treated cells the intensity of the 
C83-Gal4 band is significantly increased seven-fold (p<0.01) and the AICD-Gal4 
band is significantly decreased by 80% (p<0.01; Figure 2B). These results are 
consistent with the substrate / product relationship between C83-Gal4 and AICD-Gal4. 
The size difference between C83-Gal4 and AICD-Gal4 is what is expected for -
secretase cleavage of C83-Gal4. It is also interesting to note that AICD is normally 
difficult to detect by Western blot analysis, however the AICD-Gal4 fusion levels are 
quite high. This suggests that AICD-Gal4 catabolism by IDE and/or other proteases is 
greatly reduced compared to unmodified AICD (Edbauer et al., 2002a). 
L-685,458 treatment of SY5Y-APP-Gal4 cells results in a concentration-
dependent decrease in AICD-Gal4 mediated luciferase activity; at a concentration of 
2.5 M there is a ~75% decrease in luciferase activity (Figure 2). The L-685,458 
concentration required for 50% inhibition of AICD-Gal4 mediated luciferase activity 
is 1.25 M.  
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The phorbol ester, PMA (phorbol 12-myristate 13-acetate), stimulates -
secretase activity (Allinson et al., 2004). Treatment of SY5Y-APP-Gal4 cells with 
PMA (1 M for 10 hours) increased levels of the -secretase cleavage products 
sAPP  and C83-Gal4, four-fold and two-fold, respectively (p < 0.01; Figures 2D & 
2E). In addition, Western blot analysis revealed a two-fold increase in AICD-Gal4 
levels (p < 0.01; Figure 2D & 2E). This two-fold increase in AICD-Gal4 levels 
suggested that a similar PMA-induced increase in AICD-Gal4 mediated luciferase 
activity should be observed. Indeed, when we measured luciferase activity as a 
function of increasing PMA concentration (Figure 2F), we observed a dose-dependent 
increase in luciferase activity. The PMA-induced increases in luciferase activity 
plateaus at 50 nM PMA. At concentrations of 50 nM and higher, we observed 
approximately a two-fold increase in AICD-Gal4 mediated luciferase activity in close 
agreement with the observed two-fold increase in AICD-Gal4 by Western blot 
analysis.  
TAPI-1 (Tumor necrosis factor-  protease inhibitor 1) inhibits -secretase 
mediated shedding of the APP ectodomain (Slack et al., 2001). Treating the SY5Y-
APP-Gal4 cells with TAPI-1 (20 M for two hours; Figure 2G & 2H) resulted in a 
modest, yet significant decrease of sAPPα (31%, p<0.05), C83-Gal4 (27%, p<0.01) 
and AICD-Gal4 levels (36%; p<0.01), as well as in AICD-Gal4 mediated luciferase 
activity (38%; p<0.01). In addition, TAPI-1 exhibits a dose-dependent effect with 20 
M resulting in a 37% decrease in AICD-Gal4 mediated luciferase activity (Figure 
2I). Again, these data show that alterations in AICD-Gal4 levels as detected by 
Western blot can be accurately detected by the AICD-Gal4 mediated luciferase assay.  
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Finally, we treated SY5Y-APP-Gal4 cells with a -secretase inhibitor ( -
secretase inhibitor II). This inhibitor prevents BACE-mediated cleavage of APP and 
generation of A  (Abbenante et al., 2000). Treating these cells resulted in no 
observable change in AICD-mediated luciferase activity. This result is not surprising 
given the very low levels of -secretase cleaved APP (C99-Gal4) that we observe in 
these cells compared to the high levels of -secretase cleaved APP (C83-Gal4) we 
observe (Figures 2A, 2D, 2G). We estimate that of all the APP molecules undergoing 
- or -secretase cleavage only about 10% are cleaved by -secretase, using our 
Western blot data (data not shown). Therefore, inhibition of BACE, even if effective, 
may result in an undetectable change in the levels of cleavage products in this 
experimental scheme.  
In summary, pharmacologic modulation of - and -secretase activities alters 
AICD-Gal4 mediated luciferase activities that accurately correspond to the changes in 
AICD-Gal4 levels determined by Western blot analysis.  
 
     Genetic manipulation of secretase levels modulates AICD-Gal4 mediated 
luciferase activity. To further validate the AICD-Gal4 mediated luciferase assay as a 
reporter of APP metabolism, we over-expressed and knocked-down the expression of 
genes involved in -, - & -secretase activities. Again, we compared the effects of 
over-expression or knock-down on levels of APP proteolytic products quantified by 
Western blot analysis to AICD-Gal4 mediated luciferase activity in SY5Y-APP-Gal4 
cells.  
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 Over-expression experiments were conducted by transiently transfecting 
individual over-expression plasmids or empty vector controls into the SY5Y-APP-
Gal4 cells. Cell lysates and conditioned media were collected 24 – 48 hours post 
transfection. ADAM10 and ADAM17 over-expression promoted -secretase cleavage 
of APP and increased sAPPα secretion as compared to "empty vector" transfected 
cells (Figure 3A – 3D). ADAM10 and ADAM17 over-expression also significantly 
increased C83-Gal4 and AICD-Gal4 levels as detected by Western blot (Figure 3A – 
3D). Specifically, AICD-Gal4 levels increased approximately three-fold for both 
(Figure 3B & 3D). Measuring AICD-Gal4 mediated luciferase activity, we found that 
over-expression of ADAM10 and ADAM17 resulted in a statistically significant three 
to four fold increase in luciferase activity (Figure 3E). Furthermore, over-expression 
of the -secretase gene (BACE) or individual components of the -secretase complex 
(PSEN1, PEN2, APH1, and NCSTN) or another -secretase member ADAM9 also 
results in increased luciferase activity (Figure 3E). Specifically, BACE over-
expression significantly increased luciferase activity approximately two fold (p < 
0.01), PEN2 and NCSTN over-expression increased luciferase activity up to two fold 
(p < 0.01.)  However, over-expression of PSEN1 and APH1 did not result in any 
significant change in luciferase activity.  
We knocked-down the genes responsible for - and -secretase using 
commercially available shRNAs (Paddison et al., 2004). A control shRNA, which is 
not complementary to any known human gene, was used as a negative control. SY5Y-
APP-Gal4 cells were transfected with individual shRNAs and selected with 2 g/ml 
puromycin for 5 to 7 days. Conditioned media and cell lysates were collected from 
  45 
these cells and utilized for Western blot analyses and luciferase assays. shRNAs 
specific for APP, ADAM10, and ADAM17 were tested for their ability to knock-down 
their target genes (Figure 4A, 4B, 4C). Knock-down of these target genes was robust 
and we have observed significant protein knock-down with at least two different 
shRNA sequences for each target gene. Consistent with this knock-down of ADAM 10 
and ADAM17, sAPP  levels were decreased significantly (Figure 4D & 4E). In 
addition, Western blot analyses showed AICD-Gal4 levels were also decreased when 
APP, ADAM10 and ADAM17 were knocked-down (Figure 4A, 4B, 4C). Knock-
down of these target genes also decreased AICD-Gal4 mediated luciferase activity 
(Figure 4F). Specifically, APP knock-down significantly decreased luciferase activity 
about 80% (p < 0.01); furthermore -secretase (ADAM10, and ADAM17) knock-
down significantly decreased luciferase activity 40-60% (p < 0.01). Individual -
secretase components, PSEN1, Pen2, APH1, and NCSTN, were also knocked-down 
and this resulted in significant 30-50% decreases in luciferase activity (p < 0.01).  
 
Genetic manipulation of Fe65 and Tip60 levels modulates AICD-Gal4 
mediated luciferase activity. To determine if changes in AICD metabolism 
modulated AICD-Gal4 mediated luciferase activity, we over-expressed and knocked-
down Fe65 and Tip60. Transient over-expression of Fe65 significantly increased 
luciferase activity more than two-fold (p < 0.01), while transient over-expression of 
Tip60 resulted in a 30% increase in luciferase activity that was not significant (Figure 
5A). Knock-down of Fe65 and Tip60 resulted in a significant 40-50% decrease in 
luciferase activity (Figure 5B; p < 0.01).  
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Ubiquilin 1 regulates AICD-Gal4 levels. Having shown that monitoring AICD-
Gal4 mediated luciferase activity accurately measures changes in AICD-Gal4 levels 
induced by changes in secretase activity/levels, we wanted to determine if this 
approach could detect regulators with a less direct role in APP proteolysis and AICD 
signaling. We decided to test Ubiquilin 1 because (i) the gene encoding Ubiquilin 1 
(UBQLN1) is located in a region of chromosome 9 that displays linkage to AD in 
several independent samples (Blacker et al., 2003a; Holmans et al., 2005; Lee et al., 
2006; Myers et al., 2002b; Olson et al., 2002; Pericak-Vance et al., 2000), (ii) a 
polymorphism in UBQLN1 modulates AD risk in several independent samples 
(Bertram et al., 2005; Kamboh et al., 2006; Slifer et al., 2005), (iii) Ubiquilin 1 can 
modulate APP trafficking to the cell surface in HEK-293 and H4 cell lines (Hiltunen 
et al., 2006), and (iv) Ubiquilin 1 can modulate -secretase activity, though the 
consequences of this modulation on -secretase substrates were not determined (Mah 
et al., 2000; Massey et al., 2004; Massey et al., 2005). Given this, testing Ubiquilin 1 
would determine if our genetic screen can detect regulators of APP trafficking and 
presenilin endoproteolysis. Furthermore, the role of Ubiquilin 1 in APP metabolism 
regulation has not been previously investigated in SH-SY5Y cells. 
SY5Y-APP-Gal4 cells were transfected separately with five different Ubiquilin 
1 shRNAs, APP shRNA and the control shRNA. Cell lysates were collected and 
utilized for luciferase assays. Individually, all five Ubiquilin 1 shRNA constructs 
significantly decreased luciferase activity. They resulted in 50% (p < 0.01), 60% (p < 
0.01), 40% (p < 0.01), 60% (p < 0.01), and 60% (p < 0.01) decreases in luciferase 
activity, respectively (Figure 6A) as compared to cells expressing the control shRNA. 
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To confirm the role of Ubiquilin 1 in AICD-mediated transcriptional activity 
suggested by these results, we transiently over-expressed Ubiquilin 1 in SY5Y-APP-
Gal4 cells and measured luciferase activity. We observed that Ubiquilin 1 over-
expression resulted in an approximately 90% (p < 0.05) increase in luciferase activity 
compared to the empty vector control (Figure 7A).   
 
Ubiquilin 1 regulates APP and PS1. To begin to gain insight into the 
mechanism(s) by which Ubiquilin 1 modulates AICD-Gal4 mediated luciferase 
expression, we utilized Western blot analysis of cell lysates and conditioned media 
from SY5Y-APP-Gal4 cells in which Ubiquilin 1 was knocked-down or over-
expressed to monitor APP and Ubiquilin 1 metabolism. Specifically, we analyzed cell 
lysates and conditioned media of cells expressing Ubiquilin 1 shRNA number 2, since 
transfection with this shRNA led to the largest decrease in luciferase activity. 
Expression of this shRNA resulted in a robust Ubiquilin 1 knock-down and led to 
significantly decreased levels of mature full-length APP, immature full-length APP, 
AICD-Gal4, C83-Gal4, and sAPP  (Figures 6B & 6C). To determine if Ubiquilin 1-
induced changes in APP mRNA levels underlie the observed changes in full length 
APP levels, we performed real-time, quantitative PCR on SY5Y-APP-Gal4 cells 
stably expressing either control or Ubiquilin 1 shRNAs. No Ubiquilin 1-induced 
changes in APP mRNA levels were observed (Figures 6D). This suggests that 
Ubiquilin 1 regulation of full-length APP levels occurs post-transcriptionally.  
We studied Ubiquilin 1 over-expression to determine if we observed the 
converse effects on APP proteolytic products and full-length APP. Indeed, we 
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observed that Ubiquilin 1 over-expression resulted in increased levels of mature and 
immature full-length APP, AICD-Gal4, C83-Gal4, and sAPP  (Figures 7B & 7C).  
The Ubiquilin 1-induced effects on full-length APP are greater on mature APP 
levels than on immature APP levels (Figure 6C & 7C). This results in a decrease in the 
ratio of mature to immature full-length APP-Gal4 when Ubiquilin 1 is knocked-down 
(p < 0.01; Figure 6C) and an increase in this ratio when Ubiquilin 1 is over-expressed 
(p < 0.05; Figure 7C). 
Since Ubiquilin 1 has been reported to regulate PS1 endoproteolysis in HEK-
293 cell lines, we sought to determine if the Ubiquilin 1-induced changes that we 
observed in AICD-Gal4 and C83-Gal4 levels may be due in part to changes in PS1 
endoproteolysis  (Massey et al., 2005).  Ubiquilin 1 knock-down in SY5Y-APP-Gal4 
cells decreased PS1 carboxy-terminal fragment levels (PS1-CTF; Figure 6E) and 
Ubiquilin 1 over-expression increased PS1-CTF levels (Figure 7D). We did not 
observe any changes in the levels of ADAM 10, ADAM 17 or BACE when Ubiquilin 
1 was over-expressed or knocked-down (data not shown).   
Finally, we over-expressed Ubiquilin 1 in naïve SH-SY5Y to ensure that the 
results we observed are not limited to the SY5Y-APP-Gal4 cell line. We found that in 
these naïve cells Ubiquilin 1 over-expression resulted in increased total, mature and 
immature APP, sAPP as well as PS1 CTF, consistent with our findings in SY5Y-APP-
Gal4 cells (data not shown). 
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Discussion 
        Taking advantage of the APP intracellular domain’s (AICD) ability to activate 
transcription, we established an assay to monitor APP metabolism in the human 
neuroblastoma cell line, SH-SY5Y. We are using this assay in combination with 
RNAi-mediated knock-down of positional candidate genes as a genetic screen to 
identify regulators of APP metabolism. Here we describe validation of this 
experimental approach using pharmacologic and genetic modulation of known APP 
metabolism regulators. We find that AICD-Gal4 mediated luciferase activity is 
significantly and accurately changed when secretases, Fe65, Tip60, or Ubiquilin 1 
levels / activities are modulated pharmacologically or genetically. The ability of 
Ubiquilin 1 to regulate APP metabolism in SH-SY5Y cells had not been investigated 
previously. Our initial findings show that in these cells Ubiquilin 1 regulates total APP 
levels, APP maturation and PS1 endoproteolysis. Our results lead us to conclude that 
the genetic screen we describe is capable of identifying genes that encode regulators of 
APP proteolysis, APP maturation, APP levels, and AICD activity.  
 
Validation of AICD-Gal4 luciferase assay.  
The functional assay for identifying APP metabolism regulators relies on the ability of 
an AICD-Gal4 fusion to transactivate a firefly luciferase reporter gene (Cao and 
Sudhof, 2001). While the biological role of AICD-mediated transactivation is unclear 
(Chen and Selkoe, 2007; Hebert et al., 2006; Herz, 2007; Pardossi-Piquard et al., 
2005), we utilized this transactivation function purely as a reporter of APP processing 
and therefore APP metabolism. We determined that monitoring AICD-Gal4 mediated 
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luciferase activity is correlated to AICD-Gal4 levels by utilizing pharmacologic and 
genetic agents to regulate secretase activities and thereby modulate AICD-Gal4 levels. 
In SH-SY5Y cells stably expressing an APP-Gal4 fusion protein and a Gal4-UAS 
driven luciferase reporter construct (SY5Y-APP-Gal4 cells), we utilized TAPI-1 and 
L-685,458 to inhibit - and -secretases respectively. TAPI-1 inhibits -secretase 
cleavage of APP as well as several other cell surface proteins including TNF  (Slack 
et al., 2001). L-685,458 is a potent and selective cell-permeable -secretase inhibitor 
(Shearman et al., 2000). Both of these inhibitors decreased AICD-Gal4 levels and 
decreased AICD-Gal4 mediated luciferase activity to similar levels. Inhibiting BACE 
activity did not have an appreciable effect on AICD-Gal4 levels or AICD-Gal4 
mediated luciferase activity, which is not surprising since the majority of APP 
processing occurs via the -secretase pathway in SH-SY5Y cells. Stimulation of -
secretase using PMA (Lanni et al., 2004) increased AICD-Gal4 levels and increased 
AICD-Gal4 mediated luciferase activity to similar levels.  
     To further validate our functional assay, we over-expressed and knocked-down 
genes that encode the -, -, and -secretases. Similar to the effects of pharmacologic 
modulators of secretases, over-expressing or knocking-down secretase genes resulted 
in predictable alterations in AICD-Gal4 levels as measured by Western blot analysis. 
The changes in luciferase activity induced by secretase over-expression or knock-
down mirrored the trends observed in the Western blot analysis. Knock-down of APP 
had the most dramatic effect on AICD-Gal4 mediated luciferase activity while knock-
down of genes encoding - and -secretases resulted in significant decreases in AICD-
Gal4 mediated luciferase.  
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To assess the quality of the AICD-Gal4 mediated luciferase assay we calculated 
the “Z-factor” for the assay in response to the known APP metabolism 
modulators(Zhang et al., 1999). The Z-factor is a dimensionless metric that takes assay 
dynamic range and data variation into consideration to assess the utility and reliability 
of the assay. Scores between 0.5 and 1.0 indicate an excellent assay (Zhang et al., 
1999). Using the data we collected, we calculated Z-factors for pharmacologic and 
genetic modulation of the secretases (Table 1). For all of these conditions we obtain Z 
values between 0.5 and 1.0, indicating that our experimental approach is robust and 
has the capability of identifying APP metabolism regulators that increase or decrease 
AICD generation.   
 
AICD metabolism regulators modulate AICD-Gal4 luciferase activity. 
 AICD-Gal4 mediated transactivation has been shown to require Fe65 and Tip60.  
Fe65 is an adaptor protein that binds to the NPTY sequence in AICD and mediates 
intracellular trafficking of AICD-Gal4 from the cytoplasm into the nucleus (Cao and 
Sudhof, 2001). Once inside the nucleus, the AICD-Gal4/Fe65 complex recruits the 
histone acetyltransferase, Tip60. Fe65 and Tip60 are both required for AICD-Gal4 
transactivation activity. We observed increased AICD-Gal4 mediated luciferase 
activity when we over-expressed Fe65 or Tip60 and decreased luciferase activity when 
either of these genes was knocked-down.   
Ubiquilin 1 modulates APP metabolism in SH-SY5Y cells. Having validated our 
experimental approach using direct regulators of APP proteolysis and AICD-
metabolism, we then sought to determine if Ubiquilin 1 could modulate AICD-Gal4 
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mediated luciferase activity. Ubiquilin 1 has been shown to regulate presenilin1 
endoproteolysis and APP trafficking in HEK-293 cells (Hiltunen et al., 2006; Mah et 
al., 2000; Massey et al., 2004; Massey et al., 2005) and therefore testing Ubiquilin 1 
would help to determine whether our experimental approach could detect APP 
metabolism regulators that are not directly involved in APP proteolysis nor in AICD 
signaling. When Ubiquilin 1 was knocked-down, AICD-Gal4 luciferase activity was 
significantly decreased.  
Ubiquilin 1 is a conserved protein that contains an NH2-terminal ubiquitin-like 
domain (UBL) and a COOH-terminal ubiquitin-associated (UBA) domain (Mah et al., 
2000). Through these domains, Ubiquilin 1 associates with ubiquitin ligases and the 
proteosome and is proposed to link ubiquitination with proteosome-mediated protein 
degradation. This suggests that Ubiquilin 1 plays a role in responding to protein 
misfolding, aggregation, and/or stress (Heir et al., 2006; Mah et al., 2000). In the 
brains of AD patients, there is increased Ubiquilin 1 in neurons containing 
neurofibrillary tangles (NFTs), as compared to control brains (Mah et al., 2000). In the 
brains of Parkinson’s disease patients, as well as patients with diffuse Lewy body 
disease (DLBD), there is strong Ubiquilin 1 staining of Lewy bodies (Mah et al., 
2000). Finally, a polymorphism in the UBQLN1 gene has been shown to increase AD 
risk in family-based and large case-control samples (Bertram et al., 2005; Kamboh et 
al., 2006; Slifer et al., 2005). 
The role of Ubiquilin 1 in AD pathogenesis may be due to its ability to regulate 
formation of active -secretase complexes and/or regulate APP trafficking (Hiltunen et 
al., 2006; Mah et al., 2000; Massey et al., 2004; Massey et al., 2005). Monteiro and 
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colleagues have found that Ubiquilin 1 can regulate full-length Presenilin1 (PS1), 
Presenilin2 (PS2), Nicastrin, and PEN-2 levels as well as PS1 and PS2 
endoproteolysis (Mah et al., 2000; Massey et al., 2004; Massey et al., 2005). 
Specifically, Ubiquilin 1 over-expression increased full-length presenilin (PS1 and 
PS2) levels in HeLa cells. In HEK-293 cells, Ubiquilin 1 over-expression decreased 
presenilin endoproteolysis while Ubiquilin 1 knock-down increased presenilin 
endoproteolysis (Massey et al., 2005). In addition, Monteiro and colleagues show that 
nicastrin and Pen-2 levels are decreased by Ubiquilin 1 over-expression and increased 
by Ubiquilin 1 knock-down in HEK-293. In addition to these effects on -secretase 
components, Hiltunen and colleagues reported that Ubiquilin 1 knock-down decreased 
steady-state full-length immature APP levels, increased trafficking of APP from 
intracellular compartments to the cell surface, and increased steady-state sAPP  levels 
in HEK-293 and H4 cell lines (Hiltunen et al., 2006). These effects on APP levels and 
secretion altered A 40 and A 42 levels. However, Ubiquilin 1 knock-down did not 
alter -, -, or -secretase levels or C83 and C99 levels in these cell lines.  
Here we found that in the human neuroblastoma cell line, SH-SY5Y, Ubiquilin 1 
regulates total full-length APP, the ratio of mature to immature APP, as well as PS1 
endoproteolysis. To arrive at these conclusions, we over-expressed and knocked-down 
Ubiquilin 1 in SY5Y-APP-Gal4 cells and monitored APP metabolism using Western 
blot analysis. We found that Ubiquilin 1 knock-down decreased levels of AICD-Gal4, 
C83-Gal4, sAPP , full-length mature and immature APP, and the ratio of mature to 
immature APP. Ubiquilin 1 over-expression elicited the opposite effect on the levels 
of these molecules. 
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The fact the ratio of mature to immature APP is altered by Ubiquilin 1 in the 
absence of APP mRNA level changes suggests that Ubiquilin 1 modulates trafficking 
through the secretory pathway in SH-SY5Y cells. This conclusion was reach by 
Hiltunen and colleagues when investigating the role of Ubiquilin 1 on APP 
metabolism in H4 and HEK-293 cell lines (Hiltunen et al., 2006).  
Given the existing reports that Ubiquilin 1 regulates PS1 levels and 
endoproteolysis in HeLa and HEK-293 cells, respectively, we sought to determine if 
the observed changes in APP processing may be due, in part, to Ubiquilin 1 mediated 
changes in PS1 metabolism (Mah et al., 2000; Massey et al., 2004; Massey et al., 
2005). Interestingly, Hiltunen and colleagues did not observe any changes in PS1 
levels or endoproteolysis upon transient Ubiquilin 1 knock-down in HEK-293 
(Hiltunen et al., 2006). In SY5Y-APP-Gal4 cells, we observed that Ubiquilin 1 knock-
down decreases PS1 endoproteolysis and Ubiquilin 1 over-expression promotes PS1 
endoproteolysis. Presumably these changes in PS1-CTF levels alter -secretase 
activity and cleavage of other -secretase substrates. At this time, it is not clear how 
Ubiquilin 1 regulates PS1 endoproteolysis. No alterations in ADAM10, ADAM17, or 
BACE levels were observed when Ubiquilin 1 was knocked-down or over-expressed. 
These results suggest that Ubiquilin 1 regulates APP metabolism not only by 
controlling the ratio of mature to immature APP but also by post-transcriptionally 
controlling total APP (mature and immature) levels and PS1 endoproteolysis. 
It is interesting to note that the effects of Ubiquilin 1 over-expression / knock-
down on APP and presenilin metabolism that we observe in SH-SY5Y cells are 
different than those observed in HEK-293 and HeLa cells (Hiltunen et al., 2006; 
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Massey et al., 2005). In SH-SY5Y cells we find Ubiquilin 1 knock-down decreased 
total, mature, and immature full-length APP, sAPP , C83 and AICD steady-state 
levels and the ratio of mature to immature APP, while over-expression increased these 
same steady-state levels. In addition, Ubiquilin 1 over-expression increased PS1 
endoproteolysis. In HEK-293 cells, Hiltunen et al. found that Ubiquilin 1 knock-down 
decreased steady-state immature full-length APP levels, increased sAPP  levels, and 
no effects were observed in C83, C99, AICD, and PS1 CTF levels (Hiltunen et al., 
2006). However, Massey et al. observed an increase in PS1 endoproteolysis in HEK-
293 cells (Massey et al., 2005). In SH-SY5Y cells however, Ubiquilin 1 seemingly has 
opposite effects on APP and presenilin metabolism than observed in HEK-293. At this 
time the reasons for these differences are not clear; they could be due to differences in 
experimental procedure (e.g. differences in cell confluency, and/or RNAi techniques 
[transient siRNA versus stable shRNA] ) and/or inherent differences in these two cell 
types. One of the noticeable differences between these cells is that in SH-SY5Y cells, 
the majority of full-length APP is mature, whereas in HEK-293 the majority of full-
length APP is immature (data not shown). Cell type dependent effects of Ubiquilin 1 
have been observed previously. In COS7 cells, Ubiquilin 1 over-expression reduced 
cell surface expression of nicotinic acetylcholine receptors (nAChRs), while in 
superior cervical ganglion neurons Ubiquilin 1 over-expression had no effect on 
nAChR levels (Ficklin et al., 2005). These cell type-dependent effects are interesting 
given the differential vulnerability observed in AD brains, where subsets of 
neocortical and hippocampal neurons preferentially degenerate (Morrison and Hof, 
2002). In addition to these cell type-dependent effects, Ubiquilin 1 has been shown to 
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function in seemingly opposite ways. Ubiquilin 1 over-expression has been shown to 
promote accumulation of some proteins [HASH-1(Persson et al., 2004), HES-
1(Persson et al., 2004), and GABAA receptor(Bedford et al., 2001)] as well as to 
promote degradation of other proteins [nAChRs(Ficklin et al., 2005) and Hepatitis C 
virus RNA-dependent RNA polymerase [NS5B](Gao et al., 2003)]. It will be 
important to study the role of Ubiquilin 1 on APP metabolism in primary neurons and 
in vivo to determine its true role in regulating APP metabolism and in AD 
pathogenesis.  
Our Ubiquilin 1 results suggest that in SH-SY5Y cells, Ubiquilin 1 regulates APP 
metabolism not only by controlling the ratio of mature to immature APP but also by 
post-transcriptionally controlling total APP (mature and immature) levels and PS1-
CTF levels.  
 
AICD-Gal4 luciferase assay accurately reports AICD-Gal4 levels.  
Finally, we were struck by the ability of the AICD-Gal4 mediated luciferase 
assay to accurately report AICD-Gal4 levels.  To determine if these measures of 
AICD-Gal4 were correlation, we plotted the change in luciferase activity versus the 
change in AICD-Gal4 levels as measured by Western blot analysis. AICD-Gal4 levels 
were modulated by pharmacologic or genetic modulation of secretases and Ubiquilin 
1. This analysis revealed a strong and significant correlation between AICD-Gal4 
levels and AICD-Gal4-mediated luciferase expression (Figure 8; R
2
 = 0.95; p = 6 *10
-
6
). The best fit line of this relationship has a slope close of 0.71 demonstrating that this 
luciferase assay provides an accurate reporter of changes in AICD-Gal4 levels. In 
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addition, measuring AICD-Gal4 mediated luciferase activity provides a simple, quick 
and inexpensive means for monitoring changes in APP metabolism. The genetic 
screen we describe can be successfully utilized to identify genes that putatively 
modulate AICD-Gal4 levels. Additional assays, including as Western blot and ELISA, 
will be necessary to confirm their role in APP metabolism regulation and gain insight 
into the mechanism of regulation.  
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Conclusions 
We have established and validated an AICD-Gal4 based functional assay in 
SH-SY5Y cells. Using this assay in combination with RNAi, we have developed a 
genetic screen to identify regulators of APP metabolism. This screen accurately, 
robustly, and easily measures changes in AICD-Gal4 levels. We demonstrate that 
these AICD-Gal4 levels can be altered by pharmacologic or genetic modulation of 
genes that directly regulate APP levels, AICD trafficking/signaling, APP maturation, 
and APP proteolysis. Using this approach, we show that Ubiquilin 1 can regulate 
AICD-Gal4 levels in SH-SY5Y cells. Ubiquilin 1 regulates AICD-Gal4 levels by 
modulating APP levels, the ratio of mature to immature APP, and PS1 
endoproteolysis. Taken together, our results demonstrate that this genetic screen is 
capable of identifying APP metabolism regulators that can modulate the APP 
proteolytic processing, APP maturation, APP levels, and AICD trafficking/signaling.   
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Methods 
Chemicals and antibodies: Phorbol 12-myristate 13-acetate (PMA), L-685,458, and 
puromycin were purchased from Sigma. TAPI-1 was purchased from Peptides 
International. -secretase inhibitor II, N-Benzyloxycarbonyl -Val-Leu-leucinal Z-
VLL-CHO, was purchased from Calbiochem. The APP C-terminal antibody (A8717; 
1:1000) and β-actin antibody (1:10,000) were purchased from Sigma. The 6E10, anti-
APP antibody was purchased from Covance and utilized for detection of sAPP  
(1:1000). The BACE1 antibody (1:1000) was purchased from Bioscience. The 
ADAM10 (C-terminal) antibody (1:1000) was purchased from ProSci. The Ubiquilin 
1 antibody (1:160) was purchased from Zymed. The ADAM17 antibody (1:1000) was 
purchased from Chemicon. The HRP-conjugated secondary antibodies (anti-mouse 
and anti-rabbit) (1:10,000) were purchased from GE.   
 
Plasmids. The plasmids APP-Gal4, APP*-Gal4 and Gal4, Gal4-UAS-luciferase 
(encoding firefly luciferase) were kindly provided from Dr. Thomas Südof, and are 
described elsewhere (Cao and Sudhof, 2001). Briefly, each of these plasmids encodes 
only the DNA binding domain of Gal4. The ADAM10 over-expression plasmid was 
kindly provided by Dr. Paul Saftig. The ADAM9 and ADAM17 were provided by Dr. 
Carl Blobel. The empty vector of ADAM9, ADAM10 and ADAM17 is pcDNA3.1. 
Ubiquilin 1 over-expression plasmid, which was constructed from pCMV vector, was 
kindly provided by Dr. Mervyn J. Monteiro.        
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Cells and cell culture. SH-SY5Y and naïve human embryonic kidney (HEK)-293 
cells were purchased from ATCC. These cell lines were cultured in Dulbecco's 
modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM 
L-glutamine, 100 units/ml penicillin, and 100 g/ml streptomycin. SH-SY5Y cells that 
stably express APP-Gal4, APP*-Gal4, or Gal-4, and carrying the Gal4-UAS-luciferase 
reporter construct were constructed by co-transfecting one of the Gal4 constructs, the 
pCDNA3.1 plasmids, along with the Gal4-UAS plasmid, and selecting resistant clones 
with 400 g/ml G418. These cells were then tested for -secretase dependent 
luciferase activity. Clonal lines that stably express luciferase were obtained and were 
maintained with media containing 200 l/ml G418.  
 
RNAi. Plasmid-based shRNA constructs were purchased from Open-Biosystems 
(Birmingham, AL). These constructs are part of the human retroviral shRNA library 
housed at the Drexel University RNAi Resource Center. We utilized the following 
target specific shRNAs: for UBQLN1 shRNAs (Open Biosystems catalog #s: 
v2HS_58534, v2HS_254856, v2HS_254715, v2HS_255129 and v2HS_58531); for 
ADAM9 shRNAs (V2HS_17130, V2HS_17127, V2HS_17126, and V2HS_17129); 
for ADAM10 shRNAs (v2HS_94294, v2HS_94297, and v2HS_94295); for ADAM17 
shRNAs (RHS3979-9619367, RHS3979-9619368, RHS3979-9619369, and RHS3979-
9619370); for BACE1 shRNAs (V2HS_25207, V2HS_25209, V2HS_25206, 
V2HS_25205, V2HS_25210); for PSEN1 shRNAs (v2HS_89932, v2HS_89931); for 
PSEN2 shRNAs (v2HS_93093); for APH1 shRNAs (v2HS_117094, v2HS_117096); 
for NCSTN shRNAs (v2HS_255892). As a negative control shRNA, we utilized the 
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non-silencing shRNA from Open Biosystems, Inc. (RHS 1707). shRNA constructs 
were transfected using Arrest-In transfection reagent (Open Biosystems, Inc.) using 
the conditions suggested by the manufacturer. Stably expressing shRNA clones were 
generated by adding 2 g/ml puromycin 24 hours post-transfection. Populations of 
resistant clones were detected five to seven days post-transfection.  
 
Western Blot Analysis. Cells were lysed in RIPA cell lysis buffer (50 mM Tris-HCL 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1mM PMSF and 1 g/ml aprotinin, 
1 g/ml leupeptin, and 1 g/ml pepstatin), and centrifuged at 14,000 rpm for 15 
minutes at 4
○
C. The resulting supernatant was transferred to a new micro-centrifuge 
tube. The protein concentration of the cell lysates was determined using the BCA 
protein assay kit (Pierce, Rockford, IL) according to the manufacturer’s instructions. 
Equal quantities of protein were loaded into the wells of 4-12% Bis-Tris 
polyacrylamide gels (Invitrogen) along with See Blue plus 2 protein marker 
(Invitrogen). Gels were run using MES running buffer and transferred to PVDF 
membrane (Immobilon P
SQ
, Millipore) using a semi-dry transfer apparatus (Owl 
Scientific) and NuPage transfer buffer (Invitrogen). PVDF membranes were blocked 
in TBST with 5% dry milk for at least two hours, washed extensively, then incubated 
with primary antibody for either one hour at room temperature or overnight at 4
○
C. 
After removing the primary antibody, membranes were extensively washed and 
incubated with either goat-anti-rabbit-HRP or goat-anti-mouse-HRP secondary 
antibodies (1:10,000; GE) for one hour at room temperature. Membranes were washed 
and developed using West Dura Extended Duration Substrate (Pierce). The blot was 
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visualized using a FluoroChem 8900 imaging system (Alpha Innotech), and signals 
were quantified using AlphaEase Fc software. To account for any differences in 
loading, target band densitometries were divided by actin densitometries obtained 
from the same lane. These corrected densitometries were normalized to controls in 
each experiment.  
 Detection of sAPP  followed the protocol detailed in Lanni et al. and 
Bergamaschi et al. (Bergamaschi et al., 1995; Lanni et al., 2004). Briefly, conditioned 
media was collected and 48% trichloroacetic acid (TCA) was added so that the TCA 
final concentration was 15%. This mixture was incubated on ice for 30 minutes, and 
centrifuged at 14,000 rpm for 20 minutes. Following this spin, the supernatant was 
aspirated and discarded. 500 l of ice cold acetone was used to resuspend the pellet. 
This mixture was placed at -20
○
C for at least 30 minutes, followed by centrifugation at 
14,000 rpm for 20 minutes. The supernatant was carefully aspirated and discarded. 
The remaining pellet was air dried for 10 minutes and then 20 l of RIPA was added 
and this sample was utilized for Western blot analysis. The sAPP  bands were 
detected using the 6E10 (1:1000) as the primary antibody. 
 
Luciferase assays. For firefly luciferase assays, 7,500 cells were plated into the 96 
well plates. In an experiment, each treatment was applied to a total of six wells. After 
treatments, conditioned media was aspirated and discarded. 100 l GLB (Glo Lysis 
Buffer, Promega) was added to lyse the cells. 30 l of each cell lysates was transferred 
to a white plate (Greiner Bio-one), and 30 l Steady-Glo (Promega) was added. 
Luciferase was measured using a Top-Count Scintillation Counter/Luminescence 
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Reader (Packard, Inc.) Another 30ul of each cell lysates was transferred to the other 
white color plate, and 30 l 20X SYBR Green (diluted in PBS from Invitrogen 
10,000X SYBR Green) was added. SYBR Green fluorescence was measured after 5 
minutes incubation in dark using an excitation wavelength of 485 nm, and emission 
wavelength of 527 nm, and an integration time of 0.1 seconds on a Fluoroscan Ascent 
FL fluorescence plate reader (Thermo Labsystems, Inc.). The luciferase signal was 
normalized to cell number by dividing the luciferase signal by the SYBR Green 
reading for the same well. For dual luciferase assays, SH-SY5Y-APP-Gal4 cells that 
stably express firefly luciferase were co-transfected with pRL-SV40, which 
constitutively over-expresses Renilla luciferase, along with other plasmids. The dual 
luciferase assay was performed 24 – 48 hours post-transfection. The media was 
aspirated and discarded. 30 l Dual-Glo luciferase substrate (Promega) was added to 
lyse the cells. All cell lysates were resuspended and transferred to a white 96 well 
plate (Greiner Bio-one). After 10 minutes incubation at room temperature, firefly 
luciferase was measured using a Top-Count Scintillation Counter/Luminescence 
Reader (Packard, Inc.). Next, 30 l Stop-Glo substrate (Promega) was added to the cell 
lysates containing Dual-Glo. After 10 minutes room temperature incubation, Renilla 
luciferase was measured using the same Top-Count Scintillation 
Counter/Luminescence Reader (Packard, Inc.) For normalization, the firefly luciferase 
signal was divided by the Renilla luciferase signal for the same well. In an experiment, 
each treatment was applied to a total of four wells. 
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RNA Extraction and Real-time, Quantitative PCR. In triplicate, cells stably 
expressing control or Ubiquilin 1 specific shRNAs were washed twice with cold PBS 
and total RNA was isolated using the RNeasy Mini Kit (Qiagen, Inc). cDNA was 
synthesized using total RNA (3.5 g), N6 random primers (12.5 M) and SuperScript 
II Reverse Transcriptase (Invitrogen). cDNAs were diluted 1:30 using RNase-free 
H2O to a final concentration of 2 ng. Diluted cDNAs were mixed with APP or 18S 
primer/probe sets (Applied Biosystems, Inc.; APP Catalog # Hs00169098_m1; 18S 
Catalog # Hs99999901_s1), 2X PCR Universal Master Mix (Applied Biosystems, 
Inc.) and amplified using an ABI 7500 Real-Time PCR System following the 
manufacturer’s directions. To determine differences in APP mRNA levels, we utilized 
the ΔΔCt method. 
 
Statistical analysis: Values in the text and figures are presented as means ± standard 
errors of at least three independent experiments. Equal variance or separate variance 
two-sample student’s t-test were used, as appropriate, to compare two groups. 
Bonferroni correction analysis was used to correct for multiple comparisons within a 
single experiment.
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Figures  
 
Figure 1 - Functional screen for regulators of APP metabolism.   
(A) Model depicting APP-Gal4 reporter system. (C) Firefly luciferase activity is 
significantly increased in SH-SY5Y cells stably expressing APP-Gal4 and Gal4-UAS 
Luciferase compared to SY5Y cells stably expressing either Gal4 / Gal4-UAS 
Luciferase or APP*-Gal4 / Gal4-UAS Luciferase. Luciferase activity was normalized 
to total cell number using SYBR Green.  Bars represent mean normalized luciferase 
expression (+/- std. error) of 16 independent trials for each cell line. ** p < 0.01; 
Student's t-tests with sequential Bonferroni correction for multiple comparisons. 
 
Figure 2 - Pharmacological modulation of secretases alters AICD-Gal4 levels and 
AICD-Gal4 mediated luciferase activity in SY5Y-APP-Gal4 cells.  
(A) Stimulation of α-secretase by PMA (1 μM PMA for 10 hours) increases sAPP , 
C83-Gal4, and AICD-Gal4 levels as detected by Western blot analysis. (B) 
Quantification of Western blot densitometry in panel A. Normalization for loading 
differences was achieved by dividing the densitometry values for individual bands by 
the densitometry values for -actin in the same lane. (C) Dose-dependent increases of 
AICD-Gal4- mediated luciferase activity with increasing concentrations of PMA (10 
hour incubation). Luciferase levels normalized to total cell number using protein 
concentration. (D) Inhibition of -secretases by TAPI-1 (20 M for two hours) results 
in decreases in sAPP , C83-Gal4, and AICD-Gal4 levels as detected by Western blot 
analysis. (E) Quantification of Western blot densitometry in panel D. (F) Dose-
  68 
dependent decreases in AICD-Gal4-mediated luciferase activity with increasing TAPI-
1concentrations (two hour incubation). Luciferase levels normalized to total cell 
number using SYBR Green. (G) Inhibition of -secretase by L-685,458 (5mM) 
decreases AICD-Gal4 levels and increases C83-Gal4 levels as detected by Western 
blot analysis. (H) Quantification of Western blot densitometry in panel G. (I) Dose-
dependent decreases in AICD-Gal4-mediated luciferase activity with increasing 
concentrations of L-685,458. For the luciferase experiments, points represent mean 
normalized luciferase activity (+/- standard error) of three independent trials, with 
luciferase levels normalized to total cell numbers using SYBR Green. ** p < 0.01; 
Student's t-tests with sequential Bonferroni correction for multiple comparisons. 
“Control” uses the same media as the treatments, and also contains the same amount 
of DMSO.  
 
Figure 3 - Over-expression of individual secretase genes in SY5Y-APP-Gal4 cells 
increases AICD-Gal4 mediated luciferase activity.  
(A) Transient over-expression of ADAM10 increases ADAM10, AICD-Gal4, C83-
Gal4, and sAPP  levels compared to cells transfected with empty vector. (B) 
Quantification of Western blot densitometry in panel A. (C) ADAM17 transient over-
expression significantly increases ADAM17, AICD-Gal4, C83-Gal4, and sAPP  
levels. (D) Quantification of Western blot densitometry in panel G. (E) Transient over-
expression of individual secretase genes increases AICD-Gal4 mediated luciferase 
activity. Luciferase was normalized to transfection efficiency, by dividing by Renilla 
luciferase activity. Individual secretase over-expression plasmids were co-transfected 
  69 
with pRL-SV40 plasmid, expressing Renilla luciferase. Bars represent the mean 
normalized luciferase activity of four independent trials and error bars represent 
standard errors. Statistical significance was determined using two-sample, one-tail t-
tests to compare each secretase gene with the empty vector, followed by sequential 
Bonferroni procedure to adjust for multiple comparisons. *p<0.05; ** p<0.01  
 
Figure 4 - Knock-down of APP and individual secretase genes in SY5Y-APP-
GAL4 cells decreases AICD-Gal4 mediated luciferase activity.  
(A) APP-specific shRNA decreases full-length APP, C83-Gal4, and AICD-Gal4 levels 
compared to the control or “non-silencing” shRNA. Results from duplicate 
transfections with each shRNA are shown. (B) ADAM10 specific shRNAs decrease 
endogenous ADAM10, C83-Gal4, and AICD-Gal4 levels compared to the control 
shRNA. Results from duplicate transfections with each shRNA are shown. (C) 
ADAM17 specific shRNAs decrease endogenous ADAM17, C83-Gal4, and AICD-
Gal4 levels compared to the control shRNA. Results from duplicate transfections with 
each shRNA are shown. (D) Knock-down of ADAM9, 10, and 17 decrease sAPP  
levels compared to control shRNA. (E) Quantification of Western blot densitometries 
in panels B – D. (F) Transfection with shRNAs specific for APP and individual 
secretase genes decreases AICD-Gal4-mediated luciferase expression compared to 
control shRNA. Bars represent the mean normalized luciferase activity of four 
independent trials and error bars represent standard errors. Statistical significance was 
determined using two-sample, one tailed t-tests to compare each secretase shRNA 
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with the control shRNA and sequential Bonferroni procedure to adjust for multiple 
comparisons. *p<0.05; ** p<0.01.  
 
Figure 5 - Genetic alteration of Fe65 or Tip60 levels modulates AICD-Gal4 
mediated luciferase activity. 
(A) Transient over-expression of Tip60 or Fe65 in SY5Y-APP-Gal4 cells increases 
AICD-Gal4 production compared to empty vector controls. (B) Knock-down of Fe65 
or Tip60 in SY5Y-APP-Gal4 cells decreases AICD-Gal4 mediated luciferase activity 
Bars represent the mean normalized luciferase activity of four independent trials and 
error bars represent standard errors. Statistical significance was determined using two-
sample, one-tailed t-tests to compare each secretase gene and "vector" or "control" and 
sequential Bonferroni procedure to adjust for multiple comparisons. * p<0.05.  
 
Figure 6 - Ubiquilin 1 knock-down regulates APP-Gal4 metabolism in SY5Y-
APP-Gal4 cells.  
(A) Ubiquilin 1 knock-down decreases AICD-Gal4-mediated luciferase activity. 
SY5Y-APP-Gal4 cells stably expressing the control shRNA, an APP specific shRNA, 
or five different shRNA targeting Ubiquilin 1 was generated. Cell lysates were utilized 
to measure AICD-Gal4 mediated luciferase activity. Bars represent the mean 
normalized luciferase activity (+/- standard error) of six independent trials. (B) SY5Y-
APP-GAL4 cells stably expressing Ubiquilin 1 specific shRNA (#2) have decreased 
Ubiquilin 1, mature and immature APP-Gal4, C83-Gal4, AICD-Gal4, and sAPP  
levels compared to cells expressing control shRNA. (C) Quantification of Western 
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blot results. Bars represent mean densitometry (+/- standard error) of three 
independent trials. Black bars represent the densitometry from Ubiquilin 1 knock-
down cells; white bars represent the densitometry from cells expressing control 
shRNA. Abbreviations: Ma APP denotes mature APP, Im APP denotes immature 
APP; Ma/Im APP denotes the mature APP/ immature APP ratio. Statistical 
significance between mock and over-expression for each measure was determined 
using a two-sample, one tailed t-test and sequential Bonferroni procedure to adjust for 
multiple comparisons. (* p<0.05; **p<0.01.) (D) Ubiquilin 1 knock-down does not 
alter APP mRNA levels compared to control shRNA using quantitative PCR. (E) 
Ubiquilin 1 knock-down decreases PS1-CTF levels in SY5Y-APP-Gal4 cells.  
 
Figure 7 - Ubiquilin 1 over-expression regulates APP-Gal4 metabolism in SY5Y-
APP-Gal4 cells.  
(A) Transient Ubiquilin 1 over-expression increases AICD-Gal4 mediated luciferase 
activity. SY5Y-APP-GAL4 cells were transiently co-transfected with UBQLN1 over-
expression plasmid and a Renilla luciferase over-expression plasmid (pRL-SV40). The 
latter was used as a transfection efficiency control to normalize AICD-Gal4 mediated 
luciferase activity. Bars represent the mean normalized luciferase activity (+/- standard 
error) of six independent trials. Statistical significance was determined using two-
sample, one-tailed t-tests to compare each experimental shRNA to the control shRNA 
and sequential Bonferroni procedure to adjust for multiple comparisons. (B) SY5Y-
APP-Gal4 cells transiently over-expressing Ubiquilin 1 have increased Ubiquilin 1, 
mature and immature APP-Gal4, C83-Gal4, AICD-Gal4, and sAPP  levels compared 
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to vector only cells. (C) Quantification of Western blot results. Bars represent mean 
densitometry (+/- standard error) of three independent trials. Black bars represent the 
densitometry from Ubiquilin 1 over-expressing cells; white bars represent the 
densitometry from cells expressing empty vector control. Abbreviations: Ma APP 
denotes mature APP, Im APP denotes immature APP; Ma/Im APP denotes the mature 
APP/ immature APP ratio. Statistical significance between mock and over-expression 
for each measure was determined using a two-sample, one tailed t-test and sequential 
Bonferroni procedure to adjust for multiple comparisons. (* p<0.05; **p<0.01.) (D) 
Ubiquilin 1 over-expression increases PS1 CTF levels in SY5Y-APP-Gal4 cells.  
 
Figure 8 - Correlation between AICD-Gal4 mediated luciferase levels and AICD-
Gal4 levels determined by Western blot analysis.  
Using data from pharmacologic (PMA, TAPI-1, L-685,458), over-expression (ADAM 
10, ADAM17, Ubiquilin 1) or knock-down (ADAM 10, ADAM17, Ubiquilin 1) 
mediated modulation of AICD-Gal4 levels we plotted the average fold change in 
AICD-Gal4 levels versus the average fold change in AICD-Gal4 mediated luciferase 
activity. For transient over-expression, luciferase activity and AICD-Gal4 levels were 
normalized to transfection efficiency by Renilla luciferase activity assays. The line is 
represents the least squares linear regression to this data.  
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Figure 2-1: Functional screen for regulators of APP metabolism 
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Figure 2-2: - Pharmacological modulation of secretases alters AICD-Gal4 levels 
and AICD-Gal4 mediated luciferase activity in SY5Y-APP-Gal4 cells. 
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Figure 2-3: Over-expression of individual secretase genes in SY5Y-APP-Gal4 
cells increases AICD-Gal4 mediated luciferase activity. 
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Figure 2-4: Knock-down of APP and individual secretase genes in SY5Y-APP-
GAL4 cells decreases AICD-Gal4 mediated luciferase activity. 
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Figure 2-5: Genetic alteration of Fe65 or Tip60 levels modulates AICD-Gal4 
mediated luciferase activity. 
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Figure 2-6: Ubiquilin 1 knock-down regulates APP-Gal4 metabolism in SY5Y-
APP-Gal4 cells. 
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Figure 2-7: Ubiquilin 1 over-expression regulates APP-Gal4 metabolism in 
SY5Y-APP-Gal4 cells. 
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Figure 2-8: Correlation between AICD-Gal4 mediated luciferase levels and 
AICD-Gal4 levels determined by Western blot analysis  
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Table 2-1: Z-factor values 
 
Z-factor values for AICD-Gal4 Luciferase assay calculated when APP metabolism is 
modulated by pharmacologic or genetic approaches. 
 
 
 
 
 
 
 
 
 
APP Metabolism Modulators Z factor 
  PMA 0.77 
Pharmacological TAPI-1 0.63 
 L685,458 0.74 
 APP 0.60 
shRNA ADAM10 0.71 
 ADAM17 0.70 
Over-expression ADAM10 0.72 
  ADAM17 0.60 
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Chapter 3 : Identification of positional candidate genes located on chromosome 
10q11-25 using a gal4 based reporter assay 
 
Introduction: 
 
Alzheimer’s disease (AD) is one of the most common forms of dementia in 
elderly. AD significantly affects regions of the brain that control thought, memory, 
and language. Although we learn more about the disease everyday, the cause and cure 
for this disease is still not known. AD is clinically characterized by subtle loss of 
memory followed by progressive dementia over a course of several years. Age is the 
biggest risk factor. The number of people affected by AD beyond the age of 65 
doubles every 10 years. Family history is another risk factor. So far, only three genes 
have been identified, mutations in which results in the rare, autosomal dominant 
Early-Onset form of AD (EOAD). Mutations in β-amyloid precursor protein (APP) 
(Goate et al., 1991), presenilin1 (PSEN1) (Sherrington et al., 1995), and presenilin2 
(PSEN2) (Levy-Lahad et al., 1995) result in increased Aβ42 peptide production.Aβ42 
is the main component of amyloid plaques. However, the majority of the AD cases 
occurs after 65 years of age and is referred to as Late Onset Alzheimer’s disease 
(LOAD). The genetic basis of LOAD has been extensively investigated and only one 
gene has been universally identified as a risk factor, the ε4 allele of the APOE gene 
(Corder et al., 1993). APOE however does not account for all the LOAD cases. This 
led to the hypothesis that there are additional genes yet to be identified that contribute 
to LOAD (Kamboh, 2004).  
Genome wide linkage screens and linkage disequilibrium studies suggests the 
presence of candidate genes other that APOE on multiple chromosomes that are 
  89 
involved with AD. Many groups have reported the presence of putative LOAD-
susceptibility loci on chromosomes 9, 10, and 12(Blacker et al., 2003b; Kehoe et al., 
1999; Myers et al., 2000; Myers et al., 2002a; Pericak-Vance et al., 1997; Pericak-
Vance et al., 2000; Rogaeva et al., 1998). 
Most of these studies utilized non-overlapping samples and applied distinct 
approaches like genome-wide linkage screens, a genome screen using plasma Aβ 
levels as a quantitative phenotype, and a candidate gene–based limited genome screen. 
In these studies a large portion of Chr.10 was repeatedly identified with linkage and/or 
association with AD (Bertram et al., 2000; Blacker et al., 2003b; Ertekin-Taner et al., 
2000; Farrer et al., 2003; Kehoe et al., 1999; Myers et al., 2000).  
The genes that are located in the chromosome 10 linkage region are considered 
positional candidate genes, and a number of them have been tested for their 
association with LOAD. However, none of these genes has been consistently 
associated with altered AD risk. Since altered APP metabolism lies at the heart of AD 
pathogenesis, we hypothesize that some of the chromosome 10 positional candidate 
genes regulate APP metabolism. To test this hypothesis we utilize a funcational assay 
to monitor APP metabolism while expression of each of the positional candidate genes 
is reduced. 
Specifically, we use shRNA mediated RNAi to knock down individual 
positional candidate genes located between 3.5 and 105 Mb on Chr.10,  since this 
region has been consistently reported by several groups to harbor candidate genes 
associated with AD. These genes are knocked down in a human neuroblastoma cell 
line (SH-SY5Y) that has been engineered to stably express APP-Gal4 and carry a Gal4 
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responsive Luciferase  reporter gene (Zhang et al., 2007). Using these SH-SY5Y-APP-
Gal4 cells, alterations in APP metabolism are monitored by increases or decreases in 
luciferase. Using this approach we have identified 16 novel modulators of APP 
metabolism located on Chr. 10. 
 
Methods: 
 
Database for Chr.10q11-25: We created a database that listed information on gene 
function and expression for all the genes in Chr.10, 3.5-105Mb. To create this 
database, we used information from publicly available databases including NCBI, 
Golden Pathway (http://genome.ucsc.edu/), and Gene Cards 
(http://www.genecards.org). Since the genomic region on Chr10q11-25 was large, we 
ranked the genes to prioritize the ones that are more likely to be involved in APP 
metabolism. Genes were ranked based on their involvement in: (i) Pathways involving 
APP metabolism and Aβ generation, aggregation and degradation; (ii) Pathways 
involving apoptosis or calcium-homeostasis; (iii) Pathways related to inflammation 
and oxidative stress; (iv) Pathways involved in tau modification (e.g. phosporylation) 
and axonal transport; (v) Pathways involved in cholesterol transport and metabolism; 
(vi) Neuroprotective, neurotropic and neuronal signaling pathways; (vii) coagulation 
pathways; and (viii) proteosomal pathways.  
We then chose the top 100 candidate genes based on their function and 
knocked them down separately using RNAi in our reporter cell line (Figure 3.2).  
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Cell lines and reagent: SH-SY5Y (neuroblastoma cells) and human embryonic 
kidney HEK-293 were purchased from ATCC. They were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2mM L-Glutamine, 
100 units/ mL penicillin, and 100ug/mL streptomycin. SH-SY5Y reporter cells stably 
expressing APP-Gal4 and Gal4-UAS-luciferase that has been previously described by 
us(Zhang et al., 2007). These cells were maintained in media containing 200ug/mL of 
G418.  
 
shRNA library: All the plasmid based shRNA constructs were purchased from Open-
Biosystems (Birmingham, AL) and supplied to us by the Drexel University RNAi 
resource center. The shRNA constructs are designed based on microRNA-30 
(miRNA30) primary transcript. If available, each gene was targeted with multiple 
shRNAs, each shRNA binding a unique target region. We used non-silencing 
shRNAmir (shNC, RHS 1707) as a negative control. This construct is designed to 
contain no homology to known genes. 
 shRNA targeting APP(shAPP) and shRNA targeting luciferase(shLuc, RHS1705) 
were used as positive controls for knockdown.  
 All the controls and gene specific shRNAs were cultured and prepared based 
on manufactures instructions. 
  
shRNA transfections, luciferase assay: For transfection in SH-SY5Y APP-Gal4 
cells, 7500 cells/well were plated in 96 well plates.  24 hours post plating, shRNA 
constructs were transfected using Arrest-In transfection reagent (Open Biosystems, 
  92 
Inc.) using the conditions suggested by the manufacturer. Stably expressing shRNA 
clones were generated by adding 2 μg/ml puromycin 24 hours post-transfection. 
Populations of resistant clones were detected 2-3 weeks post-transfection. 
Luciferase and  SYBR Green assays were performed based on parameters 
described by Zhang et al.,2007 .  
 
Statistical analysis: Values in the text and figures are represented means ± standard 
deviation of at least six replicates. Two-sample student’s t-test was used to compare 
each RNAi line to the negative control. Bonferroni correction analysis was used to 
correct for multiple comparisons within a single experiment. The α value sent for 
Bonferroni correction was set at 0.05. 
Results: 
 
Selection of positional candidate genes on Chr.10q11-25:  
Since the region implied with LOAD on Chr.10q11-25 harbors 437 genes 
(Figure 3-1), we prioritized genes based on their function and expression levels in the 
brain. We created a database for all the genes and sorted them based on the criteria 
mentioned in method section. Once identified, we chose the top 100 positional 
candidate genes. Of these top 100 candidate genes, 38% were involved in pathways 
that are involved with neuroprotective, neurotropic and neuronal signaling, 18% with 
APP metabolism and Aβ generation, and Aβ aggregation and degradation, 19% with 
calcium-homeostasis and apoptosis, and 26% with inflammation and oxidative stress, 
tau modification (e.g. phosporylation) and axonal transport, cholesterol transport and 
metabolism, coagulation pathways, and proteosomal pathway (Figure 3.3).  
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shRNA based genome wide screen for identification of putative APP metabolism 
regulators.  
We used SH-SY5Y APP-Gal4, UAS-Luc for identification of putative 
candidate genes. We assayed 200 shRNA pools each consisting of 1-3 different 
shRNAs targeting the same gene. This was done to reduce the possibility of obtaining 
false positives. Inhibition of approximately of 10% of these genes induced cytotoxicity 
resulting in death. We used shRNAs targeting Luciferase and APP as negative 
controls. We compared all of our knock down experiments to cells transfected with an 
shRNA that is not specific to any known gene (shNC). All the experiments were 
conducted in a 96 well plate in replicates of six. All the controls performed as 
expected. We obtained stables approximately 3-5 weeks post transfection. The stables 
were subjected to luciferase and SYBR Green assays. Statistical analysis was 
performed using Bonferroni correction for multiple comparisons to eliminate false 
positives. We obtained 16 putative regulators on Chr.10q11-25. Of the 16 candidate 
genes identified, knockdown of 8 genes significantly increased luciferase while 
knockdown of other 8 genes resulted in a significant decrease in luciferase activity 
(Figure 3-4). Knockdown of luciferase and APP genes resulted in about 40% and 70% 
decrease in luciferase activity.  Table 3.1 describes the location of each gene on 
Chr.10q11-25 
Discussion: 
 
According to the amyloid hypothesis, an imbalance in Aβ metabolism leads to 
neurodegeneration. Aβ is produced by proteolytic processing of APP by activity of 
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three secretases; α-, β-, and γ-secretase. A change in APP metabolism can lead to a 
change in Aβ metabolism. Multiple genome wide genetic screens identified regions on 
Chr.10 that can harbor putative candidate genes that modulate APP metabolism. To 
identify these genes, we screened a region between 3-110Mb on Chr.10 that has been 
implied to harbor AD-associated genes by genetic screen. In SH-SY5Y APP-Gal4, we 
knocked down 100 top candidate genes using shRNA mediated RNAi. This reporter 
cell line is robust and has the ability to detect AICD-Gal4 levels with high accuracy 
(Zhang et al., 2007). We identified 16 candidate genes in this region that significantly 
increased or decreased APP metabolism. Here we describe each gene and the possible 
mechanism by which each regulates APP metabolism.  
 
AP3M1 (adaptor-related protein complex 3, mu 1 subunit) 
 Knockdown of AP3M1 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant decrease in APP metabolism. AP3M1 is the medium subunit of an adaptor-
related protein complex called AP3. AP3 is a coat protein implicated in generation of 
secretory and lysosomal-related organelles as well as in synaptic vesicle biogenesis. 
AP3 facilitates budding of vesicles from the Golgi membrane and is believed to be 
involved with protein sorting to the endosomal/ lysosomal system. A decrease in AP3 
expression results in an increase in the lysosomal membrane proteins CD63, lamp-1, 
and lamp-2. There is however no change in the cell surface expression of non-
lysosomal proteins (Dell'Angelica et al., 1999). AP3 is also known to influence 
trafficking of synaptic vesicles (Figure 3-5). In mutant mice that lack the AP3 
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pathway, absence or mislocalization of several synaptic vesicle proteins has been 
observed (Voglmaier and Edwards, 2007)(Figure 3-6).                  
 APP has been shown to undergo degradation via the endosomal/lyososmal 
pathway (Figure 3-7). In our cells, knockdown of AP3M1 significantly decreases 
luciferase activity. We hypothesize that the observed decrease is due to altered 
trafficking of APP or other proteins that are involved in APP metabolism.  
 
GLUD1 (glutamate dehydrogenase 1) 
Knockdown of GLUD1 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism. In the nervous system, GLUD1 is believed to 
be involved in the synthesis and catabolism of glutamate. Glutamate is an excitatory 
neurotransmitter expressed in the mammalian nervous system. In AD brain samples, 
the amount of glutamate metabolizing enzymes, such as glutamate dehydrogenase, 
glutamine synthetase, GS-like protein, and phosphate-activated glutaminase, are 
significantly increased compared to controls (Burbaeva et al., 2005). In human Ntera 
2 neurons, stimulation of metabotropic
 
glutamate by glutamate resulted in an increase 
in sAPPα, produced by cleavage of APP by α-secretase in a non-amyloidogenic 
manner. Glutamate was also shown to increase in intracellular Ca2+. (Jolly-Tornetta et 
al., 1998). Disturbance in intracellular calcium has been linked to AD pathogenesis.  
In our cells, knockdown of GLUD1 significantly increases luciferase activity. 
We hypothesize that the observed decrease is due to a decrease in α-secreatase 
cleavage of APP. A decrease in glutamate level can also decrease the level of 
intracellular calcium, which in turn decrease APP metabolism. 
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GALNACT2 (chondroitin sulfate N-acetylgalactosaminyltransferase 2) 
Knockdown of GALNACT2 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant decrease in APP metabolism. GALNACT2 is a single-pass type II 
membrane protein located in the Golgi apparatus and in Golgi stack membrane. It has 
a Galactosyltransferase activity  and is involved in Chondroitin sulfate (CS) 
biosynthesis. GALNACT-2 transfers 1, 4-N-acetylgalactosamine (GalNAc) from 
UDP- GalNAc to the nonreducing end of glucuronic acid (GlcUA). It is required for 
addition of the first GalNAc to the core tetrasaccharide linker and for elongation of 
chondroitin chains. CSs are proteoglycans found in the extracellular matrix as well as 
on cell surfaces. They are involved with cell adhesion to extracellular matrix, cell 
proliferation, cell migration, cell morphogenesis as well as in cytokine signals. In SH-
SY5Y cells, CS has been shown to be neuroprotective under oxidative stress 
conditions. This neuroprotection is achieved by activation of protein kinase
 
C which in 
turn phosphorylates Akt, inducing synthesis of the antioxidant
 
protein heme 
oxygenase-1(Canas et al., 2007). In primary chick brain neurons, exposure to sub-
lethal doses of hydrogen peroxide(stress inducer) increased total Aβ levels without 
altering total APP and tau protein levels(Goldsbury et al., 2008). In Cos-2 (Monkey 
kidney cells) cells, alteration in APP subcellular location was observed in stress 
conditions induced by sodium azide in the presence of 2-deoxy-D-glucose, a 
glycolysis inhibitor. APP751 was accumulated in Golgi and APP695 in ER. This 
suggests that oxidative stress affects trafficking of APP(Domingues et al., 2007). 
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In our cells, knockdown of GALNACT2 significantly decreases luciferase 
activity. We hypothesize that the observed decrease is due to accumulation of APP in 
ER and Golgi, decreasing production of APP processing products. 
 
PRKG1 (protein kinase, cGMP-dependent, type I also known as PKG1) 
Knockdown of PRKG1 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism. PKG1 is a part of cGMP-dependent protein 
kinase family. It is a serine/threonine-specific protein kinase which undergoes 
activation by cGMP. PRKG1 has two isoforms; PRKGα and PRKGβ, produced by 
alternate splicing at the N-terminus. PRKG1β undergoes activation at a 10-fold higher 
rate than PRKG1α at higher cGMP concentrations. Binding of cGMP to the regulatory 
domain of PRKG results in a conformational change that removes the N-terminus 
from the catalytic core. This activated form of PRKG phosporylates different substrate 
proteins(Feil et al., 2003). Some of the targets include several calcium regulatory 
proteins in or near the sarcoplasmic reticulum, including L-type calcium channel, the 
ryanodine receptor calcium release channel, CaN and troponin I (Mendelsohn, 
2005)(Figure 3-8). 
In our cells, knockdown of PRKG1 significantly increases luciferase activity. 
APP contains many phosphorylatable amino acid residues in its C-teminal tail region 
For example, APPthr668 undergoes phosphorylation by GSK3β, Cdk5, Cdc2, Cdk1 
and JNK APPthr668 phosporylation is believed to be required for interaction between 
AICD and Fe65(Suzuki and Nakaya, 2008). We hypothesize that the observed 
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decrease is due to decrease in phosphorylation of APP which can result in altered APP 
metabolism. 
 
KCNMA1 (potassium large conductance calcium-activated channel, subfamily M, 
alpha member 1) 
  Knockdown of KCNMA1 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism KCNMA1 is a part of large conductance 
calcium sensitive potassium voltage channels called MaxiK. MaxiK is composed of 2 
subunits: the pore forming alpha subunit and a modulatory beta subunit. Association 
between these subunits is regulated by intracellular calcium (Figure 3-8). MaxiK is 
known to control smooth muscle tone and neuronal excitability. In smooth muscles 
cells, MaxiK channels are expressed on the cell surface. They hyperpolarize the 
membrane upon activation and inhibit calcium channel activity. Inhibition results in a 
reduction in intracellular free calcium levels. A reduction in MaxiK may cause an 
increase in intracellular calcium (Davies et al., 2007) (Figure 3-9 and Figure 3-10). 
 In our cells, knockdown of KCNMA1 significantly increases luciferase 
activity. We hypothesize that the observed decrease is due to increase in the levels of 
intracellular calcium and activity of calcium binding proteins. Increase in intracellular 
calcium can result in an increase the activity of calcium dependent proteins that can 
increase APP metabolism. 
 
VDAC2 (Voltage -dependent anion-selective channel protein) 
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Knockdown of VDAC2 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism. VDAC2 is a member of Voltage-dependent 
anion-selective channel protein (VDAC) family. These are pore-forming proteins 
located on the outer mitochondrial membrane and in postsynaptic membranes. VDACs 
regulate mitochondrial metabolic functions by regulating anion fluxes (Cheng et al., 
2003). VDAC2 has been shown to inhibit BAK mediated apoptotic response in cells. 
The regulation of BAK by VDAC2 has been shown to be Bax-dependent (Chandra et 
al., 2005). They form pores releasing CytochromeC from mitochondria activating 
caspase cascade.  
In our cells, knockdown of VDAC2 significantly increases luciferase activity.  
It has been suggested that APP undergoes caspase mediated cleaveage (Milligan, 
2000).  We hypothesize that VDAC2 knockdown increases BAX and BAC activity, 
activating caspase, which increases APP proteolysis. 
 
PLAU (plasminogen activator urokinase) 
Knockdown of PLAU in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant decrease in APP metabolism. PLAU encodes urokinase-type plasminogen 
activator which converts
 
plasminogen to plasmin. PLAU is a serine protease involved 
in degradation of extracellular matrix and possibly with tumor metastasis and 
proliferation. Interestingly, PLAU is a target for the Hedgehog (HH) 
pathway(Feldmann et al., 2008). Ploymorphism in PLAU is linked to LOAD. These 
polymorphisms have been suggested to decreases affinity for fibrin binding. Aß 
aggregates have been shown to induce PLAU
 
expression, increasing plasmin levels 
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which degrade both aggregated
 
and non-aggregated forms of Aß. PLAU knockout 
mice have significantly decreased levels of plasma Aβ40 and 42 levels. However, no 
change was observed in the brain (Ertekin-Taner et al., 2005).  
In adenomas in ApcMin/+ mice (a mouse model of colon cancer), knockdown 
of PLAU results in up regulation of COX-2 expression and Akt pathway (Ploplis et 
al., 2007). 
In our cells, knockdown of PLAU significantly decreases luciferase activity. In 
AD mice model, overexpression of COX-2 gene exacerbated β-amyloid 
neuropathology. Overexpression of COX-2 in CHO cells and H4 cells increase 
production of Aβ. This increase was inhibited by treatment with L685, 458 (γ-
secretase inhibitor). We however see opposite results. The can be attributed to the 
difference in the cell lines.  
 
FAS or Tumor Necrosis Factor Receptor Super Family 6 gene (TNFRSF6)  
Knockdown of FAS in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant decrease in APP metabolism. FAS encodes an antigen which plays an 
important role in the regulation of apoptosis. Interaction of FAS receptor with its 
ligand results in the formation of a death inducing signaling complex. This complex 
induces proteins like Fas-associated death domain protein (FADD), caspase8, and 
caspase10 (Figure3-11). FAS ligand has also been involved with MAPK pathway, 
activating NF-kappaB, MAPK3/ERK1, and MAPK8/JNK in fibroblasts and T-cells. 
Interestingly, transcription of FAS is regulated by CaN, a calcium dependent protein 
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phosphatase, a candidate gene known to modulate APP metabolism (Figure 3-12). 
Several groups showed positive and negative association of FAS with AD.  
In our cells, knockdown of FAS significantly decreases luciferase activity. We 
hypothesize that this decrease is because of a decrease in APP processing. It has been 
suggested that APP undergoes caspase mediated cleave (Milligan, 2000).   
 
SLIT1 (slit homolog 1 (Drosophila),  
Knockdown of SLIT1 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism. In drosophila, slit gene has been shown to 
play an important role in CNS midline formation. Human has three slit homologues: 
slit1, slit2, slit3. Each slit encodes a protein that contains conserved protein–protein 
interaction domains which includes epidermal growth factor (EGF)-like motifs and 
leucine-rich repeats (LRR) (Itoh et al., 1998). 
Slit is a major repellent at the midline of neurons in the central nervous system. Slit 
binds to its Robo (Roundabout) family of receptor. This results in axon repulsion by 
cytoskeletal rearrangements within the axon growth cone (Guthrie, 2004) (Figure 3-
13). Slit1 shares homology with LRRTM3, a neuronal gene shown to promote APP 
processing by BACE1. Knockdown of LRRTM3 in SY5Y and primary neurons inhibit 
secretion of Aβ40, Aβ42, sAPPβ and N-teminal β fragment. Conversely, 
overexpression of LRRTM3 increases Aβ secretion (Majercak et al., 2006). 
           In our cells, knockdown of SLIT1 significantly increases luciferase 
activity. We hypothesize that mechanism by which Slit1 regulates APP metabolism is 
similar to the mechanism displayed by LRRTM3 (Milligan, 2000).   
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SLK, STE20-like kinase, 
Knockdown of SLK in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant decrease in APP metabolism. SLK contains an amino-terminal 
serine/threonine kinase domain, central coiled-coil domain and a carboxy-terminal 
AT1-46 homology (ATH) domain. SLK has been associated with adhesion dynamics 
and cell cycle progression regulation. Overexpression of SLK has been shown to 
induce an apoptotic response. Cleavage of SLK by caspase 3 results in its activation. 
At the leading edge of migrating cells, SLK has been shown to co-localize with 
microtubules and adhesion components. Inhibition of SLK by either knockdown or by 
overexpression of a dominant negative form of SLK has been shown to impair 
microtubule dependent adhesion turnover and delayed migration (Wagner et al., 2008) 
(Figure 3-14). 
In our cells, knockdown of SLK significantly decreases luciferase activity. 
APP is believed to undergo processing while undergoing microtubule-dependent 
anterograde vesicular transport (Fortini, 2002) (Figure 3-15). We hypothesize that 
knockdown of SLK delays migration of vesicles, decreasing APP available for 
processing. 
 
 
CUL2 cullin 2  
Knockdown of CUL2 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism. CUL2 is a member of the cullin family of 
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proteins, components of ubiquitin E3 ligases. It is involved with ubiquitination and 
degradation of proteins. CUL2 is a component of the tumor suppressor complex, 
ElonginB/C-CUL2-RBX-1-Von
 
Hippel-Lindau (VHL). This complex ubiquitinates
 
and degrades hypoxia-inducible factor α (HIFα). Members of the Cullin family, Cul1, 
Cul2, Cul3, Cul4A, Cul4B, and Cul5 undergo neddylation (process similar to 
ubiquitination) by NEDD8 (neural precursor cell-expressed and developmentally 
down-regulated gene), a ubiquitin like protein in mammalian cells. Staining for 
NEDD8 protein as well as ubiquitin was observed in two of ten cases of 
neurofibrillary tangles and senile plaques from patients with Alzheimer’s disease (Dil 
Kuazi et al., 2003).  
In our cells, knockdown of Cul2 significantly increases luciferase activity. We 
hypothesize that knockdown of Cul2 decreases degradation of APP, secretases or 
other proteins that affect APP metabolism.  
 
SUFU suppressor of fused homolog (Drosophila) 
Knockdown of SUFU in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant decrease in APP metabolism. SUFU encodes a component of the Sonic 
hedgehog (Shh) signaling pathway. Hedgehog family proteins act as signaling 
molecules critical in the patterning, proliferation, and cell fate determination of a 
broad range of cells and tissues(McMahon et al., 2003).Activation of the Hh pathway 
results in transcriptional activity of Gli family of proteins Gli1, Gli2, and Gli3 (Figure 
3-16). The Shh pathway has been suggested to undergo activation in response to 
neuronal insults that result in neuronal loss. 
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 In our cells, knockdown of SUFU significantly decreases luciferase activity. 
Since AD is characterized by loss of neurons and synapses, we hypothesize that Shh 
pathway is activated under stress conditions and regulates APP metabolism in a Gli 
dependent fashion. 
 
PPP3CB 
Knockdown of PPP3CB in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant decrease in APP metabolism. PPP3CB is the catalytic subunit of a calcium 
and calmodulin-dependent phosphatase called Calcineurin (CaN). CaN is composed of 
a catalytic subunit and a regulatory subunit. The catalytic subunit has 3 isoforms, 
PPP3CA, PPP3CB, and PPP3CC, while the regulator subunit has 2 isoforms; PPP3R1 
and PPP3R2. One of the well known targets of CaN is NFAT. NFAT is a transcription 
factor that undergoes CaN mediated dephosphorylation. An increase in intracellular 
calcium results in CaN activation resulting in NFAT dephosporylation. This facilitates 
nuclear translocation of active NFAT. NFAT family is composed of multiple isoforms 
(NFAT1, 2, 3, 4, and, 5), all derived by alternative splicing (Rao et al., 1997) (Figure 
3-17). CaN has been shown to dephosphorylate APP at Thr668, and is believed to be 
involved with translocation of AICD into nucleus (Pierrot et al., 2006).  NFAT1, a 
transcription factor that undergoes CaN mediated dephosphorylation controls 
transcription of BACE1. APP undergoes proteolysis by BACE to liberate the Aβ 
fragment (Cho et al., 2008).  
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In our cells, knockdown of PPP3CB significantly decreases luciferase activity. 
We hypothesize that PPP3CB controls phosphorylation state of APP via NFAT 
mediated signaling. 
 
ANXA8 (Annexin VIII) 
Knockdown of ANXA8 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism. ANXA8 is a member of the Annexin super 
family of proteins. These are Ca
2+
-dependent phospholipid binding proteins that have 
been implicated in many calcium regulated processes in the cell. The C-terminal tail of 
Annexins binds to calcium at multiple sites, while the N-terminal tail enables 
interaction of Annexins with distinct cytoplasmic partners. Annexins have been 
associated with inflammation and apoptosis, ion channel regulation, endocytosis, 
exocytosis and, membrane-trafficking (Gerke et al., 2005). However, not much is 
known about the functions of ANXA8. 
In our cells, knockdown of ANXA8 significantly increases luciferase activity.  
 
GOT1 (glutamic-oxaloacetic transaminase 1, soluble (aspartate aminotransferase 1)),  
Knockdown of GOT1 in SY5Y APP-Gal4, UAS-Luc cells resulted in a 
significant increase in APP metabolism. Glutamic-oxaloacetic transaminases (GOT) 
are pyridoxal phosphate-dependent enzymes. GOT is involved with amino acid 
metabolism and is a part of urea and tricarboxy acid cycles. They are found in two 
forms; cytoplasmic GOT1 and mitochondrial GOT2 (Panteghini, 1990).  However, not 
much is known about the functions of GOT1. 
  106 
In our cells, knockdown of GOT1 significantly increases luciferase activity.  
 
HSGT1 (ecdysoneless homolog) 
Knockdown of HSGT1 in SY5Y APP-Gal4, UAS-Luc cells resulted in a significant 
decrease in APP metabolism. HSGT1 also known as GCR2. In Saccharomyces 
cerevisiae, Gcr2p is a key regulatory factor of glycolytic gene expression. HSGT1 is a 
candidate for a novel human transcription factor involved in carbohydrate metabolism 
(Kainou et al., 2006).. However, not much is known about the functions of HSGT1. 
In our cells, knockdown of HSGT1 significantly decreases luciferase activity.  
 
 
In summary, we have identified 16 novel candidate genes on Chr.10q11-25 
that encodes proteins that appear to potentially modulate APP metabolism. Further 
characterization of the mechanism by which each of these genes modulate APP 
metabolism has to be conducted both in vitro and in vivo. If a gene regulates APP 
metabolism both in vitro and in vivo; it or its protein can be a putative drug target. 
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Figures: 
 
 
 
 
 
 
 
 
 
Figure 3-1: Selection of positional candidate genes on Chr.10q11-25 
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Figure 3-2: Scheme for identification of novel regulators of APP metabolism 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Selection of top 100 candidate genes on Chr.10q11-25q21 - 26  
Knockdown of candidate genes in SH - SY5Y APP - Gal4 
Selection of positional candidate genes on chromosome  
10q21 - 26 and 9q22 
Database creation: Function, Gene expression 
434 Genes 
Identification of candidate genes based on Bonferroni correction analysis 
16 Genes 
Identification of candidate genes based on Bonferroni correction analysis 
Characterization of novel genes identified 
  
100 Genes 
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Gene 
Symbol  
Gene 
Symbol  
Gene 
Symbol 
1 CUL2 34 SARA1  67 PANK1 
2 FZD8 35 PPA1 68 PDLIM1 
3 RET 36 GPR147  69 SORBS1 
4 RASGEF1A  37 ADAMTS14  70 KCNIP2 
5 OR13A1 38 SGPL1  71 ELOV3 
6 ALOX5  39 UNC5B  72 NFKB2 
7 SYT15  40 SLC29A3  73 ANKRD1 
8 ANXA8  41 CDH23  74 HECTD2 
9 GALNACT2  42 SPOCK2  75 IDE 
10 SLC18A3 43 ASCC1  76 HTR7 
11 GDF2  44 PPP3CB  77 TNKS2 
12 GDF10 45 SEC24C  78 ENTPD1 
13 MAPK8  46 CHCHD1  79 KIF11 
14 CHAT 47 LOC196752  80 LCOR 
15 ASAH2  48 KIAA0913  81 SLIT1 
16 TMEM23  49 CAMK2G  82 FRAT1 
17 PRKG1  50 HSGT1  83 FRAT2 
18 DKK1 51 PLAU 84 SFRP5 
19 PCDH15  52 VCL  85 COX15 
20 UBE2D1  53 AP3M1  86 DNMBP 
21 ANK3  54 MYST4  87 NDUFB8 
22 JMJD1C  55 VDAC2  88 HIF1AN 
23 LRRTM3  56 KCNMA1  89 BTRC 
24 SIRT1  57 NRG3 90 GOT1 
25 CTNNA3  58 GRID1 91 CUTC 
26 HNRPH3  59 PTEN 92 CHUK 
27 CCAR1  60 FAS 93 SUFU 
28 VPS26A  61 BMPR1A 94 WNT8B 
29 HK1  62 SNCG 95 SLK 
30 KIAA1279  63 GLUD1 96 ACSL5 
31 TACR2  64 STAMBPL1 97 VTI1A 
32 NEUROG3  65 CH25H 98 TCF7L2 
33 AMID 66 LIPA 99 HABP2 
    100 CASP7 
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neuroprotective, neurotropic and neuronal signaling
APP metabolism and Aβ generation,and Aβ aggregation and degradation
calcium-homeostasis and apoptosis
 inflammation and oxidative stress, tau modification (e.g. phosporylation) and axonal transport,
cholesterol transport and metabolism, coagulation pathways, and proteosomal pathway
 
 
Figure 3-3: List and Function of top 100 candidate genes 
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Figure 3-4: Candidate genes that modulate APP metabolism 
SH-SY5Y APP-gal4 cells were transfected with control shRNA or gene-specific 
shRNA and selected with 2µg/mL puromycin for 3 weeks. The cells were washed with 
PBS and subjected to luciferase assay. 
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Gene name Luciferase # of constructs Mb* Location 
AP3M1 ↓ 1 3.5 10q22. 
CUL2 ↑ 1 35.3 10p11.21 
CSGALNACT2 ↓ 2 43.0 10q11.21 
ANXA8 ↑ 2 47.9 10q11.22 
PRKG1 ↑ 1 52.4 10q11.2 
HSGT1 ↓ 1 74.6 10q22.1 
PPP3CB ↓ 2 74.9 10q21-q22 
PLAU ↓ 1 75.3 10q24 
VDAC2 ↑ 1 76.6 10q22 
KCNMA1 ↑ 2 78.3 10q22.3 
GLUD1 ↑ 2 88.8 10q23.3 
FAS ↓ 1 90.7 10q24.1 
SLIT1 ↑ 2 98.8 10q23.3-q24 
GOT1 ↑ 1 101.1 10q24.1-q25.1 
SUFU ↓ 1 104.3 10q24.32 
SLK ↓ 1 105.7 10q25.1 
 
* Build 36.3  
 
 
 
 
Table 3-1: Candidate genes that modulate APP metabolism 
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Figure 3-5: Recycling of synaptic vesicle mediated by AP3.  
Three mechanisms by which synaptic vesicle components undergo recycling.  ynaptic  
vesicles undergoes an AP3 mediated bulk endocytosis upon strong  
stimulation(Voglmaier and Edwards, 2007). 
 
 
 
 
 
 
             
Figure 3-6: Retention of protein in the soma in AP3 knockout (mocha) mice 
compare to wild type mice. 
Trafficking of TI-VAMP expressed in granule cells of rodent dentate gyrus. In wild 
mice, Ti-VAMP is concentratedin the nerve terminals. In mocha mice which does not 
express AP- 3, TI-VAMP is blocked in the granule cell and soma (Danglot and Galli, 
2007). 
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Figure 3-6: Intracellular trafficking and degradation of APP.  
(Tate and Mathews, 2006) 
 
 
 
 
(Mendelsohn, 2005) 
 
 
 
Figure 3-7: Activity of PKG-1. Mechanism by which PKG-1 activates calcium 
dependent proteins in cells. Activation of these pathway activates and transcription 
factor (TF, including MEF2, NFAT) which can modulate APP metabolism. 
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 MaxiK Channel 
 
 
 
 
Figure 3-8:  Affect of aging on MaxiK channels. KCNMA1 is a part of large 
conductance calcium sensitive potassium voltage channels called MaxiK. A reduction 
in MaxiK channels in old animals result in an increase in free intracellular calcium. 
Calcium is beleoved to modulate APP metabolism.(Davies et al., 2007) 
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Figure 3-9: Affect of aging on MaxiK channels. A reduction in MaxiK channels in 
old animals result in an increase in free intracellular calcium (Reed, 2006). 
 
 
  
 
 
Figure 3-10: Fas mediated caspase activation and apoptosis. Fas has been shown to 
be involved with inflammation and apoptosis. Binding of Fas ligand to receptor 
activates Fas-associated protein with death domain (FADD). Procaspase 8 binds to 
Fas-FADD resulting in activation of caspase8. Caspase8 activates other caspases and 
ultimately activates apoptosis. (Kurita et al., 2001) 
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Figure 3-11: CaN mediated FAS regulation: PPP3CB, the catalytic subunit of CaN 
has been proposed to activate transcription of FasL and induce apoptosis.  
 
 
 
 
 
 
 
Figure 3-12: Slit mediated axonal attraction and repulsion (Guan and Rao, 2003). 
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Figure 3-13: Model for SLK activation and recruitment at the leading edge. 
(Wagner et al., 2008) 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-14: A model for microtubule mediated transport of APP (Fortini, 2002). 
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Figure 3-15: Activation of hedgehog pathway (Pasca di Magliano and Hebrok, 
2003).  
In absence of ligand (Shh), the HH pathway is inactive. Patched, a transmembrabe 
protein inhibits the activity of Smoothened (SMO), a seven transmembrane protein. 
This complex inhibits Gli, a transcripton factor from enterning the nucleus. This 
inhibition is mediated through the interactions with cytoplasmic proteins, including 
Fused and Suppressor of fused (Sufu). This results in inhibition of transcriptional 
activation of HH targets. In presence of the ligand, HH pathway activates gene 
transcription. 
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Figure 3-16: CaN pathway (Steinbach et al., 2007) 
Induction of intracluular calium stores and ER by IP3 results in calcium release. 
Intracellular calcium binds to ubiquitous calcium sensor calmodulin. Calmodulin is 
known to regulate a variety of intracellular proteins including Calcinuerin. Acivated 
calcinuin is known to dephosporylate NFAT, a transcription factor and regulate 
transcrition of target genes. (Muller and Rao, 2007) 
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Chapter 4 : Characterization of the role of the Shh pathway in in vitro and in vivo 
models of Alzheimer’s Disease 
 
Background 
 
The highly conserved Hedgehog (Hh) family proteins play a critical signaling role in 
the patterning, proliferation, and cell fate determination of a broad range of cells and 
tissues(McMahon et al., 2003). Hh proteins are secreted proteins, first discovered in 
Drosophila. Three known members of the Hh family are Sonic hedgehog (Shh), desert 
hedgehog (DHh), and Indian hedgehog (IHh) hedgehog. Hh ligands undergo 
maturation by autocatalysis via their C-terminal domains resulting in addition of a 
cholesterol moiety at the C-terminus of the N-terminal peptide (SHH-N). They further 
undergoes palmitoylation at the N-terminus(Daya-Grosjean and Couve-Privat, 2005). 
The Hh pathway is activated though the interaction of Hh ligand with Patched1 
(PTCH), multi-pass transmembrane receptor. This interaction activates a 
transmembrane protein Smoothened (SMO), a seven transmembrane protein which 
shares homology with the G-protein coupled receptor family. In the absence of the Hh 
ligand, PTCH acts a repressor of the pathway by repressing SMO. However, in 
presence of Hh ligand, PTCH activates SMO, resulting in nuclear translocation of 
members of Gli family.  
Gli proteins are zinc finger transcription factors, primary mediators of Hh 
signal transduction. Gli family is composed of Gli1, Gli2, and, Gli3. The Glis have 
both activator and repressor functions. In humans, Gli1 is has a strong activator 
function, Gli2 has both activator and repressor functions, and Gli3 is mostly a 
repressor(Aza-Blanc et al., 2000; Bai et al., 2004; Nguyen et al., 2005; Ruiz i Altaba, 
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1998, 1999; Stamataki et al., 2005; Tyurina et al., 2005). Full length Gli proteins act as 
strong activators. C-terminally deleted forms Gli 2 and Gli3, mediated by the 
proteasome, act as repressors.  The fly homolog of Gli, Cubitus interruptus (Ci) acts as 
both an activator and a repressor (Methot and Basler, 1999).  
In the absence of Hh ligand, Gli2 and Gli3 are expressed while Gli1 is 
transcriptionally silent. Full length Gli2 and cleaved Gli3 acts as transcriptional 
repressors silencing targets. However, in the presence of Hh ligand, Gli1 is 
transcriptionally active, possibly by the activity of Gli2 or Gli3; Gli2 becomes an 
activator; and Gli3 is inactive as it is no longer cleaved (Bai et al., 2004; Ruiz i Altaba, 
1998, 1999; Stamataki et al., 2005; Tyurina et al., 2005). Thus in the absence of Hh 
ligand, repressors are made and in the presence of ligand, activators are made. 
However, the molecular mechanisms that regulate Gli activity are not 
completely understood. In flies, Ci is shown to be regulated by Fused (FU), a 
serine/threonine kinase; suppressor of fused (SUFU); and Cos2, a kinesin-like protein. 
In the absence of Hh ligand, Ci forms a complex formed by FU, SUFU and, Cos2 
(human Kif27 homolog) and is retained in the cytoplasm. This retention results in 
proteolytic processing of full length Ci (CiA) to its repressor form (CiR). Binding of 
the Hh ligand releases this complex, there, by activating transcription by Ci (Hooper 
and Scott, 2005; Lum and Beachy, 2004). Thus Cos2 and SUFU act as negative 
regulators of Ci activity. 
Of all the Hh pathways, the best understood is the Shh pathway. Shh regulates 
patterning of neural tubes (Lupo et al., 2006)  and plays a major role in proliferation 
and differentiation of neural progenitors (Dahmane et al., 2001).This pathway is 
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believed to be silent in post-natal life. Recently, Shh was shown to be expressed in 
adult skeletal muscle, activating the injury pathway and during regeneration (Straface 
et al., 2008). Evidence suggests that certain types of neuronal cell types synthesize and 
secrete Shh. Astrocytes and glial cells respond to secreted ligand by increasing the 
expression of Gli and PTCH. In cultured fibroblasts, Shh ligand induces expression of 
brain-derived neurotrophic factor and insulin-like growth factor 1. Similarly, 
expression of cytokines involved in angiogenesis in mesenchymal cells(Dellovade et 
al., 2006). This suggests that Shh pathway undergoes activation in response to 
neuronal insults which in turn results in neuronal loss. Since the neuronal loss is so 
closely associated with Alzheimer’s disease, we hypothesized that Shh pathway is 
involved in AD. We identified two key components of this pathway, SUFU and KIF27 
from our functional screen of Chr.10 and 9, respectively. This screen was used to 
identify modulators of APP metabolism. We are interested in determining if the Hh 
pathway regulates APP metabolism.  
APP is a type-1 transmembrane protein which undergoes regulated 
intramemberous proteolysis to produce amyloid beta (Aβ). Aβ42 is considered the 
most toxic isoforms due to its hydrophobic nature, resulting in aggregation and plaque 
formation. Intracellular Aβ is though to be neurotoxic while extracellular Aβ 
oligomers and plaques are believed to cause inflammation, oxidative stress, and 
apoptosis.  
Using pharmacologic reagents and by genetic modulation, we demonstrate that 
the Shh pathway regulates APP metabolism. We are interested in determining if 
regulation of APP is mediated by Gli transcription factors. 
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Results 
 
Pharmacologic modulation of Shh pathway alters AICD-Gal4 mediated 
luciferase activity 
To determine whether Shh pathway alters APP metabolism, we used 
Cyclopamine, a plant alkaloid that blocks Shh activity by interacting with SMO (Chen 
et al., 2002b; Incardona et al., 1998). SH-SY5Y APP-Gal4 cells were treated with 
Cyclopamine or with vehicle (DMSO) for 5 hours. The final DMSO concentration was 
0.01%. A dose dependent decrease in luciferase activity was observed with increase in 
inhibitor concentration (Figure 4-1). We observed a significant decrease in luciferase 
activity at 1mM and 2mM concentration of the inhibitor (p<0.05) as compared to 
DMSO-treated controls. 
 
Genetic manipulation of components of Shh pathway modulates AICD-Gal4 
mediated luciferase activity: 
Since cyclopamine is capable of inhibiting Shh, DHh and, IHh; we wanted to 
determine if the decrease in luciferase expression in cyclopamine treated cells is 
dependent on the Shh pathway. To determine this, we knocked down individual 
components of the Shh pathway in SY5Y-APP-Gal4 cells.  We used commercially 
available shRNAs from Open Biosystems for this purpose. A control shRNA, which is 
not complementary to any known human gene, was used as a negative control. SY5Y-
APP-Gal4 cells were transfected with individual shRNAs and selected with 2 μg/ml 
puromycin for 3 weeks. Knockdown of Shh and SUFU decreased luciferase activity 
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significantly (p<0.05) (Figure 4-2). However, knockdown of KIF27 did not change 
luciferase activity in a significant manner. 
 Over-expression plasmids for individual components of Shh pathway or empty 
vector controls were transiently transfected in the SY5Y-APP-Gal4 cells. Cell lysates 
were collected 24 hours post transfection. Overexpression of SMO, Shh and SUFU 
significantly increases luciferase activity while overexpression Ptch significantly 
decreases luciferase activity (p<0.05) (Figure 4- 3).  
 
Shh pathway modulates AICD-dependent pathology in the developing Drosophila 
eye: 
  We wanted to further verify the effects of overexpression and knockdown of 
Hh pathway components on APP metabolism in a model organism. We utilized the 
previously created Drosophila melanogaster γ-secretase reporter flies (Gross et al., 
2008; Guo et al., 2003).  These flies expresses a C99-Gal4 fusion protein in the 
developing retina (Gross et al., 2008; Guo et al., 2003).  Proteolytic processing of this 
fusion protein is carried by endogenous secretase activity in the fly retina (Gross et al., 
2008; Guo et al., 2003). Processing releases an AICD-Gal4 fragment that  activates the 
transcription of a cell death activator called Grim (Chen et al., 1996). Expression of 
Grim causes apoptosis. Apoptosis results in a rough eye phenotype, loss of 
pigmentation, disrupted bristle morphology (Figure 4- 7B: Grim fies, Figure 4- 7A: 
wild type files).  
To demonstrate that the rough eye phenotype was dependent on APP 
metabolism, we treated GMR-APP-Gal4, UAS:Grim flies with L-685, 458, a γ-
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secretase inhibitor. Control flies were treated with vehicle (DMSO). The rough eye 
phenotype was scored from + to +++ based on the severity of the rough eye 
phenotype. In the treatment flies, 100nM and 250nM of L685, 458 significantly 
suppressed (p<0.0001) the rough eye phenotype (Figure 4- 5) (Table 4-1). This shows 
that the observed rough eye phenotype is γ-secretase mediated and not a non-specific 
mechanism.  
To investigate if Shh inhibition in reporter flies decreases APP metabolism, we 
treated the GMR-APP-Gal4, UAS:Grim flies with  Cyclopamine, a plant alkaloid that 
blocks Shh activity by interacting with SMO (Chen et al., 2002b; Incardona et al., 
1998). Controls flies were treated with Vehicle (DMSO). The flies were scored from + 
to +++ based on the severity of rough eye phenotype.   We observed that treatment 
with 100 nM Cyclopamine significantly suppressed (p<0.0001) the rough eye 
phenotype (Table 4- 2; Figure 4- 6), due to a decrease in AICD production and 
resulting decrease in Grim protein expression. 
Since cyclopamine is capable of inhibiting Shh, DHh and, IHh; we wanted to 
determine if the decrease in Grim expression in cyclopamine treated flies is dependent 
on Shh pathway. To determine this, we crossed GMR-APP-Gal4, UAS: Grim flies 
with mutant flies including Hh
AC
, a Null loss-of-function allele, Kif27 (Cos2
W1
 and 
Cos2
k16101
 strong loss-of-function alleles, and Cos2
5 
and
 
Cos2
3
, Moderate loss-of-
function allele, and SMO
3
, Null loss-of-function alleles. The progeny were scored 
from + to +++ based on the severity of rough eye phenotype. Combining the reporter 
constructs with Loss of function of Hh
AC
, Cos2
W1
,
 
Cos2
k16101 
or
 
SMO
3 
significantly 
enhances the rough eye phenotype (p<0.001), (Figure 4-7)(Table 4- 3). 
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SUFU modulates APP metabolism: 
To determine the role of SUFU in APP metabolism, we transiently 
overexpressed wild type SUFU or ex8SUFU mutant (DXC8-SUFU) in SH-SY5Y 
APP-gal4 cells. ex8SUFU mutant lacks the carboxy-terminal half of SUFU. This 
demolishes binding of SUFU with Gli1 or Gli2 (Taylor et al., 2002). Over-expression 
was conducted by transiently transfecting individual over-expression plasmids or 
empty vector controls into the SY5Y-APP-Gal4 cells. Cells were collected 24 hours 
post transfection. We observed a significant increase in AIDCD-dependent luciferase 
activity with overexpression of either wild type SUFU or ex8 mutant SUFU. 
Interestingly, we observed a significant decrease in luciferase activity between wild-
type SUFU and ex8 mutant SUFU (Figure 4-4). 
 
microRNA regulate APP metabolism: 
To determine if microRNAs modulate APP metabolism in our reporter cell 
line, we overexpressed Dicer and Exportin5 (Exp5), components of the microRNA 
pathway. Overexpression of Dicer and Exp5 in SH-SY5Y APP-Gal4 cells 
significantly increased AICD-mediated luciferase activity in these cells (Figure 4- 8). 
SUFU metabolism has been shown to be regulated by miR-214 and miR-378 (Flynt et 
al., 2007; Lee et al., 2007). To determine if miR-214 and miR-378 regulate SUFU in 
our reporter cell line, we over-expressed of miR-214 and miR-378 in SH-SY5Y APP-
Gal4. Overexpression of these microRNAs significantly increases AICD-mediated 
luciferase activity (Figure 4- 9). 
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Discussion 
 
 
According to the amyloid hypothesis, imbalance in Aβ metabolism leads to 
neurodegeneration. Aβ is produced by proteolytic processing of APP by the activity of 
three secretases; α-, β-, and γ-secretase. A change in APP metabolism can lead to a  
change in Aβ metabolism. Multiple genome-wide genetic screens identified regions on 
Chr.10 that can harbor putative candidate genes that modulate APP metabolism. To 
identify these genes, we screened the region between 3-110Mb on Chr.10, a region 
implied to harbour genes associated with AD by multiple genetic screens. We 
conducted an RNAi based screen in SH-SY5Y APP-Gal4 and identified SUFU, a key 
component of the hedgehog pathway as a putative regulator of APP metabolism. 
Interestingly, KIF27, another component of HH pathway was identified in a similar 
manner on Chr.9. This led us to investigate the role of the HH pathway in APP 
metabolism. 
Here we show that the SHH pathway modulates APP metabolism both in vitro 
and in vivo. For in vitro experiments, we used SY5Y APP-Gal4 cells and for in vivo 
experiments, we used a Drosophila model of AD. These flies overexpress C99-Gal4 
that activates transcription of UAS-GRIM.  Activation of GRIM in the eyes results in 
a rough eye phenotype due to loss of pigmentation, as well as eye bristles (Guo et al., 
2003). To determine if the rough eye phenotype was secretase-dependent, we inhibited 
endogenous γ-secretase activity using L685, 458. We observed suppression in the 
rough eye phenotype suggesting that rough eye phenotype is indeed secretase 
dependent.  
  129 
 To determine if the Hh pathway was involved with APP metabolism, we used 
Cyclopamine, a plant alkaloid that interacts with SMO and inhibits the Hh pathway 
(Chen et al., 2002b; Incardona et al., 1998). Inhibition of the Hh pathway with 
Cyclopamine in vitro and in vivo significantly decreased APP metabolism.  
Since Cyclopamine inhibits SHH, DHH and, IHH, we knocked down SHH 
protein in our reporter cell line using RNAi. Shh knock down resulted in a significant 
decrease in AICD-mediated luciferase activity. To determine if Shh regulated APP 
metabolism in vivo, we crossed GMR-APP-Gal4, UAS:Grim with Hh
AC
 (Shh loss-of-
function mutant). We observed a significant suppression of rough eye phenotype in the 
progeny. This suggests that Shh pathway regulates APP metabolism both in vitro and 
in vivo.  
To determine whether KIF27, a gene identified from our functional screen 
modulated APP metabolism in flies, we crossed GMR-APP-Gal4, UAS: Grim with 
two independent Cos2 (drosophila homolog of KIF27) loss of function mutants 
(Cos2
W1
 and Cos2
k16101
). We observed that the progeny had a significant enhancement 
in rough eye phenotype. Knockdown of KIF27 in the reporter cell line also resulted in 
a significant increase in luciferase activity.  
To determine whether other components of the Shh pathway modulated APP 
metabolism, we overexpressed SHH, PTCH, SMO, SUFU in SY5Y-APP-Gal4 cells. 
We observed that overexpression of SHH, SMO, and, SUFU significantly increased 
luciferase activity while overexpression of PTCH significantly decreased luciferase 
activity. To determine if we observe similar effects in flies, we crossed GMR-APP-
Gal4, UAS:Grim with SMO
3
loss of function mutants. We, however, obtained the 
  130 
opposite results. Inhibition of SMO in flies enhanced the rough eye phenotype. We 
think that this is due a to difference in the cell types. 
 Since knockdown and overexpression of SUFU produced expected opposite 
effects, we overexpressed a mutant form of SUFU that lacked the carboxy-terminal 
half of SUFU abolishing its interaction with Gli1 and Gli2. Overexpression of mutant 
SUFU has been shown to activate SHH pathway (Taylor et al., 2002). This is possibly 
due to the activity of Gli3. We observed similar results in our reporter cell line. 
Overexpression of mutant SUFU significantly decreased luciferase activity compared 
to wild SUFU. However, Overexpression of mutant-SUFU significantly increased 
luciferase activity compared to the control. This suggests that APP metabolism is 
regulated in a Gli dependent manner.  
Interestingly, SUFU has been shown to be regulated by microRNAs. To 
determine if our reporter cell line was capable of detecting microRNA inducible 
changes, we overexpressed Dicer and Exp5, two components of the microRNA 
pathway. With overexpression of Dicer and Exp5, we observed a significant increase 
in AICD-mediated luciferase activity. We chose miR214 and miR378, as they both are 
directly regulated by SUFU (Flynt et al., 2007; Lee et al., 2007). Overexpression of 
miR214 and miR378 significantly increased luciferase activity in our reporter cell 
lines. However, this is opposite to what we expected to see. We think that this is due 
to difference in the cell types. However, it is interesting to observe that miR214 and 
miR378 regulate APP metabolism. 
In summary, we show that the Shh pathway regulates APP metabolism both in 
vitro and in vivo. Shh pathway is believed to be active only during developmental 
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stages. We here find that this pathway is active in adult flies and is capable of 
modulating APP metabolism. It will be important to determine if whether metabolism 
is Gli dependent. It will also be important to determine whether Shh directly affects 
APP or secretases or controls APP metabolism by altering other proteins that can 
affect APP metabolism. 
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Methods: 
 
Pharmacologic reagents used: Cyclopamine (Sigma Aldrich) was used for some 
experiments. Cyclopamine was dissolved in DMSO. Cyclopamine was used for 
treatment of APP-Gal4-SY5Y cells for 5 hours. Following the treatments, the cells 
were washed twice with cold PBS and lysed with GLB (Promega, Inc.). Lysates were 
used for luciferase assay using Steady Glo (Promega, Inc.). Luciferase counts were 
normalized to total DNA concentration that was measured using the SYBR Green 
(Invitrogen), L-685,458, -secretase transition state inhibitor was purchased from 
Sigma Aldrich.  
 
Plasmids: Renilla luciferase plasmid pRLSV40 (Promega). SMO-M2, PTCH-Luc, 
hSHH H2 were generously gifted by Dr. Rune Toftgård. pcDNA3.1−MycSUFU and 
pcDNA3.1MycSUFUex8 were generously gifted by Dr. Christian Smith. 
 
Cell lines and reagent: SH-SY5Y (neuroblastoma cells) and human embryonic 
kidney (HEK)-293 were purchased from ATCC. They were cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2mM L-Glutamine, 
100 units/ mL penicillin, and 100ug/mL streptomycin. SH-SY5Y reporter cells stably 
expressing APP-Gal4 and Gal4-UAS-luciferase that has been previously described by 
us (Zhang et al., 2007). These cells were maintained in media containing 200ug/mL of 
G418.  
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RNAi: Plasmid-based shRNA constructs were purchased from Open-Biosystems 
(Birmingham, AL). These constructs are part of the human retroviral shRNA library 
housed at the Drexel University RNAi Resource Center. We utilized the following 
target-specific shRNAs: KIF27, SUFU, SHH shRNAs from Open Biosystems. As a 
negative control shRNA, we utilized the non-silencing shRNA from Open Biosystems, 
Inc. (RHS 1707). shRNA constructs were transfected using Arrest-In transfection 
reagent (Open Biosystems, Inc.) using the conditions suggested by the manufacturer. 
Stably expressing shRNA clones were generated by adding 2 μg/ml puromycin 24 
hours post-transfection. Populations of resistant clones were detected five to seven 
days post-transfection. 
 
Transfections and Luciferase assay: For transfection in SH-SY5Y APP-Gal4 cells, 
7500 cells/well were plated in 96 well plates.  24 hours post plating, shRNA constructs 
were transfected using Arrest-In transfection reagent (Open Biosystems, Inc.) using 
the conditions suggested by the manufacturer. Stably expressing shRNA clones were 
generated by adding 2 μg/ml puromycin 24 hours post-transfection. Populations of 
resistant clones were detected 2-3 weeks post-transfection. 
For transient transfections in SY5Y-APP Gal4 cells, 10,000 cells/well were 
plated in 96 well plates. 24 hours post plating, over-expression plasmids were 
transfected using Arrest-In™ transfection reagent (Open-Biosystems) using conditions 
suggested by the manufacturer. 24 hours post transfection, lysates were collected and 
subjected to luciferase assays. 
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For luciferase assay, SYBR Green assay and Dual-Glo assays, we used the 
protocol and parameters descried by us (Zhang et al., 2007) .  
 
Fly lines: All flies were raised on standard cornmeal/molasses/agar media. For drug 
treatment, Cyclopamine or L-685,458 was added to standard fly medium to a final 
concentration of 100nM (Cyclopamine) or 100nM and 250nM (L-685,458). For 
control, DMSO was used (0.01% concentration). Larvae were raised on 100nM 
Cyclopamine or 100nM or 250nM L-685,458 or vehicle containing food. Upon 
enclosure, they were scored for phenotypic effects. 
 For crossing experiments, we used Hh
AC
, Cos2
W1
, Cos2
k16101
, Cos2
5
, Cos2
3,
 SMO
3 
, 
UAS:LacZ, (Bloomington Stock Center, http://flybase.bio.indiana.edu/), Canton S, 
and GMR-App-Gal4, UAS:Grim / Cyo (Gross et al., 2008; Guo et al., 2003).  All 
crosses were performed at 25 C.  GMR-APP-Gal4, UAS:Grim / Cyo flies were 
outcrossed to both w
1118
 and Canton S genotypes to determine the reference eye 
phenotype for the GMR-APP-Gal4, UAS:Grim adult eyes, as previously described 
(Gross et al., 2008; Guo et al., 2003).  Adult eyes were immersed in 95% ethanol and 
photographed using a Canon PowerShot S70 digital camera mounted to a Leica Mz 
125 stereomicroscope.  
Fly lines expressing loss or gain of function mutations were crossed with γ-
secretase reporter flies (Gross et al., 2008; Guo et al., 2003) and the progeny were 
scored (+ to +++) for effects on eye phenotype. “+” is a rough eye, where at least one-
half of the eye field is wild type. “++” is a rough eye where more than one-half of the 
eye is rough, usually affecting the whole eye, but not always. “+++” is a strong rough 
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eye where the entire eye is affected, and there is a strong loss of pigment in the 
posterior one-half of the eye. To determine if there is a statistically significant change 
in phenotype relative to wild type we performed a G-test of homogeneity.  
 
Statistical Analysis: Values in the text and Figures are represent means ± standard 
deviation of at least six replicaes. Two-sample student’s t-test was used to compare 
two groups. For in vivo studies, a G-test of homogeneity was performed to determine 
statistical significance. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  136 
Figures: 
 
 
 
 
 
 
 
 
Figure 4-1: Dose-dependent decreases in AICD-Gal4-mediated luciferase activity 
with increasing concentrations of Cyclopamine 
Points represent mean normalized luciferase activity (+/- standard deviation), with 
luciferase levels normalized to total cell numbers using SYBR Green. Two tail 
student's t-test was utilized to test for significance. "Control" uses the same media as 
the treatments, and also contains the same amount of DMSO. 
* indicates p < 0.05. 
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Figure 4-2: Transfection with shRNAs specific for Shh and SUFU decreases 
AICD-Gal4-mediated luciferase expression compared to control shRNA 
 Knockdown of Kif27 does not change Gal4-mediated luciferase expression in a 
significant manner. Error bars represent standard deviation. Statistical significance 
was determined using two-sample, two tailed t-tests to compare SUFU and Shh 
shRNA with the control shRNA.  
* indicates p < 0.05. 
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Figure 4-3: Transient over-expression of individual components of Shh pathway 
increases AICD-Gal4 mediated luciferase activity 
 Luciferase was normalized to transfection efficiency, by dividing by Renilla 
luciferase activity. Over-expression plasmids for individual components of Shh 
pathway were co-transfected with pRL-SV40 plasmid, expressing Renilla luciferase. 
Error bars represent standard errors. Statistical significance was determined using two-
tail Student's t-test compared with the empty vector.                       
   * indicates p < 0.05. 
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Figure 4-4: Effect of mutant SUFU on APP metabolism 
Transient over-expression of mutant SUFU- ex8 decreases AICD-Gal4 mediated 
luciferase activity compared to wild type SUFU and increases luciferase activity 
compared to control. Luciferase was normalized to transfection efficiency, by dividing 
by Renilla luciferase activity. Each over-expression plasmid was co-transfected with 
pRL-SV40 plasmid, expressing Renilla luciferase. Error bars represent standard errors. 
Statistical significance was determined using two-tail Student's t-test compared with 
the empty vector.  
* indicates p < 0.05. 
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Figure 4-5: AICD dependent rough eye phenotype in Drosophila 
(A) GMR-APP-Gal4, UAS: Grim flies treated with vehicle (DMSO), and (B) GMR-
APP-Gal4, UAS: Grim flies treated with L-685,458; γ-secretase inhibitor. L685, 458 
treated eyes exhibit suppression of rough eye phenotype.  
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  % showing Phenotype  
Drugs Genotype n + ++ +++ p-value* 
None w-(wildtype) 64 25 67 8 n.s.  
(= 0.89) 
10% DMSO w-(wildtype) 87 23 60 17  
-secretase       
100 nM w-(wildtype) 65 64 35 1  1.6 X 10
-7
 
250 nM w-(wildtype) 95 53 44 3 1.16 X 10
-5
 
 
 
 
 
Table 4-1: Quantitative analysis of AD fly eyes fed with L-685, 458   
(Guo et al., 2003). The progeny were scored (+ to +++) for effects on eye phenotype. 
“+” is a rough eye, where at least ½ of the eye field is wild type. “++” is a rough eye 
where more than ½ of the eye is rough, usually affecting the whole eye, but not 
always. “+++” is a strong rough eye where the entire eye is affected, and there is a 
strong loss of pigment in the posterior ½ of the eye. We determine if there is a 
statistically significant change in phenotype relative to wild type we performed a G-
test and report the p-values. “n.s.” indicates p-values greater than 0.05.  
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Figure 4-6: AICD dependent rough eye phenotype in Drosophila. Treated with 
Cyclopamine 
 (A) GMR-APP-Gal4, UAS: Grim flies treated with vehicle (DMSO), and (B) GMR-
APP-Gal4, UAS: Grim flies treated with Cyclopamine. Cyclopamine treated eyes 
exhibit suppression of rough eye phenotype. 
.  
 
 
 
 
 
C GMR-APP-Gal4 UAS:GRIM 
+ Cyclopamine 
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  % showing Phenotype  
Drugs Genotype n + ++ +++ p-value* 
None w-(wildtype) 64 25 67 8 n.s.  
(= 0.89) 
10% DMSO w-(wildtype) 87 23 60 17  
100nM Cyclopamine w-(wildtype) 73 52 47 1 1.04 X 10
-5
 
 
 
 
Table 4-2: Quantitative analysis of AD fly eyes fed with Cyclopamine 
 (Guo et al., 2003). The progeny were scored (+ to +++) for effects on eye phenotype. 
“+” is a rough eye, where at least ½ of the eye field is wild type. “++” is a rough eye 
where more than ½ of the eye is rough, usually affecting the whole eye, but not 
always. “+++” is a strong rough eye where the entire eye is affected, and there is a 
strong loss of pigment in the posterior ½ of the eye. We determine if there is a 
statistically significant change in phenotype relative to wild type we performed a G-
test and report the p-values. “n.s.” indicates p-values greater than 0.05. Treatment with 
100nM Cyclopamine shows a significant (p<0.0001) suppression of rough eye 
phenotype.  
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Figure 4-7: AICD dependent rough eye phenotype in Drosophila crossed with 
Shh, Cos2 loss of function mutants 
 (A) Wild type fly (B) GMR-APP-Gal4, UAS: Grim (C) GMR-APP-Gal4, UAS: Grim 
flies crossed with Hh
AC
 (loss-of function mutant of Shh) suppressed eye phenotype, 
(D) GMR-APP-Gal4, UAS: Grim flies crossed with Cos2
W1
 (loss-of function mutant 
of Kif27) enhances eye phenotype. 
 
 
  145 
 
 
 
  % showing Phenotype   
Gene(s) Genotype n + ++ +++ p-value Nature of Allele 
Control w-(wildtype) 136 37 55 8 -- outcrossed wild-
type 
  69 23 62 15  outcrossed wild-
type 
Hedgehog  Hh
AC
 147 76 24 -- 1x10
-16
 Null loss-of-
function 
Cos2(Kif27) Cos2
W1 
 163 -- 7 93 1x10
-63
 Strong loss-of-
function 
 Cos2
k16101
 72 -- 25 75 1x10
-25
 Strong loss-of-
function 
 Cos2
5
 158 28 63 9 n.s. 
(P=0.5) 
Moderate loss-
of-function 
 Cos2
3
 77 21 65 14 n.s. 
(P=0.16 
Moderate loss-
of-function 
Smoothened SMO
3
 184 17 63 20 P<0.001 Null loss-of-
function 
 
Table 4-3: Quantitative analysis of AD fly eyes crossed with Shh, Cos2, or SMO 
loss of function mutants 
(Guo et al., 2003). The progeny were scored (+ to +++) for effects on eye phenotype. 
“+” is a rough eye, where at least ½ of the eye field is wild type. “++” is a rough eye 
where more than ½ of the eye is rough, usually affecting the whole eye, but not 
always. “+++” is a strong rough eye where the entire eye is affected, and there is a 
strong loss of pigment in the posterior ½ of the eye. We determine if there is a 
statistically significant change in phenotype relative to wild type we performed a G-
test and report the p-values. “n.s.” indicates p-values greater than 0.05. Loss of 
function of Shh in AD flies shows a significant (1x10
-16
) rescue of rough eye 
phenotype.  Loss of function of Cos2 in AD flies shows a significant (1x10
-63  
and 
1x10
-25
 ) enhancement in of rough eye phenotype. Loss of function of SMO in AD 
flies shows a significant (P<0.001) enhancement of rough eye phenotype.   
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Figure 4-8: Transient over-expression of Exportin5 and Dicer increases AICD-
Gal4 mediated luciferase activity 
 Luciferase was normalized to transfection efficiency, by dividing by Renilla 
luciferase activity. Individual over-expression plasmids were co-transfected with pRL-
SV40 plasmid, expressing Renilla luciferase. Error bars represent standard errors. 
Statistical significance was determined using two-tail Student's t-test compared with 
the empty vector. 
 * indicates p < 0.05 
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Figure 4-9: Transient over-expression of miR-378 and miR-214 increases AICD-
Gal4 mediated luciferase activity 
 GFP is the empty vector. Luciferase was normalized to transfection efficiency, by 
dividing by Renilla luciferase activity. Individual members over-expression plasmids 
were co-transfected with pRL-SV40 plasmid, expressing Renilla luciferase. Error bars 
represent standard errors. Statistical significance was determined using two-tail 
Student's t-test compared with the empty vector.  
* indicates p < 0.05 
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Chapter 5 : CaN and Alzheimer’s disease 
 
Clcineurin (CaN; protein phosphatase 2B) is a class of protein phosphatase that 
belongs to the family of Ca2＋/calmodulin-dependent serine/ threonine protein 
phosphatesas (Klee et al., 1998; Stewart et al., 1982) . Based on its calcium binding 
properties and its location in neurons, Klee et al in 1979 coined the term CaN(Klee et 
al., 1979). CaN expression is not restricted to nervous system tissues. The protein is 
widely distributed in mammalian tissues and cells, including adipose
 
tissue, adrenal 
cells, bone osteoclasts, B and T lymphocytes, heart, spinal cord, kidney, liver, lung, 
olfactory bulb, pancreas, placenta, platelets, retina, skeletal muscle, smooth muscle, 
spleen,
 
testis and sperm, thymus,
 
and thyroid (Rusnak and Mertz, 2000). CaN is highly 
expressed in specific regions of the brain, such as cerebral cortex, striatum, substantia 
nigra, cerebellum, and hippocampus (White et al., 2000) and is largely absent from 
glia and interneurons in the hippocampus (Sik et al., 1998).  CaN is the most abundant 
phosphatase in the CNS (Mansuy, 2003). In mammals, CaN has been shown to be 
associated with the regulation of enzymes and ion channels, chemotaxis and neuronal 
growth cone path finding, membrane vesicle trafficking, development of cardiac 
valves and osteoclasts, and genetic programs of activation in lymphocytes and 
differentiation in skeletal muscle (Hogan and Li, 2005). 
CaN is known to regulate by phosphorylation of a wide range of effector 
proteins ranging from transcription factors to enzymes, transmembrane ion channels, 
and proteins involved in apoptosis (Aramburu et al., 2000; Rusnak and Mertz, 2000). 
In adults, CaN has been shown to play an essential role in the activation of T Cells 
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which is controlled by the binding of CaN to transcription factors of the Nuclear 
Factor of Activated T-cells (NFAT) family. CaN binds NFAT transcription factors and 
dephosphorylates
 
then at multiple phosphorylated serine residues. This 
dephosphorylation results in translocation of NFAT in to the nucleus where it 
regulates gene expression. Some of the targets of CaN substrates within the CNS 
include CREB, MAP2, Tau, Tubulin, Inhibitor-1, DARPP-32, NMDAR, AMPAR, 
IP3R, RyR, Synapsin I, GAP43, MARCKS, Dynamin I, NOS, Bcl2, Bad (Hernandez-
Espinosa and Morton, 2006) 
CaN and NFAT 
The NFAT family is composed of five members named NFATc1/2/c, 
NFATc2/1/p, NFATc3/4/x, NFATc4/3 and NFAT5/TonEBP (Graef et al., 2001a; 
Macian, 2005; Rao et al., 1997). All the NFAT members contain the rel DNA binding 
domain. However, NFATc1-c4 also contains multiple Ca
2+
 sensor/translocation 
domains (Graef et al., 2001b; Jain et al., 1995). An increase in intracellular calcium 
activates CaN which directly dephosphorylates Ca
2+
 sensor/translocation domains 
located on NFAT. This results in exposure of the nuclear localization sequence and 
nuclear import of NFAT (Beals et al., 1997a; Okamura et al., 2004). (Figure 5-1) 
NFAT undergoes nuclear export upon undergoing sequential rephosphorylation of the 
Ca
2+
 sensor/translocation domain mediated by kinases including GSK-3β (Beals et al., 
1997b; Neal and Clipstone, 2001; Sheridan et al., 2002). Apart from phosphorylation, 
NFATs also undergo other post-translational modifications such as acetylation and 
sumoylation (Garcia-Rodriguez and Rao, 1998; Terui et al., 2004; Yang et al., 2001). 
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(Figure 5-2) Once inside the nucleus, NFAT initiates transcription of effector 
proteins. 
No direct transcriptional targets of NFAT have been identified in the nervous system. 
Not much is known about NFAT binding partners that might control transcription of 
specific genes important in neuronal development. However, NFAT activity has been 
shown to stimulated by substance P(Seybold et al., 2006), bradykinin (Jackson et al., 
2007), and Wnt pathway (Saneyoshi et al., 2002) 
Properties of CaN:  
CaN is a heterodimer, composed of a 57-59 kDa catalytic subunit (CaN-A) and 
a calcium binding 19 kDa regulatory subunit (CaN-B) (Stewart et al., 1982). The 
holoprotein (80KDa) is formed by the non-covalent interaction between CaN-A and 
CaN-B (Klee et al., 1983). These subunits are tightly associated and can be 
disassociated by the use of denaturants (Merat and Cheung, 1987). At subcellular 
level, approximately one half of the CaN pool is located in the cytosol while the other 
half is associated with the plasma membrane(Klee et al., 1988). 
Mammalian CaN-A has 3 isoforms(α, β, and γ ) and CaN-B has 2 isoforms( B1 
and B2) (Wu et al., 2007). The catalytic subunit of CaN-A is 521 residues in length 
and contains three regulatory domains: a CaN-B-binding helical domain (BBH, 348–
368), a calmodulin binding region (CBD, 391–414), and an autoinhibitory loop (AID, 
468–490) (Hashimoto et al., 1990; Hubbard and Klee, 1989). The regulatory subunit, 
CaN-B is 170 residues long and contains two Ca2＋-binding domains, domain 1 
(residues 1-84) and domain 2 (residues 86- 169). Both the domains are linearly 
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arranged and each domain in turn contains two Ca
2+
-binding EF-hand motifs (Rusnak 
and Mertz, 2000). (Figure 5-3) 
Activation of CaN 
CaN is a metallo-proteophosphatase activated by metals. In vitro experiments 
suggest that Ca
2+
, Mn
2+
 and Ni
2+
 are the most important activators of CaN and CaN-A. 
Brain has the highest concentration of Mn2+ which correlates with high levels of CaN 
activity in the brain (Ping et al., 2004). 
Influx of calcium from L-type channel or NMDA receptor can stimulate 
NFAT-dependent transcription. This stimulation has shown to up regulate inositol-1, 
4, 5-trisphosphate Receptor1 (IP3-R1) in a CaN dependent manner in the cerebellar 
granule neurons (Carafoli et al., 1999; Genazzani et al., 1999). Similarly, in cultured 
hippocampal neurons, influxes of calcium from L-type channels have shown to 
increase NFAT transcriptional activity (Graef et al., 1999). This suggests that a 
positive feed back exists. An increase of calcium by either neurotrophin signaling or 
L-type Ca
2+
 channels would activate NFAT transcriptional activity, which would in 
turn upregulate IP3-R1 receptors. (Figure 5-1) 
During the inactive state, the autoinhibitory domain of CaN-A sterically blocks 
its active site by interacting with the catalytic core (Kissinger et al., 1995). Activation 
of phosphatase activity of CaN requires the binding of both Ca
2+
/ CaN-B and 
Ca
2+
/calmodulin complex to CaN-A (Wu et al., 2007). Calmodulin is an acidic protein 
which is 148 residues in length and contains four calcium
 
binding EF-hand motifs. 
Under normal conditions, an increase in calcium concentration results in binding of 
Ca
2+
/calmodulin to heterodimeric CaN, resulting in a conformational shift. This 
  152 
releases the autoinhibitory domain from the active site of CaN-A. This 
Calcium/calmodulin activation of CaN is reversible (Fig2A). Therefore, a positive 
feedback loop might exist whereby an initial Ca
2+
 increase caused by neurotrophin 
signaling or L-type Ca
2+
 channels would activate NFAT transcriptional activity and 
feedback to modulate Ca
2+
 amplitude over time by the upregulation of more IP3-R1 
receptors (Nguyen and Di Giovanni, 2008).(Figure 5-4) (Figure 5-1) 
In addition to this reversible activity by Ca
2+
/calmodulin, other mechanisms 
exist by which CaN can be activated in a Ca
2+
/calmodulin-independent manner. 
In vitro and in vivo studies suggest that CaN can also be activated in a 
Ca
2+
/calmodulin independent manner. CaN-A can be cleaved by proteases such as 
calpain, trypsin, and chymotrypsin C irreversibly activate CaN (Hubbard and Klee, 
1989; Manalan and Klee, 1983; Wang et al., 1989; Wu et al., 2004). These proteases 
cleave the CBD and the AID. The catalytic and CaN B-binding domains remain intact 
as they are resistant to cleavage by proteases (Hashimoto et al., 1990; Hubbard and 
Klee, 1989) (Fig2B). Thus the proteolytic cleavage of CaN-A results in the removal of 
the regulatory domain transforming CaN into constitutively active form which does 
not require the presence of Ca
2+
/calmodulin for activation (Hubbard and Klee, 1989; 
Perrino et al., 1995). (Figure 5-4) 
Regulation of CaN: 
Several endogenous regulators of CaN have been identified both in vitro and in 
vivo. The most widely used regulators for CaN are the fragments of the regulatory 
proteins RCAN1/MCIP/calcipressin/Rcn1p, Cabin1/cain, AKAP79, and the 
autoinhibitory peptide from CaN-A.  
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One of the first endogenous inhibitors of CaN to be identified was A-kinase 
anchoring protein (AKAP79). It is a 79-kDa protein that binds membrane vesicles 
through its NH2 terminus and anchors proteins like PKA, PKC, and CaN (Carr et al., 
1992; Coghlan et al., 1995; Klauck et al., 1996).  Based on AKAP79 truncation and 
deletion mutants, residues 315-360 were shown to be necessary and sufficient for 
AKAP79-CaN anchoring in HEK293 cells (Dell'Acqua et al., 2002). AKAP79 has 
been shown to bind to the residues 30-98 and 311-336 on CaN-A, not requiring the 
CaN-B subunit. This binding inhibits the phosphatase activity of CaN towards its 
substrates. 
 Overexpression of AKAP79 in HEK293 results in a decrease in NFAT activation due 
to a decrease in NFAT dephosphorylation (Kashishian et al., 1998). 
Cabin1 (CaN binding protein) /cain (CaN inhibitor) is a 2,220-residue 
phosphoprotein. Its gene is located on 22q11.23. Cabin1 binds to CaN at two distinct 
domains in an noncompetitive fashion to inhibit the CaN enzymatic activity(Jang et 
al., 2007). It has been shown to negatively regulate endocytosis of neurotransmitters in 
neuronal cells(Lai et al., 2000). Overexpression of full length or C-terminal fragment 
of cabin1 in Jurkat cells results in a suppression of NFAT dephosphorylation which in 
turn represses transcriptional activation of CaN responsive elements in the IL2 
promoter (Jang et al., 2007). 
Another inhibitor of CaN is RCAN1 (Down syndrome candidate region 1). 
RCAN1 is highly expressed in brain, spinal cord, kidney, liver, mammary gland, 
skeletal muscle,
 
and heart. This gene is located on chromosome 21 and is highly 
expressed in in the brain of Down syndrome fetuses. RCAN1 binds to the catalytic 
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subunit of CaN near the active site and negatively regulates the phosphatase activity. 
In primary human endothelial cells, RCAN1 overexpression results in repression of 
transcriptional activation of inflammatory marker
 
genes like Cox-2, E-selectin, and 
Tissue factor. Conversely, RCAN1 knockdown results in an increase in NFAT 
activity, stimulating the expression of these genes (Fuentes et al., 2000; Hesser et al., 
2004). 
Apart from the endogenous regulators of CaN, fungal derived 
immunosuppressant dugs Cyclosporin A (CsA) and FK506 are specific and potent 
inhibitors of CaN activity. FK506 and CsA, when complexed with their respective 
endogenous immunophilins, Cyclophilin (CyP) and FK506 binding Protein12 
(FKBP12), inhibit CaN activity. Since CaN is involved with generating an immune 
response, CsA and FK506 are used clinically in patients with autoimmune diseases 
and as well as in post-transplant patients. Based on the studies using the crystal 
structure of CaN, both CyP–CyA and FKBP12– FK506 have been shown to bind a 
composite surface formed by CaN-A and CaN-B subunits(Hubbard and Klee, 1989). 
Both these complexes bind to multiple sites on the CaN complex including the N-
terminus of the CaN-B binding helix, CaN-B subunit and the catalytic domain of CaN-
A to regulate CaN activity (Figure 2C) (Parsons et al., 1994; Perrino et al., 1995). The 
binding of these complexes to CaN inhibits its dephosphorylation activity.  
Comparison analysis of complex binding revealed that 20 out of 25 residues are 
commonly involved with the binding of CyA-CsA and FKBP12-FK506. There are, 
however, a significant number of residues that are distinct, and the bonding pattern for 
both the complexes are significantly different from each other. This would explain 
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why CaN mutants show selective resistance to FK506 or CsA (Ke and Huai, 2003). 
Yeast FKBP12 and Cyclophilin A do not require their respective immunosuppressant 
to interact with CaN-A. Using affinity chromatography, Cardenas et al showed that 
both FKBP12 and Cyclophilin A bind to CaN-A in absence of the 
immunosuppressant. However, binding of these immunophilins have a very small 
effect on CaN activity (Cardenas et al., 1994). In a Ppia (mice homolog of CyA) 
knockout study in mice, Ppia 
–/– 
CD4
+
 T cells were resistant to the inhibitor CsA. 
Immunosupressible doses of CsA in Ppia
–/– 
mice failed to block the allogeneic 
challenge (Colgan et al., 2005). This observed effect was equivalent to diminished 
inhibition of CaN. This showed that immunophilins like CyP and FKBP12 are 
required for pharmacological inhibition of CaN. 
Calcium and Alzheimer’s disease: 
Alzheimer’s disease (AD), first described by Alois Alzheimer in 1906, is a 
chronic neurological disorder resulting in cognitive disability. The neuropathological 
hallmarks of AD include deposition of extracellular amyloid plaques composed of 
amyloid beta peptide-42 (Aβ42) and intracellular neurofibrillary tangles composed of 
hyperphosphorylated forms of microtubule-associated protein tau in characteristic 
regions of the brain. Neurofibrillary tangles are composed of abnormally 
hyperphosphorylated tau protein, due to either an increase in kinase activity or/and a 
decrease in phosphatase activity. These hallmarks are preceded by a progressive loss 
of neurons and synaptic degeneration. There is no known cure for AD. Aβ42, the main 
constituent of the amyloid plaques, is derived from the proteolytic processing of a 
transmembrane protein called APP by β-, and γ-secretase. Different isoforms of Aβ 
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are produced during the processing; Aβ40 and Aβ42 being the predominant forms. 
Aβ42, the main constituent of the amyloid plaques, is more hydrophobic than Aβ40 
and has the ability to form insoluble aggregates. 
Age is the major risk factor for AD. The early onset (EOAD) form of the 
disease (prevalent before the age of 65) is due to familial mutations which are 
“causative” and fully penentrant. EOAD is observed in less that 5% of AD patients. 
Over 120 mutations in three genes namely Presenilin1 (PS1), Presenilin2 (PS2), and 
APP results in EOAD. In addition to amyloid hypothesis and tau hypothesis, a third 
hypothesis that has come into light recently is the Calcium
 
hypothesis, first proposed 
by Khachaturian in 1994. According to this hypothesis, disturbances in intracellular 
calcium
 
cause neurodegenerative disorders (Khachaturian, 1994). Calcium plays a 
major role in neuronal growth, activity, growth and differentiation, synaptic plasticity, 
and learning and memory, necrosis, apoptosis, and degeneration (Berridge et al., 
2000). Influx of calcium
 
from calcium
 
channels of the plasma membrane or calcium
 
release from ER stores has been shown to increase the generation of Aβ (Querfurth 
and Selkoe, 1994). An increase in cytosolic calcium
 
concentration has been shown to 
transiently phosphorylate APP and Tau thereby increasing Aβ production (Pierrot et 
al., 2004; Pierrot et al., 2006). It has been challenging to obtain evidence of disrupted 
calcium homeostasis in AD brain compared to normal brain. However, an increase in 
the levels of free calcium, calcium bound proteins  and calcium-dependent proteases 
have been observed in AD postmortem brain samples(Green et al., 2007). 
PS mutations that cause Familial AD (FAD) are also associated with 
abnormalities in calcium
 
signaling.  These genes affect calcium release from the ER 
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stores as well as the entry of calcium through store operated channels (LaFerla, 2002). 
Studies in cells, animals, as well as in FAD patients show that expression of mutant 
PS is associated with exaggerated release of calcium from ER (Etcheberrigaray et al., 
1998).  
FAD mutations in PS1 and PS2 have been shown to exaggerate IP3-mediated 
calcium signaling, increasing intracellular calcium levels (Chan et al., 2000; 
Stutzmann et al., 2004). Alterations in the inositol 1, 4, 5-trisphosphate receptor 
(InsP3R)-mediated calcium release was considered a fundamental defect in AD and 
was used as a predictive diagnostic feature of AD-derived peripheral cells. IP3R is 
known to be targeted by CaN. IP3R protein expression is completely abolished in 
cultured cerebellar granule of rats when CaN is inhibited by FK506 and cyclosporin 
A. Ablation of CaN decreases IP3R mRNA levels suggesting that the regulation is at 
transcriptional level. Thus CaN plays a crucial role in regulating IP3R function by 
dephosphorylation as well as regulating IP3R expression (Genazzani et al., 1999)   
FAD mutations in PS1 and PS2 have also been shown to enhance ryanodine-
receptor-mediated calcium release (Chan et al., 2000; Smith et al., 2005), causing a 
deficit in capacative calcium entry (Akbari et al., 2004; Leissring et al., 2000; Yoo et 
al., 2000) and increasing the vulnerability to excitotoxic insult (Guo et al., 1999a; Guo 
et al., 1999b).  
In PS1 FAD cells, an increase in Aβ42/Aβ40 ratio is observed after attenuation 
of capacitative calcium
 
entry in the cells. This is probably due to alteration in APP 
processing that is dependent on the activity of calcium
 
transporters in the plasma 
membrane (Yoo et al., 2000).  This PS mediated effect on calcium regulation seems to 
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be independent of γ-secretase activity (Akbari et al., 2004; Tu et al., 2006). Exogenous 
application of synthetic or oligomeric Aβ aggregates has shown to elevate intracellular 
calcium rapidly in cultured neurons (Demuro et al., 2005; Guo et al., 1999b; Mattson 
et al., 1993a; Mattson et al., 1992). 
However, the direct relation between PS, calcium, and AD has not yet been 
established. 
CaN and Alzheimer’s disease: 
 
In cells, depolarization results in an increase in
 
cytosolic calcium concentration 
that activates several signaling
 
pathways and different protein kinases and 
phosphatases. Under depolarizing conditions, CaN has been shown to transiently 
phosphorylate  the microtubule-associated protein 
 
tau as well as APP. 
Phosphorylation is mediated by glycogen
 
synthase kinase 3 (GSK3β) and cyclin-
dependent kinase 5 (CDK5) protein kinases (Ahlijanian et al., 2000; Aplin et al., 1996; 
Hanger et al., 1992; Iijima et al., 2000) followed by dephosphorylation by CaN. APP 
contains eight putative phosphorylation sites including Y653, S655, T668, S675, 
Y682, T686, and Y687 respectively in the cytoplasmic and luminal region (based on 
APP695)(Lee et al., 2003b). Thr668 is the major phosphorylation site on APP. 
Phosphorylation at Thr668 is carried out by GSK3β and CDK5 in neurons and by  
Cdk1/cdc2 in non-neurons (Reviewed in (Suzuki and Nakaya, 2008). Transient 
phosphorylation of Thr668 has been shown to be indispensable for intracellular Aβ42 
accumulation. Mutant APPT668A was shown to not produce any intraneuronal Aβ 
compared to APPT668 (Pierrot et al., 2006).  Inhibition of
 
phosphorylation of APP on 
Thr668 has shown to influence the amyloidogenic pathway of APP by promoting 
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BACE1 mediated APP cleavage, increasing Aβ generation (Lee et al., 2003b). 
Phosphorylation of APPT668 has been observed to be elevated in AD brain samples 
(Lee et al., 2003b).  
Thr668 phosphorylation is believed to induce a conformational change in the 
cytoplasmic region of APP, resulting in its interaction with Fe65. Fe65 is believed to 
play an important role in signal transduction and gene activation. Intracellular 
localization of Fe65 is determined by the phosporylated state of APP at Thr668. 
Proteolysis of APP by caspase-3 and caspase-8 at Asp664 and Ala665 generates a 
cytotoxic fragment which results in neuronal toxicity. Thr888 phosphorylation of APP 
is believed to prevent this cleavage by caspases (Gervais et al., 1999; Taru et al., 
2004).  
Many groups have attempted to correlate CaN activity and protein levels with 
the number of tangles and plaques found in the different regions of AD brain. In aged 
rats, upregulation of CaN activity negatively correlates with cognitive performance 
(Foster et al., 2001). Conversely, downregulation of CaN activity using an 
autoinhibitory peptide has shown to improve memory in rodents (Malleret et al., 
2001). Inhibition of CaN using FK506, a potent inhibitor of CaN has shown to 
enhance phosphorylation of tau at serine positions 262, 198, 199, and/or 202 and 396 
and/or 404 (Luo et al., 2008). Transgenic AD mice model overproducing Aβ, shows 
an upregulation in CaN enzymatic activity in the CNS. An Aβ induced cognitive 
deficit is also observed in these mice in absence of neuronal loss. Treatment of these 
mice with CaN inhibitor FK506 improves memory function, indicating that CaN is a 
part of the pathway that results in an Aβ mediated memory loss (Dineley et al., 2007). 
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This shows that CaN is a major phosphatase and maybe involved with AD, the 
mechanism of its action is however not known yet.  
CaN activity has been shown to be important for learning and memory. 
Knockout of CaN in the forebrain region of the mice has shown to impair bidirectional 
synaptic plasticity and working/episodic-like memory (Zeng et al., 2001).  
Studies show that RCAN1, an endogenous CaN regulator, can bind and inhibit 
CaN activity. RCAN1is overexpressed in Down syndrome fetus and in the cerebral 
cortex and hippocampus of sporadic AD patients (Ermak et al., 2001). Post-mortem
 
brain samples of Down syndrome patients, who have a third copy of the APP gene, 
show two- to-three fold increase in RCAN1 mRNA levels compared to controls. There 
is an age- related increase in RCAN1 protein in the pyramidal neurons of the temporal 
lobe. Increased RCAN1expression has been observed in individuals with moderate to 
severe AD. The number of RCAN1-positive pyramidal neurons correlated with the 
number of neurofibrillary tangles in the temporal cortex (Cook et al., 2005).  Tissues 
from human trisomy 21 fetal brain exhibit altered CaN mediated signaling (Chang et 
al., 2003). 
Studies in model organisms support the role of RCAN1 in AD pathogenesis. 
Gain function of drosophila ortholog of RCAN1, Nebula displayed severe learning 
defects in several basic learning assays (Chang et al., 2003). Neurons for these mutant 
flies displayed an increase in the number of mitochondria of smaller size, a decrease in 
ATP production, and an increase in reactive oxygen species (ROS) levels compared to 
controls (Chang and Min, 2005). In primary neuronal cells transfected with RCAN1-
EGFP, RCAN1 colocalizes with synaptophysin. This suggests that RCAN1 is 
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expressed on synaptic vesicles. Overexpression of RCAN1 resulted in a formation of 
aggresome-like inclusion
 
bodies and reduction in synaptophysin expression in neural 
processes. These inclusion
 
bodies are seen in both DS and AD brains. A reduction in 
synaptophysin expression suggests that RCAN1 is involved in exocytosis (Ma et al., 
2004).  
Cells from mutant overexpression and knockout RCAN1 suggest that RCAN1 
regulates the number of vesicles undergoing
 
exocytosis as well as the rate at which the 
vesicle fusion pore opens
 
and closes. A reduced level of exocytosis is observed in both 
overexpression and knockout mice. However, they observed that the reduction of 
exocytosis was not due to a change in CaN activity (Keating et al., 2008). 
However, RCAN1 knockout mice exibit a deficit in spatial learning and 
memory,
 
reduced associative cued memory, and impaired late-phase long-term
 
potentiation (L-LTP). These deficits are very similar to mice with increased CaN 
activity. RCAN1 knockout mice exhibit an increase in CaN activity and a decrease in 
phosphorylation of CaN substrates like dopamine and cAMP-regulated 
phosphoprotein-32(Hoeffer et al., 2007). The mechanism by which RCAN1 is 
associated with AD is yet to be elucidated. 
Disturbed calcium homeostasis is believed to be closely associated with 
neurodegeneration of the brains of AD patients. Calpain I, like CaN is another major 
protein in the brain which is regulated by calcium and is shown to be activated in AD 
brain. Active Calpain I cleaves CaN C-terminal to the autoinhibitory domain at lysine 
501, generating of a 57-kDa active truncated form of CaN. This truncated active form 
of CaN maintains its Ca (2+)/calmodulin dependence for its activity (Figure 5-4). 
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Calpain I mediated cleavage and activation of CaN correlates with the number of NFT 
in the brain (Liu et al., 2005). This strongly suggests that a disturbance in calcium 
homeostasis can result in over activation of CaN resulting in hyperphosporylation of 
Tau protein, a characteristic hallmark of AD. Over-activated calpains can result in 
degradation of proteins essential for neuronal survival. Inhibition of calpain using 
inhibitors such as E64 and BDA-410 in transgenic mice overexpressing human APP 
and PS1 resulted in restoration of synaptic function in hippocampal cultures as well as 
in hippocampal slice. Calpain inhibition also improved spatial-working memory and 
associative fear memory in these mice. CREB phosphorylation and synaptic protein 
synapsin I distribution which are dependent on CaN activity appeared normal 
compared to control mice suggesting that calpain inhibition helped in restoration of 
normal phosphorylation of these proteins (Trinchese et al., 2008). Inhibition of calpain 
has also been shown to play an important role in Aβ accumulation. MDL 28170, a 
calpain III inhibitor inhibits generation of Aβ46, an intermediate in Aβ40 and 42 
production in N2A cells overexpressing PS1 and the APP695 with Swedish mutation 
that increases both Aβ 40 and 42 levels (Dong et al., 2006). The effect of calpain 
inhibitor on Aβ levels however is very controversial.   
Cleavage of APP by Beta-site APP-cleaving enzyme 1 (BACE1) results in the 
production of Aβ42 which accumulate to form plaques. DNA sequences within the 
BACE1 gene promoter region is regulated and directly bound by NFAT1. Treatment 
of cells with Aβ peptide resulted in an up-regulation of BACE1 expression due to an 
increase in NFAT1 activation. NFAT1 has been observed to be active in brain of 
Tg2576 mice. Primary cortical cells from these mice generated more Aβ upon 
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induction with calcium ionophore. This effect was reversed by CyA treatment (Cho et 
al., 2008).  
In transgenic mice overexpressing APP and PS1, CaN has been shown to be 
upregulated in astrocytes where it triggers inflammatory response (Norris et al., 2005).  
In neurons, CaN activation results in endocytosis of the NMDA receptors. This results 
in reduced synaptic currents (Snyder et al., 2005).  CaN has been shown to activate 
pro-apoptotic member of BCL-2 family by dephosphorylation (Springer et al., 2000; 
Wang et al., 1999). When rat cortical neurons were treated with Aβ (Aβ 25-35 and Aβ 
1-40), CaN activity increased without affecting its CaN levels. This activity increase 
was accompanied with a decrease in phosphorylation of BAD, a proapoptotic member 
of the BCL-2 gene family. Aβ treated neurons demonstrated higher levels of BAD 
when compared to control neurons. This effect was reversed with treatment with 
FK506. This alteration in the phosphorylation state of BAD can result in release of 
cytochrome C resulting in an apoptotic cascade(Agostinho et al., 2008). 
Inhibition of CaN has shown to protect neuronal cells from death mediated by 
Aβ(Agostinho and Oliveira, 2003). In hippocampal slices, CaN abolishes LTP that are 
promoted by Aβ(Chen et al., 2002c) 
When rat cortical neurons were treated with Aβ (Aβ 25-35 and Aβ 1-40), CaN 
activity increased without affecting its CaN levels. This activity increase was 
accompanied with a decrease in phosphorylation of BAD. Aβ treated neurons 
demonstrated higher levels of BAD when compared to control neurons. This effect 
was reversed with treatment with FK506. This alteration in the phosphorylation state 
  164 
of BAD can result in release of cytochrome C resulting in an apoptotic 
cascade(Agostinho et al., 2008). 
All the evidences suggest that CaN is involved with neurodegenerative effects 
of Aβ. However, the relationship between Aβ and CaN is yet to be established. Once 
the mechanism of mode of action of CaN is determined, it can act as a putative drug 
target for AD 
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Figures 
 
 
 
 
 
 
Figure 5-1: Calcium dependent activation of CaN and NFAT activity 
Induction of intracluular calium stores and ER by IP3 results in calcium release. 
Intracellular calcium binds to ubiquitous calcium sensor calmodulin. Calmodulin is 
known to regulate a a variety of intracellular proteins including Calcinuerin. Acivated 
calcinuin is known to dephosporylate NFAT, a transcription factor and regulate 
transcrition of target genes. (Muller and Rao, 2007) 
 
 
 
 
 
 
  166 
 
 
 
 
 
Figure 5-2: Model for CaN and NFAT activation  
 
(Burkard et al., 2005) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  167 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-3: Catalytic and Regulatory subunits of CaN                                                                                                                                     
Schematic representation of the calcinurin subunits. Calcineirin A is the catalutic 
subunit. TI contains a catalytic domain (residues 70-328), the CaN B binding domain 
(residues 348ﾝ362), the calmodulin binding domain (residues 391- 414), and the 
autoinhibitory domain (residues 468-490). The regulatory sbunit is relatively smaller 
and contains four Ca2＋-binding EF-hand motifs 
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Figure 5-4: Regulation of CaN activity 
 
Adapted from Shibasaki, Hallin et al. 2002 and Wu, Tomizawa et al. 2004 (Shibasaki 
et al., 2002; Wu et al., 2004) 
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Chapter 6 : Calcineurin as in vitro and in vivo regulator of APP metabolism 
Introduction 
Alzheimer's disease (AD) is a progressive and irreversible brain disorder with 
no known cause or cure. It’s the most common form of neurodegenerative disease and 
the fifth leading cause of death in the elderly (Sparks, 2008). The pathological 
hallmarks of AD are the presence of dense intraneuronal neurofibrillary tangles 
(composed of hyperphosporylated Tau protein) and extracellular amyloid plaques in 
the outer matrix of the brain. Amyloid plaques are composed of Aβ peptide aggregates 
primarily Aβ42. Aβ42 is produced by proteolysis of Amyloid Precursor Protein (APP) 
by β-secretase (BACE) and γ-secretase. 
In AD brain, a disruption in calcium homeostasis has been observed. Calcium 
plays a major role in neuronal growth, activity, differentiation, synaptic plasticity, 
learning and memory, necrosis, apoptosis, and degeneration (Berridge et al., 2000). 
Influx of calcium
 
from calcium
 
channels of the plasma membrane or due to calcium
 
release from ER stores has also been shown to increase Aβ generation (Querfurth and 
Selkoe, 1994).  An increase in cytosolic calcium
 
concentration has been shown to 
increase transient phosphorylation of APP and Tau (Pierrot et al., 2004; Pierrot et al., 
2006), thereby increasing intraneuronal Aβ42 levels and related neuronal toxicity.  
APP at Thr668 undergoes phosphorylation by GSK3 and CDK5, and 
dephosphorylation by Calcineurin (CaN). Intraneuronal accumulation of Aβ42 was not 
observed upon expression of mutant APPT668A. Phosphorylation of APP appears to 
be indispensable for neurotoxic
 accumulation of intraneuronal Aβ (Pierrot et al., 
2006). Phosphorylation of Thr668 is also required for binding of Fe65, a nuclear 
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adaptor protein utilized for nuclear translocation of GSK3β, APP, BACE1, Tip60 and, 
neprilysin, some of the genes whose expression is regulated by AICD (Cao and 
Sudhof, 2001; Kim et al., 2003; Kimberly et al., 2001; von Rotz et al., 2004). Thus, 
many groups have attempted to correlate CaN activity and protein levels with the 
number of tangles and plaques in different regions of the brain of AD patients. 
 CaN (CaN; protein phosphatase 2B) is a class of protein phosphatase that 
belongs to the family of Ca2＋/calmodulin-dependent serine/ threonine protein 
phosphateses (Klee et al., 1998; Stewart et al., 1982) . It is a heterodimer, composed of 
a 57-59 kDa catalytic subunit (CaN-A) and a calcium binding 19 kDa regulatory 
subunit (CaN-B) (Stewart et al., 1982). The holoprotein (80KDa) is formed by the a 
non-covalent interaction between CaN-A and CaN-B (Klee et al., 1983). Mammalian 
CaN-A has 3 isoforms(α, β, and γ ) and CaN-B has 2 isoforms( B1 and B2) (Wu et al., 
2007). CaN is known to regulate a wide range of effector proteins ranging from 
transcription factors to enzymes, transmembrane ion channels, and proteins involved 
in apoptosis (Aramburu et al., 2000; Rusnak and Mertz, 2000). One of the well known 
targets of CaN is NFAT. NFAT is a transcription factor that undergoes CaN mediated 
dephosphorylation. Increase in intracellular calcium results in CaN activation resulting 
in NFAT dephosporylation. This facilitates nuclear translocation of activating 
transcription. NFAT family is composed of multiple isoforms (NFAT1, 2, 3, 4, and, 
5), all derived by alternative splicing (Rao et al., 1997). 
In mouse primary cortical cells and SH-SY5Y cells, NFAT1 has been shown to 
directly interact with the BACE1 promoter up regulating BACE1 expression. NFAT1 
activation was also elevated in Tg2576 mouse brains carrying the APP-Swedish 
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mutation. Calcium ionophore and Aβ42 peptide increased intracellular Calcium 
concentration, increase in BACE1 expression via CaN-NFAT1 signaling (Cho et al., 
2008). Tg2576 APP AD model of transgenic mice display an increase in CaN activity. 
Inhibition of CaN in these animals using CaN inhibitor, FK506 improved memory 
function (Dineley et al., 2007). 
 Here, we demonstrate that APP protein levels are modulated by intracellular 
calcium via CaN activity in SH-SY5Y neuroblastoma cells. We observe a decrease in 
both mature and immature APP upon inhibition of CaN by a pharmacological inhibitor 
as well by genetic means.  
  
 
 
 
 
 
 
 
 
 
 
 
 
Results 
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Pharmacologic modulation of CaN alters AICD-Gal4 mediated luciferase activity 
and full length APP: 
Fungal derived immunosuppressant drugs CyclosporinA (CsA) and FK506 are 
specific and potent inhibitors of CaN activity when complexed with their respective 
endogenous immunophilins, Cyclophilin (CyP) and FK506 binding Protein12 
(FKBP12). These drugs bind to the active site of CaN resulting in an inhibition of its 
phosphatase activity. SH-SY5Y APP-Gal4, UAS-Luc cells were treated with CsA or 
FK506 for 5 hours. Vehicle control was treated with DMSO. The final DMSO 
concentration was 0.01%. A dose dependent decrease in luciferase activity was 
observed with an increase in inhibitor concentration (Figure 6-1). We observed a 
significant decrease in luciferase activity at    250 nM and 500nM concentration of the 
inhibitor (p<0.05). 
 To determine the effect of CsA and FK506, SY5Y-APP-Gal4, UAS-Luc cells 
were treated with 250nM CsA or FK506 and DMSO control for 5 hours. Cells were 
lysed and lysates were subjected to Western blot (Figure 6-2). The blot was probed 
with Anti-APP-CTF. Actin was used for normalization. Inhibition of CaN with CsA 
resulted in  a decrease in APP levels of approximately 70% of both mature and 
immature APP as compared to controls. Inhibition of CaN with FK506 resulted in a 
decrease of approximately 40% in both mature and immature APP as compared to 
controls. All the knockdowns were statistically significant (Figure 6-3) (p<0.05) 
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Genetic manipulation of different subunits of CaN modulates AICD-Gal4 
mediated luciferase activity and full length APP: 
PPP3CB was one of the candidate genes identified from the genome wide 
screen in SY5Y-APP Gal4, UAS-Luc performed by us. Knockdown of PPP3CB 
significantly decreased AICD-mediated luciferase activity (p<0.05) (Figure 6-4).  
Similarly, transfection with shRNAs specific for PPP3CA, PPP3CC, significantly 
decreased AICD-Gal4-mediated luciferase and knockdown of PPP3R2 significantly 
increased AICD-Gal4-mediated luciferase expression (p<0.05). Transfection with 
shRNAs specific for PPP3R1 did not significantly increased AICD-Gal4-mediated 
luciferase. (Figure 6-5). Transfection with shRNAs specific for RCAN1, AKAP79, 
CyclophilinA, and FKBP1B increased AICD-Gal4-mediated luciferase expression 
compared to control shRNA (p<0.05) (Figure 6-6). SY5Y-APP-Gal4 cells were 
transfected with individual shRNAs and selected with 2 μg/ml puromycin for 3 weeks. 
At least two shRNAs targeting different regions of each target gene was used. 
To determine if inhibition of individual subunits of CaN modulated APP 
protein levels, we knocked down members of catalytic subunit, regulatory subunit as 
well as the endogenous regulators of CaN,  PPP3CC, PPP3R2, RCAN1, and CyA. 
Inhibition of PPP3CC by RNAi significantly decreases the levels of total APP while 
knockdown of PPP3R2 significantly increases the levels of total APP. Knockdown of 
CyA, an endogenous regulator of CaN significantly increases the levels of total APP  
while knockdown of RCAN1 did not change levels of total APP(Figure 6-7 and 
Figure 6- 8). 
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CaN modulates AICD-dependent pathology in the developing Drosophila eye: 
We wanted to further reconfirm the results obtained in cell culture in another 
model system. We utilized the previously created Drosophila melanogaster γ-
secretase eye reporter flies (Gross et al., 2008; Guo et al., 2003).  These flies expresses 
a C99-Gal4 fusion protein in the developing retina (Gross et al., 2008; Guo et al., 
2003).  Proteolytic processing of this fusion protein is carried by endogenous secretase 
activity in the fly retina (Gross et al., 2008; Guo et al., 2003). Processing releases 
AICD-Gal4 fragment that  activates the transcription of a cell death activator called 
Grim (Chen et al., 1996). Expression of Grim causes apoptosis. Apoptosis results in a 
rough eye phenotype, loss of pigmentation,and  disrupted bristle morphology (Figure 
6- 7B: Grim fies, Figure 6- 7A: wild type files).  
In the treatment flies, 100nM of CsA and FK506 in the food significantly 
suppressed (p<0.0001) the rough eye phenotype (Figure 6- 9) (Table1). To 
recapitulate the results obtained in cells in flies, we crossed GMR-APP-Gal4, 
UAS:Grim flies with Drosophila carrying  a mutation of the homolog of PPP3R2 
(CanB2
EP774
, Null loss-of-function allele, or CanB
d09902
 Intronic P-element insertion). 
The progeny were scored from + to +++ based on the severity of rough eye phenotype. 
We observed a significant enhancement in rough eye phenotype (p <0.0001) for 
CanB2
EP774
 but not for CanB
d09902
 (Figure 6- 10) (Table1) 
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Discussion 
 
According to the amyloid hypothesis, imbalance in Aβ metabolism leads to 
neurodegeneration. Aβ is produced by proteolytic processing of APP by activity of 
three secretases; α-, β-, and γ-secretase. A change in APP metabolism can lead to a 
change in Aβ metabolism. At elevated levels, Aβ aggregates to form extracellular 
insoluble plaques. It is, however, believed that oligomeric, soluble forms of Aβ, rather 
than amyloid plaques result in neuronal toxicity and death. Multiple genome wide 
genetic screens identified regions on Chr.10 that can harbor putative candidate genes 
that modulate APP metabolism. To identify these genes, we screened the region 
between 3-110Mb on Chr.10, a region implied by multiple genetic screens. We 
conducted an RNAi based screen in SH-SY5Y APP-Gal4 and identified PPP3CB, a 
catalytic subunit of CaN as a putative regulator of APP metabolism. Interestingly, 
PPP3R2, a regulatory subunit of CaN was identified in a similar manner on Chr.9. 
Knockdown of PPP3CB significantly decreases AICD-mediated luciferase activity 
while knockdown of PPP3R2 significantly increases luciferase activity. This was very 
interesting as regulatory subunit of CaN is believed to control the catalytic subunit.  
 Since both PPP3CB and PPP3R2 are a part of CaN, we wanted to determine 
the effect of inhibition of CaN using pharmacologic inhibitors. We treated SY5Y-
APP-Gal4 cells with FK506 and CsA. Treatment of SY5Y-APP-Gal4 cells with 
different concentration of FK506 and CsA resulted in a concentration dependent 
decrease in AICD-mediated luciferase activity. To recapitulate the results in a model 
organism, we used a Drosophila model AD. We observed similar results in this model 
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too.  Inhibition of endogenous CaN using FK506 and CsA in Drosophila resulted in a 
suppression of the rough eye phenotype.  
To determine the mechanism by which AICD-luciferase levels decrease, we 
treated SY5Y-APP-Gal4 cells with FK506 and CsA in SH-SY5Y APP-Gal4 cells and 
observed its effect on full length APP. Treatment resulted in a significant decrease in 
both mature and immature APP (Figure 6-2 and Figure 6-3), suggesting that CaN 
modulates full length APP levels.   
To determine the mechanism by which individual subunits regulate CaN 
activity as well as APP metabolism, we knockdown PPP3CA, PPP3CC, PPP3R1 and 
PPP3R2 in SH-SY5Y-APP Gal4 cells. Knockdown of the catalytic subunits 
significantly decreased luciferase activity while knockdown of regulatory subunits 
significantly increased luciferase activity. At protein levels, knockdown of PPP3CC 
significantly decreased levels of full length mature and immature APP while 
knockdown of PPP3R2 subunits significantly increased levels of full length mature 
and immature APP. This suggests that CaN regulates full length APP. 
To determine if PPP3R2, a gene identified from our functional screen 
modulated APP metabolism in flies, we crossed GMR-APP-Gal4, UAS: Grim with 
two independent CanB2
EP774
 (Drosophila homolog of KIF27), Null loss-of-function 
alleles. We observed that the progeny had a significant enhancement in rough eye 
phenotype. Knockdown of PPP3R2 in reporter cell line also resulted in a significant 
increase in luciferase activity.  
To determine if the endogenous regulators of CaN regulated APP metabolism, 
we knockdown RCAN1, AKAP79, FKBP12, and Cyclosporine A in SH-SY5Y APP-
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Gal4 cells. We obtained a significant increase in luciferase activity upon knockdown. 
Since these regulators normally inhibit CaN activity, this experiment indicates that 
inhibition of CaN decreases APP metabolism. 
CaN has been shown to dephosphorylate APP at Thr668. This site is located at 
the N terminal of the 681GYENPTY678 motif. Phosphorylation at Thr668 changes 
the conformation of APP, suppressing the interaction between Fe65 and AICD (Ando 
et al., 2001). However, we do not see results consistent with the idea. By inhibiting 
CaN using pharmacologic and genetic reagents, we inhibit dephosphorylation of 
APPThr668 resulting in a steady phosporylated state of APPThr668. Since the 
phosporylated state of APP has been shown to decrease the interaction between Fe65 
and AICD, we expect to see a decrease in AICD mediated luciferase. We do observe a 
decrease in AICD-mediated luciferase but we also observe a decrease in full length 
APP. This suggests that CaN is regulating the levels of full length APP.  
NFAT, a transcription factor, is a target for CaN that undergoes CaN-mediated 
dephosphorylation. Interestingly, BACE1, a secretase that is required for Aβ 
production has been shown to be regulated by NFAT1. An NFAT1 binding sire was 
identified in the BACE1 promoter. Aβ has been shown to disrupt calcium 
homeostasis(Mattson et al., 1993b) and increase cytosolic calcium levels(Brorson et 
al., 1995; Mattson et al., 1992). Treatment of cells overexpressing BACE1 promoter 
with Aβ resulted in nuclear translocation of NFAT1 and interaction with BACE1 
promoter (Cho et al., 2008). This is possibly an explanation as to how calcium 
dysregulation in AD brain increases BACE expression levels which inturn increases 
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Aβ production. Increased Aβ production further results in disrupted calcium 
homeostasis. 
It is not known if APPThr668 undergoes dephosphorylation in a NFAT 
mediated mechanism. It will be interesting to determine if the effect of CaN on full 
length APP is mediated via NFAT. 
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Methods:  
Pharmacologic reagents: FK506 and CsA were used for some experiments and were 
dissolved in DMSO. APP Gal4 SY5Y, UAS-Luc cells were treated with250nM of 
FK506 and CsA or 5 hours. Following the treatments, the cells were washed twice 
with cold PBS and lysed with GLB (Promega, Inc.). Lysates were used for luciferase 
assay using Steady Glo (Promega, Inc.). Luciferase counts were normalized to total 
DNA concentration that was measured using the SYBR Green (Invitrogen).  
 
Cell lines and reagent:  SH-SY5Y (neuroblastoma cells) and human embryonic 
kidney (HEK)-293 cells were purchased from ATCC. They were cultured in 
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% FBS, 2mM 
L-Glutamine, 100 units/ mL penicillin, and 100ug/mL streptomycin. SH-SY5Y 
reporter cells stably expressing APP-Gal4 and Gal4-UAS-luciferase that has been 
previously described by us(Zhang et al., 2007) were maintained in media containing 
200ug/mL of G418.  
 
RNAi: Plasmid-based shRNA constructs were purchased from Open-Biosystems 
(Birmingham, AL). These constructs are part of the human retroviral shRNA library 
housed at the Drexel University RNAi Resource Center. We utilized the following 
target specific shRNAs for PPP3CA, PPP3CB, PPP3CC, PPP3R1, and PPP3R2. As a 
negative control shRNA, we utilized the non-silencing shRNA from Open Biosystems, 
Inc. (RHS 1707). shRNA constructs were transfected using Arrest-In transfection 
reagent (Open Biosystems, Inc.) using the conditions suggested by the manufacturer. 
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Stably expressing shRNA clones were generated by adding 2 μg/ml puromycin 24 
hours post-transfection. Populations of resistant clones were detected five to seven 
days post-transfection. 
 
Drug treatment, transfections and Luciferase assay: For transfection in SH-SY5Y 
APP-Gal4 cells, 7500 cells/well were plated in 96 well plates.  24 hours post plating, 
shRNA constructs were transfected using Arrest-In transfection reagent (Open 
Biosystems, Inc.) using the conditions suggested by the manufacturer. Stably 
expressing shRNA clones were generated by adding 2 μg/ml puromycin 24 hours 
post-transfection. Populations of resistant clones were detected 2-3 weeks post-
transfection. 
For transient transfections in SY5Y-APP Gal4, UAS-Luc cells, 10,000 cells/ 
well were plated in 96 well plates. 24 hours post plating; over-expression plasmids 
were transfected using Arrest-In™ transfection reagent (Open-Biosystems) using 
conditions suggested by the manufacturer. 24 hours post transfection; lysates were 
collected and subjected to luciferase assays. 
For drug treatment experiments in SY5Y-APP-Gal4 cells, 10,000 cells/well 
were plated in a 96 well plates and the cells were treated with CaN inhibitors for 5 
hours.  
For luciferase assay, SYBR Green assay and Dual-Glo assays, we used the protocol 
and parameters descrbied by us previously (Zhang et al., 2007) .  
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Western Blot Analysis:  Cells were lysed in RIPA cell lysis buffer (50 mM Tris-HCL 
pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 1mM PMSF and 1 g/ml aprotinin, 
1 g/ml leupeptin, and 1 g/ml pepstatin), and centrifuged at 14,000 rpm for 15 
minutes at 4
○
C. The resulting supernatant was transferred to a new micro-centrifuge 
tube. The protein concentration of the cell lysates was determined using the BCA 
protein assay kit (Pierce, Rockford, IL) according to the manufacturer’s instructions. 
Equal quantities of protein were loaded into the wells of 4-12% Bis-Tris 
polyacrylamide gels (Invitrogen) along with See Blue plus 2 protein marker 
(Invitrogen). Gels were run using MES running buffer and transferred to PVDF 
membrane (Immobilon P
SQ
, Millipore) using a semi-dry transfer apparatus (Owl 
Scientific) and NuPage transfer buffer (Invitrogen). PVDF membranes were blocked 
in TBST with 5% dry milk for at least two hours, washed extensively, then incubated 
with primary antibody for either one hour at room temperature or overnight at 4
○
C. 
After removing the primary antibody, membranes were extensively washed and 
incubated with either goat-anti-rabbit-HRP or goat-anti-mouse-HRP secondary 
antibodies (1:10,000; GE) for one hour at room temperature. Membranes were washed 
and developed using West Dura Extended Duration Substrate (Pierce). The blot was 
visualized using a FluoroChem 8900 imaging system (Alpha Innotech), and signals 
were quantified using AlphaEase Fc software. To account for any differences in 
loading, target band densitometries were divided by actin densitometries obtained 
from the same lane. These corrected densitometries were normalized to controls in 
each experiment.  
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Fly lines: All flies were raised on standard cornmeal/molasses/agar media. For drug 
treatment, FK506 or CsA was added to standard fly medium to a final concentration of 
100nM. For control, DMSO was used (0.01% concentration). Larvae are raised on 
FK506 or CsA or vehicle containing food. Upon enclosion, they were scored for 
phenotypic effects.  For crossing experiments, we used CanB2
EP774  
or CanB
d09902 
 
(Bloomington Stock Center, http://flybase.bio.indiana.edu/), Canton S, and GMR-App-
Gal4, UAS:Grim / Cyo (Gross et al., 2008; Guo et al., 2003).  All crosses were 
performed at 25 C.  GMR-APP-Gal4, UAS:Grim / Cyo flies were outcrossed to both 
w
1118
 and Canton S genotypes to determine the reference eye phenotype for the GMR-
APP-Gal4, UAS:Grim adult eyes, as previously described (Gross et al., 2008; Guo et 
al., 2003).  Adult eyes were immersed in 95% ethanol and photographed using a 
Canon PowerShot S70 digital camera mounted to a Leica Mz 125 stereomicroscope.  
Fly lines expressing loss or gain of function mutations were crossed with 
AICD reporter flies (Gross et al., 2008; Guo et al., 2003) and the progeny were scored 
(+ to +++) for effects on eye phenotype. “+” is a rough eye, where at least one-half of 
the eye field is wild type. “++” is a rough eye where more than one-half of the eye is 
rough, usually affecting the whole eye, but not always. “+++” is a strong rough eye 
where the entire eye is affected, and there is a strong loss of pigment in the posterior 
one-half of the eye. To determine if there is a statistically significant change in 
phenotype relative to DMSO-fed flies we performed a G-test of homogeneity and 
report the p-values. Control flies are AD flies outcrossed to control for crossing to 
mutant lines.  
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Statistical Analysis: Values in the text and Figure 6-s are represented means ± 
standard deviation of at least six replicates. Two-sample student’s t-test was used to 
compare two groups. For in vivo studies, a G-test of homogeneity was performed to 
determine statistical significance. 
 “*” indicates p < 0.05 and “n.s.” indicates p-values greater than 0.05.       
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Results 
 
 
 
 
 
 
 
Figure 6-4: Effect of knockdown of PPP3CB on APP metabolism 
Transfection with shRNAs specific PPP3CB AICD-Gal4-mediated luciferase 
expression compared to control shRNA. Knockdown of Kif27 does not change Gal4-
mediated luciferase expression in a significant manner. Error bars represent standard 
deviation. Statistical significance was determined using two-sample, two tailed t-tests 
to compare SUFU and Shh shRNA with the control shRNA.  
* indicates p < 0.05. 
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Figure 6-1: CsA and FK506 mediated dose response decreases AICD- mediated 
Gal4 luciferase in a dose dependent manner. 
Dose-dependent decreases in AICD-Gal4-mediated luciferase activity with increasing 
concentrations of the CaN Inhibitors, FK506 or CsA. For the luciferase experiments, 
points represent mean normalized luciferase activity (+/- standard deviation), with 
luciferase levels normalized to total cell numbers using SYBR Green. Two tail 
student's t-test was utilized to test for significance between treatment and no-treatment 
control. 
* indicates p < 0.05. "Control" uses the same media as the treatments, and also 
contains the same amount of DMSO. 
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Figure 6-2: Effect of CsA and FK506 treatment on APP 
Inhibition of CaN activity by FK506 (250nM), CsA(250nM), or DMSO for 5 hours 
decreases AICD-Gal4 levels and decreases full-length APP as detected by Western 
blot analysis. 
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Figure 6-3: Quantification of CsA and FK506 mediated knockdown of FL-APP 
Quantification of Western blot densitometry. Normalization for loading differences 
was achieved by dividing the densitometry values for individual bands by the 
densitometry values for β-actin in the same lane and then normalizing to DMSO 
control 
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Figure 6-1: Effect of knockdown of PPP3CA, PPP3CC, PPP3R1, and PPP3R2 on 
APP metabolism 
Transfection with shRNAs specific for PPP3CA, PPP3CC, decreases AICD-Gal4-
mediated luciferase expression compared to control shRNA. Transfection with 
shRNAs specific for PPP3R1, PPP3R2 increases AICD-Gal4-mediated luciferase 
expression compared to control shRNA. Error bars represent standard deviation. 
Statistical significance was determined using two-sample, two tailed t-tests to compare 
gene knockdowns with control shRNA 
* indicates p < 0.05. 
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Figure 6-2: Effect of knockdown of endogenous regulators of CaN on APP 
metabolism 
Transfection with shRNAs specific for RCAN1, AKAP79, CyclophilinA, and 
FKBP1B increases AICD-Gal4-mediated luciferase expression compared to control 
shRNA. Knockdown of Kif27 does not change Gal4-mediated luciferase expression in 
a significant manner. Error bars represent standard deviation. Statistical significance 
was determined using two-sample, two tailed t-tests to compare RCAN1, AKAP79, 
CyclophilinA, and FKBP1B with the control shRNA.  
 
* indicates p < 0.05. 
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Figure 6-3: Effect of knockdown of CaN subunits on APP protein levels 
Inhibition of CaN activity by FK506 or DMSO decreases AICD-Gal4 levels and 
decreases full-length APP as detected by Western blot analysis. 
 
 
 
 
  
Figure 6-4: Quantification of effect of knockdown of CaN subunits on APP 
protein levels. 
 Inhibition of CaN activity by FK506 or DMSO decreases AICD-Gal4 levels and 
decreases full-length APP as detected by Western blot analysis. 
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Figure 6-5: AICD dependent rough eye phenotype in Drosophila fed with FK506 
or CsA 
(A) GMR-APP-Gal4, UAS: Grim flies treated with vehicle (DMSO), and (B) GMR-
APP-Gal4, UAS: Grim flies treated with FK506. FK506 treated eyes exhibit 
suppression of rough eye phenotype. 
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                                                                             % showing Phenotype                  
Drugs Genotype n + ++ +++ p-value* 
None w-(wildtype) 64 25 67 8 0.89 (n.s.) 
10% DMSO w-(wildtype) 87 23 60 17  
100 nm FK506 w-(wildtype) 53 91 9 - 8.2x10
-16
 
100 nM CsA w-(wildtype) 78 49 48 3 9.0x10
-5
 
 
* Comparison to 10%DMSO by G-test of homogeneity 
Table 6-1: Quantitative analysis ofγ-secretase reporter flies fed with 100nM 
FK506 or CsA 
The progeny were scored (+ to +++) for effects on eye phenotype. “+” is a rough eye, 
where at least ½ of the eye field is wild type. “++” is a rough eye where more than ½ 
of the eye is rough, usually affecting the whole eye, but not always. “+++” is a strong 
rough eye where the entire eye is affected, and there is a strong loss of pigment in the 
posterior ½ of the eye. We determine if there is a statistically significant change in 
phenotype relative to10% DMSO-def flies by performing a G-test and report the p-
values. “n.s.” indicates p-values greater than 0.05.  
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Figure 6-6: AICD dependent rough eye phenotype in Drosophila crossed with 
Can
B2EP774
 loss of function mutants. 
(A) Wild type fly (B) GMR-APP-Gal4, UAS: Grim (C) GMR-APP-Gal4, UAS: Grim 
flies crossed with CanB2
EP774
 (loss-of function mutant of CaNB2-PPP3R2) suppressed 
eye phenotype, (D) GMR-APP-Gal4, UAS: Grim flies crossed with CanB2
EP7741
 (loss-
of function mutant of CanB2, PPP3R2) enhances eye phenotype. 
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  % showing Phenotype   
Gene(s) Genotype n + ++ +++ p-value Nature of Allele 
control w-(wildtype) 137 37 55 8 -- outcrossed wild-
type 
 UAS:lacZ 129 34 42 18  outcrossed to 
UAS:lacZ 
CaN CanB2
EP774
 80 3 25 72 <0.0001 loss-of-function 
 CanB
d09902
 67 26 62 12 n.s. Intronic P-element 
insertion 
 
 
 
 
Table 6-2: Quantitative analysis of AD fly eyes crossed with Can
B2EP774
 or 
CanB
d09902
 
(Guo et al., 2003). The progeny were scored (+ to +++) for effects on eye phenotype. 
“+” is a rough eye, where at least ½ of the eye field is wild type. “++” is a rough eye 
where more than ½ of the eye is rough, usually affecting the whole eye, but not 
always. “+++” is a strong rough eye where the entire eye is affected, and there is a 
strong loss of pigment in the posterior ½ of the eye. We determine if there is a 
statistically significant change in phenotype relative to wild type we performed a G-
test and report the p-values. “n.s.” indicates p-values greater than 0.05. Loss of 
function  
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Chapter 7 Discussion 
 
 
Alzheimer's disease (AD) is a progressive and irreversible brain disorder and 
the most common form of dementia. The pathological hallmarks of AD are the 
presence of dense intraneuronal neurofibrillary tangles, composed of 
hyperphosporylated Tau protein; and extracellular amyloid plaques, composed of -
amyloid peptide. Plaque formation could be the result of either an increase in Aβ 
production or a decrease in the of Aβ clearance. Aβ oligomers are believed to induce 
synaptic loss resulting in neuronal death(Shankar et al., 2008). APP undergoes 
sequential proteolysis by α-, β-, and γ- secretases to produce A , P3, and AICD 
(Brown et al., 2000; Ebinu and Yankner, 2002; Urban and Freeman, 2002). Several 
genes have been identified encoding enzymes that directly metabolize APP to generate 
A ; however, it is not fully understood how APP metabolism is regulated.  
To date, 4 genes APP, PS1, and PS2, and ApoE have been implicated in 
familial AD, mutations in which increase Aβ. The ε4 allele of APOE is a major risk 
factor for AD; studies estimate that approximately 50% of LOAD patients do not have 
the ε4 allele. Daw et al. has proposed the existence of 4-7 additional loci other than 
APOE that can result in LOAD(Daw et al., 2000). A genome-wide linkage analysis 
and linkage disequilibrium study suggests the presence of candidate genes on multiple 
chromosomes. The most prominent among all the chromosomes has been the linkage 
on chromosome 10 which has been observed in a number of non-overlapping samples 
from studies employing distinct approaches. Genes located in the linkage regions are 
considered as biological candidate genes which may modulate Aβ metabolism directly 
or indirectly. To accelerate the understanding of a complex disease like AD, it is 
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essential to identify these genes that modulate AD risk and determine their mode of 
action. Given the centrality of APP metabolism in AD, it is crucial to identify 
regulators of APP metabolism, including, but not limited to, APP proteolysis. 
Regulation of APP metabolism can occur by numerous mechanisms, including 
regulation of APP transcription, APP translation, APP maturation, intracellular 
trafficking of full-length APP and APP cleavage products, APP proteolysis, and APP 
degradation. While Komano and colleagues have used a genetic screen to specifically 
identify regulators of -secretase activity (Komano et al., 2002), a screen that will 
identify APP metabolism regulators that act through multiple mechanisms is needed.  
To identify modulators of APP metabolism, we established and validated a 
luciferase based, AICD-mediated high throughput assay in SH-SY5Y cells. We 
validated this functional assay using pharmacologic agents, as well as forward and 
reverse genetics. We over-expressed, knocked-down genes that encode the -, -, and 
-secretases as well as monitored the effects of pharmacologic modulators of 
secretases on AICD mediated luciferase assays as well on AICD-Gal4 levels as 
measured by Western blot analysis. The changes in luciferase activity induced by 
secretase over-expression or knock-down mirrored the trends observed in the Western 
blot analysis. Knock-down of APP had the most dramatic effect on AICD-Gal4 
mediated luciferase activity while knock-down of genes encoding - and -secretases 
resulted in significant decreases in AICD-Gal4 mediated luciferase. To assess the 
quality of the AICD-Gal4 mediated luciferase assay we calculated the “Z-factor” for 
the assay in response to the known APP metabolism modulators (Zhang et al., 1999). 
The Z-factor is a dimensionless metric that takes assay dynamic range and data 
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variation into consideration to assess the utility and reliability of the assay. Scores 
between 0.5 and 1.0 indicate an excellent assay (Zhang et al., 1999). For 
pharmacologic and genetic modulation of the secretases conditions, we obtain Z 
values between 0.5 and 1.0, indicating that our experimental approach is robust and 
has the capability of identifying APP metabolism regulators that increase or decrease 
AICD generation.   
We chose the region located between 3.5 -105 Mb region on Chr.10 which 
harbors approximately 437 genes. This region has been consistently reported by 
several groups to harbor candidate genes associated with AD (Bertram et al., 2000; 
Blacker et al., 2003b; Ertekin-Taner et al., 2000; Farrer et al., 2003; Kehoe et al., 
1999; Myers et al., 2000). To identify the regulators of APP metabolism located on 
Chr. 10, we used shRNA mediated RNAi to knock down individual genes in 
combination with a previously described AICD-Gal4 based luciferase assay (Zhang et 
al., 2007). We knocked down the top 100 positional candidate genes and identified 16 
positional candidate genes in the region on chromosome 10 associated with LOAD.  
These genes identified from the screen can be putative drug targets. With an 
increase in expected AD population in years to come, it is very important to 
understand the underlying cause of the disease for the development of more effective 
diagnosis and treatment.  
To further validate our data in a different and higher model system, we utilized 
the previously created Drosophila melanogaster γ-secretase reporter flies (Gross et al., 
2008; Guo et al., 2003).  These flies expresses a C99-Gal4 fusion protein in the 
developing retina (Gross et al., 2008; Guo et al., 2003).  Proteolytic processing of this 
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fusion protein is carried by endogenous secretase activity in the fly retina (Gross et al., 
2008; Guo et al., 2003). Processing releases an AICD-Gal4 fragment that  activates the 
transcription of a cell death activator called Grim (Chen et al., 1996). Expression of 
Grim causes apoptosis. Apoptosis results in a rough eye phenotype, loss of 
pigmentation, disrupted bristle morphology. 
To demonstrate that the rough eye phenotype was dependent on APP 
metabolism, we treated GMR-APP-Gal4, UAS:Grim flies with L-685, 458, a γ-
secretase inhibitor. Control flies were treated with vehicle (DMSO). In the treatment 
flies, 100nM and 250nM of L685, 458 significantly suppressed (p<0.0001) the rough 
eye phenotype. This shows that the observed rough eye phenotype is γ-secretase 
mediated and not a non-specific mechanism.  
We focused on two genes, PPP3CB and SUFU, that we identified from our 
screen to determine their role in APP metabolism. We chose these genes because we 
identified genes, PPP3R2 and KIF27, two genes that are intimately associated with 
PPP3CB and SUFU. To gain insight into the mechanism by which these two candidate 
genes may modulate APP metabolism, we performed in vitro as well as in vivo 
experiments. 
PPP3CB is the catalytic subunit of the phosphatase, CaN which has been 
shown to dephosphorylate APP at Thr668. CaN activity has been shown to be 
upregulated in the CNS of Tg2576 animal model overproducing Aβ. Acute treatment 
of these mice with FK506 has shown to improve memory function. This suggests that 
CaN mediates some of the Aβ dependent cognitive effects and is crucial for synaptic 
plasticity and memory function (Dineley et al., 2007). NFAT1, a transcription factor 
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controlled by CaN has been shown to stimulate BACE1 expression, resulting in 
accelerated Abeta generation with an increase in intracellular calcium concentration. 
NFAT1 has been shown to specifically binding the BACE1 gene promoter region and 
regulate BACE1 expression. Treatment with CaN inhibitor was shown to block 
BACE1 expression (Cho et al., 2008). 
An increase in cytosolic calcium has been shown to induce the activity of 
kinases and phosphatases. This results in phosphorylation of both microtubule-
associated protein tau and APP by GSK-3β and cdk5, followed by a 
dephosphorylation of these proteins by CaN. Transient phosphorylation of APP at 
thr668 results in accumulation of intraneuronal Aβ. Intraneuronal Aβ is believed to be 
toxic (Pierrot et al., 2006) 
In differentiating PC12 cells (rat adrenal medulla), mature APP that is 
phosphorylated at Thr668 in neurons has been shown to be located in the neuritis, 
mostly in the growth cones. Expression of mutant APP with Thr668Glu has shown to 
remarkably reduced neurite
 
extension (Ando et al., 1999). This suggests that Thr668 
phosphorylated APP plays an important role in neurite outgrowth of differentiating
 
neurons. 
Interestingly, in CHO cells and in cultured rat neurons, expression of 
APPT668D in neurons resulted in increased β-CTF production and decreased γ-
secretase cleavage and decreased extracellular Aβ40 production. However, neuronal 
expression of APPT668A mutant produced increased amounts of Aβ40 compared to 
APP695 cells. This suggests that phosphorylation of APP at Thr668 increases β-
secretase cleavage and decreases γ-secretase cleavage of APP resulting in decreased 
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Aβ40 production (Feyt et al., 2007). Apart from the secretases, the Thr668 
phosporylated APP has been shown to be less vulnerable to cleavage by caspase-3 and 
caspase-8 compared to APPT668A mutants in HEK293 cells. In apoptotic cells, APP 
has been shown to undergo cleavage by caspases after the Asp664 residue (with 
respect to the numbering conversion for the APP695 isoform). Fragments produced 
cleavage of APP by caspase has been observed to be elevated in AD brain samples 
compared to controls (Taru et al., 2004) 
Apart from APP processing, Thr668 phosporylation has also been suggested to 
regulate APP trafficking. Prolyl isomerase Pin1 has been shown to bind APP and 
regulate APP processing. Pin1 is suggested to control APP isomerization by binding to 
the phosphorylated Thr668–Pro motif in conformation, catalyzing its conversion to the 
trans isomer that undergoes rapid dephosphorylation, promoting non-amyloidogenic 
processing of APP. This affects APP processing decreasing Aβ production.  Pin1 has 
been shown to co-localize with APP in the primary vesicles localized at the plasma 
membrane as well as in AP-2 coated clathrin-coated vesicles. This co-loacalization has 
been observed to be absent in endosomes.  This suggests that Pin1 binding affects the 
trafficking of APP and decreases Aβ production. In cell culture, overexpression of 
Pin1 results in increased Aβ secretion while Pin1 knockout in mice results in increased 
Aβ42 production (Pastorino et al., 2006).  
On contrary, no change in the levels or subcellular distributions of holoAPP, 
sAPPα, sAPPβ, CTFα, CTFβ, Aβ40 and Aβ42 was observed in the brains of 
APPT668A mutant mice compared to wild-type mice(Feyt et al., 2007).  
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Fe65 is another adaptor protein that has been shown to interact with AICD and 
activate gene transcription. Cao and Sudhof used the Gal4 dependent transactivation 
assay demonstrated that AICD interacted with Fe65 translocating into the nucleus and 
activating gene transcription. Not much is known about the mechanism by which 
AICD-mediated signaling is regulated (Cao and Sudhof, 2001). Phosphorylated state 
of AICD at Thr668 is believed to regulate the interaction between Fe65 and AICD and 
determine the Fe65-dependent gene transactivation of AICD. In PC12 cells, Fe65 was 
shown to bind to phosporylated APP.  Inhibition of Thr668 mutation using inhibitors 
or expression of mutant APPT668A mutant resulted in a dramatic decrease in nuclear 
translocation of AICD and AICD mediated neurotoxicity. An upregulation of 
phosphorylated APP-CTFs at T668 has been observed in human AD brain samples, in 
Tg2576 mouse brains as well as in mutant mice overexpressing swAPP695.  
Contrarily, data indicating that phosphorylation of AICD does not regulate the
 
translocation of FE65 and that AICD translocates into the nucleus in an FE65 
independent manner has been shown. Mutant
 
AICD with Thr668Ala when 
overexpressed was shown to mostly localize to the nucleus suggesting that 
phosphorylation of AICD does not regulate the
 
translocation of FE65 and that FE65 
does not accompany AICD
 
into the nucleus. Phosphorylation of APP is beleived to 
release the membrane-bound
 
FE65, which then tranlocates to the nucleus upregulaing 
AICD mediated transcripton (Figure 7-1A).  
Since our in vitro model is so intimately associated with Fe65, we speculated 
that the decrease in APP metabolism upon knockdown of PPP3CB is due to decrease 
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in dephosporylated state of AICD. We hypothesize that CaN dephosphorylates APP at 
Thr668 and regulates its nuclear localization (Figure 7-1B).  
We observed that knockdown of individual catalytic or regulatory subunits of 
CaN modulated APP metabolism. Specifically, knockdown PPP3CA and PPP3CC 
significantly decreases luciferase activity while knockdown PPP3R1 and PPP3R2 
significantly increases luciferase activity. Interestingly, knockdown of endogenous 
CaN inhibitors RCAN1, AKAP79, FKBP12, and cyclophilin A resulted in a significant 
increase in luciferase activity upon knockdown. This indicates that inhibition of CaN 
activity by either inhibiting the catalytic subunit or by inhibiting catalytic activity 
decreases APP metabolism suggesting that CaN negatively regulates APP metabolism.  
 To determine the mechanism by which APP metabolism is regulated by CaN, 
we observed the effect of knockdown of catalytic and regulatory subunits on full 
length APP. At protein levels, knockdown of PPP3CC significantly decreases levels 
of full length mature and immature APP while knockdown of PPP3R2 subunits 
significantly increases levels of full length mature and immature APP. This suggests 
that change in AICD mediated luciferase activity was due to change in full length 
APP. 
To validate the knockdown data, we pharmacologically inhibited CaN and 
observed its effect on AICD mediated luciferase and full length APP. We observed 
that treatment of SY5Y-APP-Gal4 cells with different concentration of FK506 and 
CsA resulted in a concentration dependent decrease in AICD-mediated luciferase 
activity. At protein levels, inhibition of CaN activity using 250nM of FK506 or CsA 
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resulted in a decrease in full length APP. This data confirmed that CaN negatively 
regulated full length APP.  
To validate and confirm the results obtained in vitro, we used Drosophila AD 
model. Loss of function mutation of CanB2, drosophila homolog of PPP3R1 in GMR-
APP-Gal4, UAS:Grim significantly enhanced the rough eye phenotype. We have 
observed similar result in out in vitro model system. Knockdown of regulatory 
subunits, PPP3R1 or PPP3R2 in reporter cell line also resulted in a significant 
increase in luciferase activity.  
Phosphorylation at Thr668 is proposed to alter the conformation of this domain 
suppressing the interaction between Fe65 with AICD as well as APP (Ando et al., 
2001). Our results are consistent with this model. By inhibiting of CaN using 
pharmacologic and genetic reagents, APP fails to undergo dephosphorylated. Since 
phosporylated APP is proposed to decrease the interaction between Fe65 and AICD, 
we expect to see a decrease in AICD mediated luciferase. We do observe a decrease in 
AICD-mediated luciferase. We also observe a decrease in full length APP. This 
suggests that CaN is regulating the levels of full length APP as well.  
It is not known if APPThr668 undergoes dephosphorylation by NFAT 
mediated mechanisms. It will be interesting to determine if the effect of CaN on full 
length APP is mediated via NFAT.  
Preliminary data suggest that CaN regulates metabolism of full length APP. 
Inhibition of catalytic activity of CaN using RNAi and pharmacologic reagents 
decreased FL length APP levels as well as in AICD-mediated luciferase activity. 
There are various mechanisms by which APP levels can be modulated in the cells.  
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 A change in APP trafficking can modulate the amount of APP transported to 
the plasma membrane and other organelles where it undergoes secretase mediated 
processing. A decrease in rate at APP trafficking can decrease the amount of FL-APP 
undergoing proteolysis. CaN can regulate proteins that are involved in trafficking of 
APP. Dynamin; a protein involved in endocytosis undergoes dephosphorylation to 
promote retrieval of synaptic vesicles following exocytosis. Dynamin undergoes re-
phosphorylation for the next round of endocytosis followed by a second stimulus. 
Inhibition of CaN can result in persistent phosphorylation of dynamin that might 
interfere with endocytosis (Cousin et al., 2001). Modulation in endocytosis can also 
modulate FL-APP levels. An increase in endocytosis can result in a decrease in cell-
surface APP levels. An increased rate of endocytosis can also result in more APP 
being subjected to degradation. 
 A change in location of APP in the cells is another mechanism by which FL-
APP levels can be modulated.  Fe65 has been proposed to bind to APP and regulate its 
trafficking. Fe65 bound APP is believed to be trafficked to the cell surface where it 
can undergo α-secretase mediated proteolysis (Sabo et al., 1999). Overexpression of 
Fe65 has been shown to increase proteolytic processing of APP (Guenette et al., 1999; 
Sabo et al., 1999). 
Recently, BACE1 gene expression was shown to be regulated by NFAT, a 
transcription factor regulated by CaN (Cho et al., 2008). Similarly, NFAT can also 
modulate the expression of FL-APP. Inhibition of CaN can result in an NFAT-
mediated decrease in APP gene expression resulting in a decrease in APP levels. A 
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change in APP mRNA half-life or stability can also modulate levels of full length 
APP.  
To determine the mechanism by which CaN regulates the levels of full-length 
APP (Figure7-3), we will  
(1) Overexpress and knockdown the regulatory, catalytic subunits of CaN,   
(2) Overexpress  and knockdown the endogenous regulators of CaN, 
(3) inhibit CaN activity using pharmacologic inhibitors against CaN, 
(4) use commercially available auto-inhibitory peptide against CaN,   
and observe its effect on levels of FL-APP, APP mRNA, APP trafficking and APP 
localization. Once we determine the mechanism by which APP levels are regulated 
by CaN, we will determine the mechanism by which CaN…. 
 
To determine if CaN regulates APP via NFAT (Figure7-4), we will 
(1) Overexpress and knockdown NFAT 
(2) Use VIVIT, a peptide that blocks the interaction between CaN and NFAT.  
and observe its effect on levels of FL-APP, APP mRNA, APP trafficking and APP 
localization. If we observe a change in any of these, we will conclude that CaN 
regulates APP metabolism via NFAT. 
Once we determine the mechanism in vitro, we will use available AD animal 
models to characterize the mechanism. To determine if any polymorphism in this gene 
pre-disposes people to AD, we will further identify alleles in all the subunits and 
overexpress them to identify the mechanism by which different alleles modulate APP 
metabolism. 
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Another gene that we identified from this screen is SUFU. SUFU is a key 
component of the hedgehog (Hh) signaling pathway as a putative regulator of APP 
metabolism. Interestingly, KIF27, another component of Hh pathway, located on 
Chr.9 was identified in a similar manner.  
The Hedgehog gene was identified from a genetic screen to identify genes 
involved in Drosophila body segmentation. Hedgehog signaling pathway has been 
shown to be involved in embryonic development and in maintenance of stem cells in 
adults. Mutation and misregulation of hedgehog genes have been shown to be linked 
with cancer. SHH is a major regulator of neuron cells. SHH has been shown to be 
active in multiple tissues and plays a role in for development of skin, hair, intestine, 
pancreas and brain, from the embryo stage to the adult stage. Sonic Hedgehog is 
considered a major regulator of neuron cells.  
In adult humans, a dysregulation of the SHH-GLI pathway has been shown to 
be involved in a number of tumors, such
 
as basal skin cell carcinomas, 
medulloblastomas, and pancreatic
 
and lung cancers (Sanchez et al., 2005). 
The Hh pathway is activated though the interaction of Hh ligand with Patched1 
(PTCH), multi-pass transmembrane receptor (refer to the figure in previous chapter). 
This interaction activates a transmembrane protein Smoothened (SMO), a seven 
transmembrane protein which shares a homology with the G-protein coupled receptor 
family. In absence of the Hh ligand, PTCH acts a repressor of the pathway by 
repressing SMO. However, in presence of Hh ligand, PTCH activates SMO, resulting 
in nuclear translocation of members of Gli family. Gli proteins are zinc finger 
transcription factors, primary mediators of Hh signal transduction. Gli family is 
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composed of Gli1, Gli2, and, Gli3. The Glis have both activator and repressor 
functions. In humans, Gli1 is has a strong activator function, Gli2 has both activator 
and repressor functions, and Gli3 is mostly a repressor (Aza-Blanc et al., 2000; Bai et 
al., 2004; Nguyen et al., 2005; Ruiz i Altaba, 1998, 1999; Stamataki et al., 2005; 
Tyurina et al., 2005). Full length Gli proteins act as strong activators. C-terminally 
deleted forms Gli 2 and Gli3, mediated by proteasome act as repressors.  The fly 
homolog of Gli, Cubitus interruptus (Ci) acts as both activator and repressor (Methot 
and Basler, 1999).  
However, the molecular mechanisms that regulate Gli activity are not 
completely understood. In flies, Ci is shown to be regulated by Fused (FU), a 
serine/threonine kinase; suppressor of fused (SUFU); and Cos2, a kinesin-like protein. 
In absence of ligand, Ci forms a complex formed by FU, SUFU and, Cos2 (human 
Kif27 homolog) and is retained in the cytoplasm. This retention results in proteolytic 
processing of full length Ci (CiA) to its repressor form (CiR). Binding of the Hh 
ligand releases of this complex, there by activating transcription by Ci (Hooper and 
Scott, 2005; Lum and Beachy, 2004). Thus Cos2 and SUFU act as negative regulator 
of Ci activity.  
Since HH pathway modulates the activity of Gli transcription factors, we 
speculate that the change in luciferase activity is due to change in AICD metabolism 
mediated by HH pathway (Figure7-2).  
Pharmacologically, we used cyclopamine, a plant alkaloid that interacts with 
SMO, to inhibit the Hh pathway (Chen et al., 2002b; Incardona et al., 1998). This 
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treatment in our in vitro and in vivo model systems significantly decreased APP 
metabolism.  
We also sought to determine if genetic manipulation of the Hh pathway could 
alter APP metabolism. We overexpressed SHH, PTCH, SMO, KIF27, and SUFU in 
SY5Y-APP-Gal4 cells. We observed that overexpression of SHH, SMO, and SUFU 
significantly increased luciferase activity while overexpression of PTCH significantly 
decreased luciferase activity. Knockdown of SHH, SUFU in SH-SY5Y APP-Gal4 
cells significantly decreased luciferase activity while knockdown of KIF27 
significantly increased luciferase activity.  
To determine if KIF27 modulated APP metabolism in flies, we crossed GMR-
APP-Gal4, UAS: Grim with two independent Cos2 (the Drosophila ortholog of 
KIF27) loss of function mutants (Cos2
W1
 and Cos2
k16101
). We observed that the 
progeny had a significant enhancement in rough eye phenotype, which is consistent 
with what we observed in SH-SY5Y cells. To determine if we observe similar effects 
in vivo, we crossed GMR-APP-Gal4, UAS:Grim flies with SMO
3 
loss of function flies. 
Inhibition of SMO enhances the AICD-Gal4 dependent rough eye phenotype, a result 
opposite of what we observed in SH-SY5Y cells. We think that this is due to 
difference in the cell types. In our hands, we have observed a cell-type dependent 
difference in APP metabolism.  
By and large our manipulation of Hh signaling in in vitro and in vivo settings 
has produced consistent results. The effect overexpression of Hh pathway components 
is opposite to when these components are knocked down. This provides with 
preliminary evidence that Hh pathway regulates APP metabolism, a novel finding. 
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Since knockdown and overexpression of SUFU produced opposite of what we 
expected, we overexpressed a mutant form of SUFU that lacked the carboxy-terminal 
half of SUFU (SUFU Ct) abolishing its interaction with Gli1 and Gli2, but not Gli3. 
Overexpression of mutant SUFU has been shown to activate Hh pathway (Taylor et 
al., 2002). This is possibly due to the activity of Gli3. In our in vitro reporter system, 
overexpression of SUFU Ct significantly decreased luciferase activity compared to 
wild-type SUFU. However, overexpression of SUFU Ct significantly increased 
luciferase activity compared to the control. This suggests that APP metabolism is 
regulated in a Gli dependent manner.  
In summary, these results provide preliminary evidence the Hh pathway 
regulates APP metabolism both in vitro and in vivo. Previously it was believed that the 
Hh pathway was active only during developmental stages. We here find that this 
pathway is active in adult flies and is capable of modulating APP metabolism. It will 
be very interesting to determine if this metabolism is in a Gli dependent manner. It 
will also be interesting to determine if Hh directly affects APP or secretases or 
controls APP metabolism by altering other proteins that can affect APP metabolism. 
 
There are various mechanisms by which AICD mediated luciferase and GRIM 
activity can be modulated by the HH pathway. HH pathway can modulate APP 
metabolism by  
(1) modulating APP levels post- transcriptionally 
(2) modulating APP  trafficking or localization  
(3) modulating secretase mRNA levels 
(4) modulating secretase levels post- transcriptionally 
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(5) modulating secretase trafficking  or localization 
(6) modulating secretase activity 
HH pathway can modulate AICD mediated luciferase by modulating metabolism of 
APP, Secretases, Fe65, Tip60, and AICD. Since our assay is dependent on the 
transactivation property of AICD, HH can also modulate luciferase activity by 
(Figure7-6). 
(7) modulating AICD  trafficking or localization and half-life 
(8) modulating Fe65 levels post-transcriptionally, Fe65  trafficking or localization, 
Fe65 activity 
(9) modulating Tip60 levels post-transcriptionally, Tip60 trafficking or 
localization, Fe65 activity 
 
To determine the mechanism by which HH pathway regulates APP metabolism, 
we will overexpress and knockdown members of HH pathway and use pharmacologic 
inhibitors against HH to determine the change in Aβ levels. A significant change in 
Aβ levels would suggest that HH pathway modulates APP metabolism. No change in 
Aβ levels would indicate that HH pathway modulates members of transactivation 
pathway or is a non-specific effect.  (Figure7-5) 
To further determine the mechanism by which HH pathway modulates APP 
metabolism, we will genetically and pharmacologically modulate HH pathway and 
observe its effect on FL-APP, CTFs, APP mRNA, APP trafficking, and APP 
localization. We will also observe the effect of HH pathway modulation on secretase 
activity, protein levels, mRNA level, trafficking, and localization. (Figure7-6) 
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Similarly, to further determine the mechanism by which HH pathway modulates 
transactivation pathway, we will observe the effect of HH pathway on protein levels, 
mRNA levels, activity, trafficking, and localization of FE65, Tip60, and AICD. 
To determine if the modulation in luciferase activity is mediated in a Gli 
dependent mechanism, we will overexpress and knockdown Gli1, Gli2, and Gli3 and 
observe its effect on APP metabolism. If we do not observe a change in APP 
metabolism, we will conclude that HH pathway modulates APP metabolism in a Gli 
independent mechanism. (Figure7-7) 
Once we determine the mechanism by which HH modulates APP metabolism, 
in vitro, we will use available AD animal models to characterize the mechanism. To 
determine if any polymorphism in this gene pre-disposes people to AD, we will 
further identify alleles in all the HH members and overexpress them to identify the 
mechanism by which different alleles modulate APP metabolism. 
       
Significance of the findings: 
AD is a complex disease cause by a combination of age, genetic, and 
environmental factors. These factors cause or increase the risk of acquiring the 
disease. There are additional genetic and environmental factors other than APOE that 
may be located on other chromosomes and are involved with development of the 
disease. Given the centrality of APP in AD; we developed, established and validated 
an RNAi based screen in SH-SY5Y neuroblastoma cells to identify regulators of APP 
metabolism. We screened Chr. 10q11-25; a region implicated by genetic studies to be 
associated with AD and identified 16 putative candidate genes located in this region. 
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These genes as well as their related signaling pathway genes can act as putative drug 
targets.   
Most drugs are inhibitors that block the action of target protein or other related 
proteins in the pathway. For development and identification of drugs, the mechanism 
by which these genes modulate APP metabolism should be clearly understood. Drug 
screens to identify compounds that block the activity of the gene of interest can be 
employed. These drugs will be tested and validated both in vitro and in vivo for 
toxicity and their potential therapeutic activity against the target. 
Gene therapy is a very promising future in the field of AD therapeutics. Delivery 
of genes that can decrease Aβ production or increase Aβ degradation can potentially 
delay the onset of the disease if not cure the disease. AD is caused by neuronal loss. 
Identification of genes that are involved in cell proliferation and differentiation signals 
can be used for regeneration of tissues in AD brain. 
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Figures 
 
A. 
 
 
B. 
 
 
 
 
Figure 7-1:  Model for CaN dependent AICD-mediated gene transcription and 
regulation of FE65 nuclear localization.  
APP undergoes processing by α-,β-, and γ- secretase to generate AICD. AICD 
translocates into the nucleus in an Fe65in-dependent mechanism. Phosphorylation of 
APP at thr668 releases Fe65, a membrane bound adaptor protein, tranlocating it into 
the nucleus. It is further trapped into the nucleus with AICD where it activates 
transcription. In presence of CaN, thr668 undergoes dephosphorylation which  
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Figure7-2: Model for HH mediated APP metabolism regulation.  
In absence of ligand (Shh), the HH pathway is inactive. Patched, a transmembrabe 
protein inhibits the activity of Smoothened (SMO), a seven transmembrane protein. 
This complex inhibits Gli, a transcripton factor from enterning the nucleus. This 
inhibition is mediated through the interactions with cytoplasmic proteins, including 
Fused and Suppressor of fused (Sufu). This results in inhibition of transcriptional 
activation of HH targets. In presence of the ligand, HH pathway activates gene 
transcription. We propose that HH pathway is involved in the regulation of AICD 
mediated gene transcrition.  
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Figure7-3: Scheme to characterize the mechanism by which Calcineurin  
modulates APP metabolism 
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Figure7-4: Scheme to characterize the mechanism by which NFAT modulates 
APP metabolism 
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Figure7-5: Scheme to determine if HH pathway modulates APP metabolism 
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Figure7-6: Scheme to characterize the mechanism by which HH pathway  
modulates APP metabolism 
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Figure7-7 : Scheme to determine if Gli regulates APP metabolism 
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APPENDIX 1: ABBREVIATIONS 
 
 
 
AD Alzheimer's disease 
ADAM a disintegrin and metalloprotease 
AICD APP Intra Cellular Domain 
AKAP79 A kinase (PRKA) anchor protein 5 
APLP1 amyloid beta (A4) precursor-like protein 1 
APLP2 amyloid beta (A4) precursor-like protein 2 
APOE Apolipoprotein E 
APP Amyloid A4 Protein Precursor 
BACE Beta-site APP cleaving enzyme  
CaN Calcineurin 
Chr. Chromosome 
CiA interruptus activator 
CiR cubitus interruptus repressor 
CNS Central nervous System 
Cos2 Costal-2 
CsA Cyclosporin A 
CTF C-Terminal Fragment 
CTF83 C-Terminal Fragment, 83 amino acid length 
CTF88 C-Terminal Fragment, 88 amino acid length 
CTF99 C-Terminal Fragment, 99 amino acid length 
CyP Cyclophilin 
DMEM Dulbecco's Modified Eagle Medium 
DSCR1 Down syndrome candidate region 1 
EOAD Early Onset Alzheimer's Disease 
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ER Endoplasmic Reticulum 
ERGIC endoplasmic reticulum-Golgi intermediate compartment 
FAD Familial Alzheimer's Disease 
FBS Fetal Bovine Serum 
Fe65 amyloid beta (A4) precursor protein-binding, family B, member 1 
Fu Fused 
GLB Glo lysis Buffer 
Gli GLI-Kruppel family member 
HH Hedgehog 
IDE Insulin degrading Enzyme 
imAPP immature APP 
Kif27 kinesin family member 27 
LOAD Late Onset Alzheimer's Disease 
LOD Likelyhood of disease 
LTD Long Term Depression 
LTP Long Term Potentiation 
Luc Luciferase 
mAPP mature APP 
miRNA micro RNA 
Nct Nicastrin 
NFAT nuclear factor of activated T cells 
PPP3CA protein phosphatase 3, catalytic subunit, alpha isoform 
PPP3CB protein phosphatase 3, catalytic subunit, beta isoform 
PPP3CC protein phosphatase 3, catalytic subunit, gamma isoform 
PPP3R1 protein phosphatase 3, regulatory subunit, alpha isoform 
PPP3R2 protein phosphatase 3, regulatory subunit, beta isoform 
PS1 presenilin 1 
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PS2 presenilin 2 
PTCH Patched 
RCAN1 regulator of calcineurin 1 
RIP Regulated intramembrane proteolysis 
RNAi RNA interferance 
ROS Reactive Oxygen Species 
sAPP soluble APP fragment 
SHH Sonic Hedgehog 
Smo Smoothened 
SUFU Supressor of Fused 
swAPP Swedish APP 
SYBR SYBR Green 
TACE tumor necrosis factor-α converting enzyme 
Tg Transgenic 
TGN Transgolgi Network 
Tip60 Tat-interactive protein 
UAS Upstream Acivating Sequence 
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APPENDIX 2: Micellaneous experiments 
 
 
Rationale: 
 Determine the sensitivity of luciferase assay 
 
 
 
 
FigureA1: Dose dependent increase in luciferase and SYBR Green activity 
To determine the effect of cell number on luciferase and SYBR Green  
activity 
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Rationle:  
 
SH-SY5Y cells have very low transfection efficiency, with 20-25% being the best. We 
optimized our transfection protocol to obtain better transfection efficiency. To select 
cells that express shRNA, we replaced CM with CM containing puromycin (2μg/mL) 
24 hours post transfection.  
We knocked-down β-secretase in SY5Y-AG4 cells using 5 different shRNA 
plasmids, targeting different regions of the BACE mRNA along with controls (shNC: 
scrambled sequence and shLUC: targeting firefly luciferase). We collected lysates and 
performed a quantitative Western blot using Anti-human BACE (1:1000, Biosource: 
AHB0241) and anti-Actin (1:5000, Sigma: A5441) antibodies. We quantified and 
compared the intensity of BACE protein between controls and target gene knockdown 
samples.  We statistically analyzed knockdown efficiency using one-tailed student’s t-
test (p≤ 0.05).  
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Quantification of BACE knockdown in SH-SY5Y cells overexpressing 
APP 
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FigureA1: RNAi proof of concept in SH-SY5Y: 
SH-SY5Y-AG4 is selected with 2μg/ml  puromycin for stable BACE knock-down.  
Cells  were assayed for BACE protein expression five  weeks. The blot is probed with  
BACE (Biosource:  AHB0241) .Equal amount of protein is loaded anti-Actin (Sigma:  
A5441).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  257 
Rationle:  
 
We optimized our transfection protocol in HEK293 to establish transfection 
efficiency. To select cells that express shRNA, we replaced CM with CM containing 
puromycin (2μg/mL) 24 hours post transfection.  
We knocked-down APP in HEK293 using 3 different shRNA plasmids, 
targeting different regions of the APP mRNA along with controls (shNC: scrambled 
sequence and shLUC: targeting firefly luciferase). We collected lysates and performed 
a quantitative Western blot using Anti-human APP (1:1000, Sigma: A717) and anti-
Actin (1:5000, Sigma: A5441) antibodies.  
 
 
 
 
 
 
 
 
FigureA2: RNAi proof of concept in HEK293 
HEK293 is selected with 2μg/ml puromycin for stable APP knock-down. Cells were 
assayed for APP protein expression three weeks. The blot is probed with APP (Sigma:  
A717) .Equal amount of protein is loaded anti-Actin (Sigma: A5441).  
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